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ABSTRACT
The goal of this research was to gain greater understanding about the management of heart
failure patients. A particular focus was to evaluate exercise tolerance and behavior. The major
findings of the first study included: (1) evidence that few heart failure patients receive adequate
information regarding physical activity; (2) performance on a six-minute walk test were ~42%
lower, and SF-36 scores were also lower in heart failure patients compared to controls; (3)
stability in hemodynamic measures and distance walked on the 6-minute walk test were
adequate, and (4) home exercise resulted in 19% improvement in maximum walking distance
and 30% improvement in physical function score on the SF-36. The second study showed the
feasibility to implement a care-managed program for heart failure patients in a family practice
setting. However, a significant barrier was recruitment. Despite this failure, patients improved
~24% on the maximum walking distance and 29%, 46%, and 13% on the physical function,
vitality, and mental health scores on the SF-36. The third study examined the motivation and
readiness of heart failure patients to engage in planned physical activity. The findings revealed
22 patients in precontemplation, 33 in contemplation, 41 in preparation, 23 in action, and 29 in
maintenance. In regards to the Transtheoretical model constructs (self-efficacy, pros and cons of
decisional balance, and experiential processes) the data revealed that self-efficacy scores were
lowest in the precontemplation and increased in linear fashion to maintenance. Decisional
balance changed from greater perceived cons and lower perceived pros in precontemplation and
contemplation to lower perceived cons and higher perceived pros in action and maintenance.
Experiential processes were used predominantly in precontemplation and contemplation,
whereas behavioral processes were more prominently used in action and maintenance. The most
important predictors of physical activity stages of change were the behavioral processes (r2= .78)

vii

followed by perceived self-efficacy (r2= .66). Finally, this study indicated that patients in preaction stages of readiness to exercise have significant lower exercise tolerance then those in
action and maintenance. These data suggest greater clinical emphasis should be placed on
strategies to move patients toward the preparation and action stages of readiness.
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CHAPTER 1. INTRODUCTION
1.1 Introduction
Heart failure is defined as the pathophysiological state in which an abnormality of cardiac
function is responsible for failure of the heart to pump blood at a rate commensurate with the
requirements of the metabolizing tissues, or to do so only from an elevated filling pressure1.
Heart failure is not a homogenous disease. Rather, it is the final common pathway of several
disorders that impair the heart’s pumping ability.
An estimated 5.0 million Americans have heart failure, a chronic condition associated with
frequent hospitalizations, widespread functional impairment, and a high mortality rate. Each
year, approximately 550,000 new cases are diagnosed and nearly 300,000 patients die of heart
failure as a primary or contributory cause2. During the last 10 years, the annual number of
hospitalizations has increased from approximately 550,000 to nearly 900,000 for heart failure as
a primary and from 1.7 to 2.6 million for heart failure as a secondary diagnosis.3
In addition to the substantial morbidity and mortality associated with this condition, there is a
significant financial impact on our society. In fact, heart failure is now the single most costly
cardiovascular illness in the United States, with total treatment costs estimated at $24.3 billion.1
The cost to society is expected to increase due to an aging population and prolonged survival
rates of individuals with cardiovascular disease, therefore imposing a large burden on individuals
and the healthcare system.
Because heart failure is not a homogenous disease, management of the patient is extremely
challenging with constant need for close monitoring and follow-up care. Primary goals of heart
failure management include a reduction in the frequency of heart failure exacerbations,
extending life, and improving quality of life. Additional goals include maximizing independence,
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improving exercise capacity, enhancing emotional well-being, and reducing resource use and
cost of care5-7.
As a result of the increasing incidence of heart failure and the complex nature of the
syndrome, the management of patients has become increasingly multidisciplinary in nature.
Moreover, the composition of the team and relative importance of its members must constantly
change depending on the status of the patient. Recent studies have shown the significant value of
the use of a multidisciplinary approach in the management of the heart failure patient5-7. These
programs emphasize the importance of close monitoring and patient education. Despite positive
outcomes from these programs, including fewer readmissions and hospital days, decreased costs,
and improved functional status and quality of life, patient participation and adherence remain
suboptimal5-7. In fact, a major criticism of many large-scale therapeutic trials in heart failure is
that the characteristics of the heart failure population at large are quite different from those being
studied. This suggests there are a tremendous number of patients with heart failure who are
currently not being reached.
A major component of the management of the heart failure patient is planned physical
activity. Such programs have shown great promise as studies have revealed dramatic
improvements in functional ability and quality of life and a reduction in healthcare costs and
mortality in patients engaged in exercise programs8. Consequently, current recommendations on
the management of heart failure patients strongly emphasize an active lifestyle, and if possible,
participation in a moderate exercise training regimen9. However, despite the benefits of physical
activity for patients with heart failure, research indicates that few individuals with heart failure
actually engage in regular physical activity10. Numerous studies have revealed that traditional
methods of promoting physical activity have been only marginally successful in patients with
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heart failure, citing failure to adhere to recommendations as a predominant factor11,12. For
example, our experience indicates that from a pool of approximately 350 heart failure patients,
we were only able to recruit 20 patients for a 6 month intervention program. This was
particularly disappointing given the fact we had an active recruiting program in place, which was
coordinated by a dedicated nurse clinician. It has been suggested that these failures are in part
due to the educational rather than behavior and motivational focus of many campaigns13.
Furthermore, many exercise programs are designed for people who have decided to begin
exercise, yet a large proportion of individuals are simply not interested or ready to engage in
physical activity programs14. Thus, in an effort to provide patients with the greatest
opportunities to help manage the heart failure syndrome, it is critical to understand the
underlying reasons that may prevent a patient from participation as well as patient readiness to
engage in physical activity behaviors. Appreciation of “barriers” to treatment will ultimately
contribute to the development of improved strategies for inclusion of all patients with this
disease.
The current document presents three research projects conducted at Louisiana State
University designed to focus on the management of individuals diagnosed with heart failure. The
focus of Chapter 2 was to evaluate physical function and perceived quality of life in patients with
heart failure. Specifically, this project (1) examined written evidence regarding exercise
recommendations to heart failure patients by their providers, (2) determined the construct
validity of the 6-min walking test and a quality of life survey between patients with heart failure
and age-matched controls; (3) examined the stability of the 6-min walking test, and (4) evaluated
the effects of a care-managed exercise program. A unique contribution of this project was the
fact it took place in a family practice clinic. Arguably it is this setting where the greatest numbers
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of heart failure patients are managed, yet very little research concerning the management of these
patients in this setting has been conducted. The first project led to the development of a grant
proposal, which was ultimately funded through the Centers for Disease Control and Prevention.
Consequently, the focus of Chapter 3 was to examine the influence of individualized, intensive
education on measures of exercise tolerance and quality of life in patients with heart failure in a
family practice setting. An important aspect of this study was the development and
implementation of a tailored education handbook, as outlined by published guidelines for the
evaluation and care of patients with heart failure by the Agency for Health Care Policy and
Research (AHCPR)15. These guidelines include recommended topics for patient and family
education and counseling, such as diet, medications, physical activity, compliance, and
recognition of worsening symptoms. The study was powered on recruiting approximately 60
patients from a pool of about 350 patients. A dedicated nurse clinician was coordinating
recruiting efforts among approximately 6 physicians who were aware and for the most
supportive of the study efforts. Despite this coordinated effort, the study failed to reach the
targeted sample size. This failure is certainly not unprecedented in clinical trials and suggests
two important problems. First, it suggests that data from many interventional trials with a focus
on behavior modification may be biased to certain individuals. Second, it indicates there are a
tremendous number of patients with heart failure who are currently not adequately reached and
even managed. Recognizing this, it is not realistic to expect patients to make changes that they
are not prepared to make that resulted in the development of the final project. In so, the focus of
Chapter 4 was to assess the motivation and readiness of patients with heart failure to make
necessary behavioral changes to aid in the management of their condition. No such studies are
currently available for this patient population, despite strong suggestions that clinicians examine
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theoretically based and practically important behavioral strategies that might be useful for
encouraging and supporting a healthy behavior (such as exercise initiation) among individuals
with chronic heart failure. Consequently, the final project aimed to (1) examine the associations
of the constructs of the Transtheoretical model of behavior change and stage of change for
planned regular physical activity; (2) determine the most important predictors of physical activity
stages of change utilizing the constructs of the Transtheoretical model; and (3) examine the
association of the stage of change construct for physical activity with maximum walking distance
achieved on a 6 minute walk test among individuals with chronic heart failure.
A summary of the unique findings and the potential relevance of each project are presented
in Chapter 5. In addition, Chapter 5 outlines some future recommendations regarding subsequent
research in this and other disease populations.
Finally, the appendices include an extensive literature review on the heart failure syndrome,
the educational workbook used in the second project, and the informed consent for project 3.
1.2 References
1. Braunwald, E. Pathophysiology of heart failure. In: Heart disease. A Textbook of
Cardiovascular Medicine. Philadelphia, PA: WB Saunders Company; (1988): 394-418.
2. American Heart Association. Heart Disease and Stroke Statistics — 2004 Update. Dallas,
Tex.: American Heart Association; 2003.
3. Haldeman GA, Croft JB, Giles WH, Rashidee A. Hospitalization of patients with heart
failure: National Hospital Discharge Survey, 1985 to 1995. Am Heart J. 1999
Feb;137(2):352-60.
4. Rich MW, Beckham V, Wittenberg C, Leven CL, Freedland KE, Carney RM. A
multidisciplinary intervention to prevent the readmission of elderly patients with congestive
heart failure. N Engl J Med. 1995 Nov 2;333(18):1190-5.
5. Rich MW. Heart failure disease management: a critical review. J of Cardiac Failure (1999)
Mar;5(1):64-75.

5

6. McAlister FA, Lawson FM, Teo KK, Armstrong PW. Systematic review of randomized trials
of disease management programs in heart failure. Am J Med (2001) Apr 1;110(5):378-84.
7. Knox D, Mischke L. Implementing a congestive heart failure disease management program
to decrease length of stay and cost. J Cardiovasc Nurs (1999)Oct;14(1):55-74.
8. Piepoli MF, Davos C, Francis DP, Coats AJ; ExTraMATCH Collaborative. Exercise training
meta-analysis of trials in patients with chronic heart failure (ExTraMATCH). BMJ. 2004 Jan
24;328(7433):189. Epub 2004 Jan 16.
9. Pina IL, Apstein CS, Balady GJ, Belardinelli R, Chaitman BR, Duscha BD, Fletcher BJ, Fleg
JL, Myers JN, Sullivan MJ; American Heart Association Committee on exercise,
rehabilitation, and prevention. Exercise and heart failure: A statement from the AHA
Committee on exercise, rehabilitation, and prevention. Circulation (2003)Mar 4; 107(8):
1210-25.
10. Sneed NV, Paul SC. Readiness for behavior change in heart failure. American Journal of
Critical Care (2003); 12: 444-453.
11. Happ MB, Naylor MD, Roe-Prior P. Factors contributing to rehospitalization of elderly
patients with heart failure. J Cardiovasc Nursing (1997); 11: 75-84.
12. Ghali JK, Kadakia S, Cooper R, Ferlinz J. Precipitating factors leading to decompensation of
heart failure: traits among urban blacks. Arch of Inter Med (1998); 148: 2013-2016.
13. Marcus BH, Emmons KM, Simkin-Silverman LR, et al. Evaluation of stage-matched versus
standard self-help physical activity interventions at the workplace. American Journal of
Health Promotion (1998); 12(4): 246-253.
14. Stephens T. Secular trends in adult physical activity: exercise boom or bust? Research
Quarterly for Exercise and Sport (1987) 58: 94-105.
15. Konstam M, Dracup K, Baker D, et al. Heart failure: evaluation and care of patients with leftventricular dysfunction. Rockville, MD: Agency for Healthcare Policy and Research, Public
Health Service, U.S. Department of Health and Human Services; June 1994. Clinical Practice
Guideline No. 11. AHCPR Publication No. 94-0612.

6

CHAPTER 2. EVALUATION OF PHYSICAL FUNCTION AND PERCEIVED
QUALITY OF LIFE IN PATIENTS WITH HEART FAILURE IN A FAMILY
PRACTICE SETTING
2.1 Introduction
An estimated 4.9 million Americans have heart failure, a chronic condition associated with
frequent hospitalizations, widespread functional impairment, and a high mortality rate1. Each
year, approximately 550,000 new cases are diagnosed and nearly 300,000 patients die of heart
failure as a primary or contributory cause1. The syndrome is the underlying reason for 12 to 15
million office visits and 6.5 million hospital days each year2. Furthermore, during the last 10
years, the annual number of hospitalizations has increased from approximately 550,000 to nearly
900,000 for HF as a primary diagnosis and from 1.7 to 2.6 million for HF as a secondary
diagnosis3. In addition to the substantial morbidity and mortality associated with this condition,
there is a significant financial impact on our society. In fact, heart failure is now the single most
costly cardiovascular illness in the United States, with total treatment costs estimated at $24.3
billion1.
Despite traditional pharmacologic treatment, the clinical phase of HF includes a marked
decline in functional state, as defined by exercise tolerance and capacity with a subsequent
decrease in quality of life. Furthermore, hospitalization rates remain high, owing in large part to
a multitude of psychosocial, behavioral, and financial factors that serve as barriers to effective
compliance with prescribed treatment. To deal with these issues, many centers have adopted a
multidisciplinary approach to HF disease management4-7. Comprehensive care programs for HF
patients have been shown to be beneficial, but have largely been conducted in tertiary care
settings. The fact the majority of patients are managed by primary care physicians warrants
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further investigation to determine whether benefits of a comprehensive HF program, observed in
tertiary settings, can be replicated in the primary care environment.
The purpose of this study was 3-fold: (1) to examine written evidence regarding exercise
recommendations to heart failure patients by their providers, (2) to determine the construct
validity of the 6-min walking test and a quality of life survey between patients with heart failure
and age-matched controls; (3) to examine the stability of the 6-min walking test, and (4) to
evaluate the effects of a care-managed exercise program on functional status and perceived
quality of life in patients with heart failure in a family practice.
2.2 Methods
•

Participants
All patients were recruited from the Family Medicine Residency Program/ Baton Rouge

General Medical Center. Men and women over the age of 18 years with diagnoses of heart
failure (regardless of etiology) were eligible for the study. The duration of heart failure in all
patients was no less than 4 months and patients were optimally managed as deemed by the
participant’s primary care physician. Those patients with acute unstable myocardial ischemia
and/or angina, other non-cardiac diseases that would interfere with the completion of the study
(uncontrolled hypertension, severe chronic obstructive pulmonary disease, or severe arthritis),
and those recovering from a recent medical emergency resulting in hospitalization (e.g. acute
myocardial infarction, coronary bypass graft surgery, radiation therapy, etc.) are excluded from
participation. Participants without heart failure were selected and matched with the patients for
age, gender, height, and weight.
•

Study Design
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This study included a retrospective analysis of medical records to evaluate the dissemination
of physical activity information for the heart failure patient. This study also included a
prospective comparison component to determine the construct validity of the two major
dependent measures (i.e. the 6-minute walk distance and SF-36 scores). The short-term stability
of the 6-min walking test was determined using a simple test-retest design. Finally, the study also
included a prospective, randomized design aimed at measuring the potential benefit of a carefully
managed exercise program for patients with chronic heart failure in a family practice setting.
•

Experimental Measurements
All tests were conducted over the course of 1 visit at the Family Medicine Residency

Program/ Baton Rouge General Medical Center under the supervision of qualified clinicians as
well as support staff from the Department of Kinesiology at Louisiana State University. Prior to
testing a medical evaluation was performed by a qualified physician. The medical evaluation
included a medical history, review of symptoms, and routine examination of the major organ
systems.
Prior to testing, each patient’s medical records were carefully examined for evidence
regarding recommendations or guidance toward incorporating physical activity into the patient’s
medical management. A simple scoring system was implemented based on the following
evidence. If no evidence of physical activity information was noted over the last year, a score of
“0” was given. In the case of simple advise to “exercise as tolerated”, a sore of “1” was given. A
score of “2” was given to more specific information about physical activity, and a “3” was given
for specific exercise prescriptions according to the AHA guidelines8.
Following the medical examination exercise tolerance was assessed using a 6-minute
walking test on a motor driven treadmill. The grade of the treadmill was set at 0%. Patients
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controlled the treadmill speed by themselves and were allowed to change it at any time. The
speed could be altered in increments of 0.1 km/hr, allowing precise measurement of walking
distance. During the testing, blood pressure and heart rate were continuously monitored. Prior
to testing the patients were instructed to walk as far as possible, avoiding chest pain or marked
dyspnea. To standardize the protocol, subjects were not be coached during testing but all subjects
were made aware of the time remaining to completion. The maximum walking distance during
the 6-minute walk test was considered the dependent measure.
After the exercise tolerance test, the patients' perceived quality of life, defined for the present
study as the subjective appraisal of general physical and emotional well-being, was assessed with
the Short Form 36 (SF-36) questionnaire. The SF-36 was designed to measure the generic health
concepts relevant across age, disease, and treatment groups. The SF-36 was constructed to
represent 8 of the most important health concepts included in the medical outcomes study and
other widely used health surveys. The SF-36 is comprised of 36 items that describe health related
physical and psychosocial dysfunction in 8 areas to include physical function, social function,
role-limitation-physical, role limitation-emotional, mental health, vitality, bodily pain, and
general health. A single item evaluates the patient’s perception of change in health over the past
year. Scores range from 0% to 100% with higher scores consistent with better health status. To
examine the stability of the maximum walking distance achieved on the 6 minute walking test,
and SF-36, both tests were repeated one week after the initial test.
•

Intervention
Participants were randomly assigned to one of 2 groups: home-exercise training or control.

Exercise training consisted of aerobic activities of progressive duration and intensity performed
on a daily basis for 16 weeks. All participants received extensive follow-up through weekly
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telephone contact with members of the research team. In addition, all participant’s were
scheduled for monthly clinic visits aimed at patient education, compliance to medication,
identification of recurrent symptoms, and evaluation of exercise logs and modification of
exercise prescription (only in those participants randomized to the exercise training group).
•

Statistical Analysis
All statistical analyses were conducted using the latest version of the SPSS statistical

package for windows. To examine the written evidence regarding exercise recommendations
simple ranking statistics were applied. To determine the construct validity of the 6-min walking
test and a quality of life survey between patients with heart failure and age-matched controls,
independent sample t-tests were conducted. The stability of the 6-min walking test was examined
using an ANOVA with repeated measures, and intraclass correlation coefficients. Finally, the
effects of the exercise program on exercise tolerance and perceived quality of life were evaluated
using a paired sample t-test. Alpha levels were set at 0.10.
2.3 Results
•

Patient Characteristics
The patient demographics in this study were characteristic of the wide range of individuals

who present to the clinic (see Table 2.1). Of the 16 patients enrolled 14 were African-American
and 2 Caucasian. There were 12 women and 4 men with a mean age of 61±14 years.
Approximately 55% of the participants had systolic dysfunction as defined by a left ventricular
ejection fraction below 45%. Thirty percent of the participants had been diagnosed with diastolic
dysfunction and the etiology of heart failure in the remaining patients was unclear. In regards to
the patients’ pharmacotherapy, 12 patients were on ACE-inhibitors, all patients were on
diuretics, 5 on beta-blockers, and 6 on digitalis glycosides. Comorbidities included hypertension
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(80%), diabetes mellitus (53%) and depression (32%). The age-matched controls did not have
any evidence of overt disease.
Table 2.1. Participant Characteristics
n
Race
Gender
B W M
F
Heart Failure
Age-Matched
p

•

16
13

14
0

2
13

4
3

12
10

Age
(yr.)

Weight
(kg)

Height
(cm)

BMI

61±14
65±11
0.341

84.6±13
77.8±13
0.181

169.0±10
169.3±11
0.941

29.8±5
27.3±5
0.186

Survey Results
The survey results indicated very little written evidence that clinicians provided patients with

information regarding physical activity. Of the 16 patients, only one had received some specific
information regarding physical activity over the last year. In contrast, there were no notes
indicating any physical activity guidance for the remaining 15 patients. No patients were
provided specific guidelines for exercise as recommended by the American Heart Association.
•

Validity and Reproducibility of the 6-minute Walk Test
A major end-point in this study concerned the maximum walking distance achieved on the 6-

min walk test. Given a lack of information on the acute responses during the 6-min walk test in
this population, a group of heart failure patients were matched with an age-matched control
group. The age-matched control group (63+6 years) consisted of individuals who had no
evidence of underlying disease as determined by previous clinical examination. As expected the
healthy participants walked significantly faster compared to the patient group at every minute of
the walk test (see Figure 2.1). Furthermore, the maximum distance walked for the healthy
participants (552.03+73.80m) was much greater in comparison to the distance achieved by the
patients with heart failure (242.35 +86.35m) (p<0.05). Thus, these data clearly show that the 6minute walk test differentiates between healthy and heart failure populations.
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Importantly test-retest data reveals adequate reproducibility for maximum walking distance
and heart rate responses for the 6-minute walking test. Results revealed an ICC and CV
of 0.97 and 8.9% for visit 1 and 2, respectively. Hemodynamic measurements prior to and during
the walk test were not significantly different from visit 1 to visit 2. The ICC and CV for heart
rate in the last minute of exercise was 0.99 and 2.0%, whereas the ICC for BP ranged from 0.694
to 0.772 with CV of 6.3 to 13.0%, respectively. The reproducibility of the measures is further
detailed in figures 2.2 through 2.5.
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Figure 2.1. Comparison of Health vs. Disease: 6-minute Walk Test. *p<0.05 Healthy Controls
vs. Heart Failure
•

Validity of the SF-36
A second major end-point in this pilot-study was the perceived quality of life measured using

the SF-36 Health Survey. The survey provides information about 8 specific concepts (i.e.
physical functioning (PF), role-physical (RP), bodily pain (BP), general health (GH), vitality
(VT), social functioning (SF), role-emotional (RE), and mental health (MH)) and 2 combined
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Figure 2.4. Blood Pressure Responses to the 6-minute Walk Test

scores (i.e. physical component score (PCS) and mental component score (MCS). Table 2.2
clearly shows that the scores are significantly lower for the heart failure patients suggesting
greater decrements in functioning and well being than the age-matched controls.
Table 2.2. Comparison of Heart Failure and Age-matched Healthy Controls: SF-36 Scales
PF
RP
BP GH VT
SF
RE
MH PCS MCS
HF
Controls

44.7

31.3

55.7 48.6

44.1

31.0

45.7

85.0* 100.0* 81.0* 84.3* 73.1* 100.0* 100.0* 90.5* 51.4*

59.1*

*p<0.05 Controls vs. HF
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Figure 2.5. Ratings of Perceived Exertion during the 6-Minute Walk Test
In addition, data in Table 2.3 compared the scores for our heart failure patients to the norms
established by Ware9. The data appear to indicate that despite the small sample size the scores
are very similar to the national norms for congestive heart failure patients.
Table 2.3. Comparison of Baton Rouge General Pilot Data and National Norms for Patients
with Heart Failure: SF-36 Scales
PF
RP
BP GH VT
SF
RE MH PCS MCS
HF

44.7

31.3

55.7 48.6

44.1

67.2

54.2

67.0 31.0

45.7

Norms

47.5

34.4

62.7 47.1

44.3

71.3

63.7

74.7 34.1

47.3

16

•

Effect of 4 Month of Care-Managed Exercise Program
The 6-minute Walk Test
The results of the study indicated modest yet statistically significant improvements in the

maximum walking distance following the 16-week period. Patients consistently selected higher
walking speeds at each minute during the test. The pattern of speed changes during the walking
tests from start to finish for heart failure patients who completed a 16-week care management
program are depicted in Figure 2.6.
80
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Post (n=6)
70
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Figure 2.6. Effects of a Care-Managed Program for Heart Failure: 6-minute Walk Test
As can be seen from these data, patients selected higher speeds in the first minute of the test
and were able to maintain these speeds throughout the 6-min walk test following the intervention
period. Consequently, the maximum walk distance improved by 19%, 241.43+88.06m to
285.65+ 99.69m (p=0.06).
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The SF-36 Health Survey
The preliminary findings on the effects of the 16-week Care-Managed Heart Failure Program
are shown in Table 2.4. The data indicate a significantly higher score on the physical functioning
(PF) component of the SF-36 in those subjects who completed the exercise arm of the pilotstudy.
Table 2.4. Preliminary Data on the Effect of a 4 Month Care-Managed Heart Failure
Program: SF-36 Scales
PF
RP
BP
GH VT SF
RE
MH
PCS MCS
Pre
45 29.167
53
49.33 50 64.58 27.78 62.67 35.83 43.2
Post
58*
25
63.17 44.33 60
50
27.78 68.67 38.17 42.53
*p<0.05 Pre vs. Post
Relationship of the 6-minute Walk Test and SF-36 Health Survey
Figure 2.7a depicts the relationship of the 6-minute walk test and the physical functioning
score on the SF-36 Health Survey. The graph shows that as the physical functioning scores on
the SF-36 decline so does the maximum walking distance on the 6-minute walking test (r2=0.72;
p<0.05). Furthermore, as shown in Figure 2.7b these preliminary data also reveal that as
maximum walking distance improved (observed measures of physical function), scores on the
physical functioning scale of the SF-36 health survey also improved (subjective measures of
physical function), indicating a positive correlation between the change in maximum walking
distance following the care-managed program and the physical functioning score on the SF-36
(r=0.59; p=0.06).
2.4 Discussion
The major findings of this study are as follows: (1) despite the overwhelming evidence of the
benefits of exercise for patients with heart failure, there appears to be a lack of evidence to
suggest that these patients are receiving adequate information regarding physical activity, (2)
both the maximum walking distance on a 6-min walking test and the SF-36, a quality of life
18
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Figure 2.7a and b Relationship of the 6-minute Walk Test and SF-36 Health Survey
survey, clearly differentiate between patients with heart failure and age-matched controls; (3) the
one-week stability in the hemodynamic measures and the distance walked on the 6-minute
19

walking test on a treadmill were adequate, and (4) home exercise with frequent patient contact
resulted in modest improvements in exercise tolerance and perceived quality of life.
•

Survey
It is not clear why the patients are apparently not receiving adequate information regarding

physical activity. However, several factors may play into this dilemma. For example, the lack of
physical activity recommendations may be secondary to a lack of appreciation of the importance
of physical activity by the primary care physician, a lack of knowledge about the current
guidelines on exercise in heart failure, an inability to discuss the subject matter effectively, a lack
of time to discuss the subject matter, fear of precipitating further health or physical problems, a
lack of confidence by the physician that the information may be put to use, and/or a lack of
knowledge about available resources for these patients. In all fairness to the clinicians, the data
from this study only suggest a lack of adequate information about physical activity. The data
were collected directly from the medical records of the patients rather than examining the
clinicians in action (i.e. the actual patient contact time). In some cases the clinician may in fact
have discussed the role of physical activity with the patient but failed to note this in the medical
records. Regardless of the barrier future research should aim to provide the clinicians with
adequate strategies and the patients with the right opportunities to gather all the necessary
information that may aid in improved management of the disease.
•

Validity and Reproducibility of the 6-minute Walk Test
The present study clearly shows that the 6-minute walking test differentiates between a

healthy and heart failure population. In fact, the reported maximum walking distance for the
heart failure patients in this study was quite consistent with previous reports10. Guyatt et al.
(1985) were one of the first to study the potential value of the 6-minute walk as an objective
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measure of exercise capacity in patients with chronic heart failure10. They administered the 6minute walking test six times over 12 weeks in 18 patients with chronic heart failure and 25 with
chronic lung disease. The subjects also underwent cycle ergometer testing, and their functional
status was evaluated by means of conventional measures. The walking test proved highly
acceptable to the patients, and stable, reproducible results were achieved after the first two
walks10. The results correlated with the conventional measures of functional status and exercise
capacity. The authors concluded that the 6-minute walk is a useful measure of functional
exercise capacity and a suitable measure of outcome for clinical trials in patients with chronic
heart failure10. The present study is somewhat unique in that the stability of the measures was
found using a treadmill test rather than the traditional hallway test. Recognizing the importance
of using the same approach when conducting repeat measures the present data clearly show the
usability of a treadmill for the purpose of obtaining the maximum walking distance on the 6minute walking test. The present data do support research by Guyatt et al.10 , who recommends a
practice walk be performed. If the difference between the first and second walk is greater than
10% a third walk should be undertaken and used as the baseline measure. In this study the
magnitude of the difference did not exceed 10% in any of the participants.
Uniquely, this is the first study to examine the stability of the hemodynamic responses to the
6-minute walking test. Interestingly, the hemodynamic measurements prior to and during the
walk test were not significantly different from visit 1 to visit 2. Blood pressure responses during
the 6-minute walking test were not significantly different from pre-test values. Moreover, testretest comparison for blood pressure in the last minute of the 6-minute walking test revealed
Interclass Correlation Coefficients ranging from -0.63 for systolic blood pressure to 0.77 for
mean arterial blood pressure, suggesting much lower stability of the blood pressure responses. In
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contrast, heart rate increased significantly from rest by the first minute of the 6-minute walking
test, and returned to pre-test levels in the second minute of recovery. The Interclass Correlation
Coefficients and Coefficient of Variation for heart rate in the last minute of exercise was 0.99
and 2.0%, respectively. The stability of the heart rate response in the last minute of exercise
suggests the potential of this parameter as an outcome measure.
In contrast, reports of symptoms and ratings of perceived exertion were inconsistent from
visit 1 to visit 2 indicating these measures may not be sensitive in this population. Although the
mean values appear similar between tests, within subject variability was high. The reason for the
variability may be the subjective nature of these measures. Furthermore, pre-test instructions
emphasize the importance to achieve a perceived exertion rating of 12 to 14 toward the end of
the test. The fact that not all patients achieved this goal possibly indicates lack of knowledge of
proper use of the scales, and/or stress or uncertainty about the test. This is an important
consideration when examining the effects of interventions.
Importantly, the average walking distance in this study was 242.35±86.35m. In light of
recent work an average walking distance below 300 meters carries a rather ominous prognosis11.
Roul et al. (1998) 11 prospectively evaluated the potential of the 6-minute walk test compared
with peak VO2 in predicting outcome of patients with New York Heart Association (NYHA)
class II or III heart failure. Death or hospitalization for heart failure was used as the judgment
criterion. Patients who walked less then or equal to 300 m had a worse prognosis than those
walking farther (p=0.013). Furthermore, the investigators found a significant correlation between
distance covered and peak VO2 (r=0.65, p=0.011). Thus, it appears that a distance walked in 6
minutes less then or equal to 300 m can predict outcome in patients with heart failure11.
Moreover, in these cases there is a significant correlation between the 6-minute walk test and
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peak VO2 demonstrating the potential of this simple procedure as a first-line screening test for
this subset of patients.
The precise mechanism for the low exercise tolerance is not fully known but involves a series
of pathophysiological abnormalities that accompany the disease12-14. In addition, the low
maximum walking distance achieved by the patients confirms previous reports indicating the sixminute walk test is a simple objective guide to disability in patients with chronic heart failure10.
•

Validity of the SF-36
According to McHorney et al.15 the widespread use of standardized health surveys is

predicated on the largely untested assumption that scales constructed from those surveys will
satisfy minimum psychometric requirements across diverse population groups. McHorney et al.
15

used data from the Medical Outcomes Study (MOS) to evaluate data completeness and quality,

test scaling assumptions, and estimate internal-consistency reliability for the eight scales
constructed from the MOS SF-36 Health Survey. Analyses were conducted among 3,445 patients
and were replicated across 24 subgroups differing in sociodemographic characteristics,
diagnosis, and disease severity. For each scale, item-completion rates were high across all groups
(88% to 95%), but tended to be somewhat lower among the elderly, those with less than a high
school education, and those in poverty. On average, surveys were complete enough to compute
scales scores for more than 96% of the sample. Across patient groups, all scales passed tests for
item-internal consistency (97% passed) and item-discriminant validity (92% passed). Reliability
coefficients ranged from a low of 0.65 to a high of 0.94 across scales (median = 0.85) and varied
somewhat across patient subgroups. Floor effects were negligible except for the two role
disability scales. Noteworthy ceiling effects were observed for both role disability scales and the
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social functioning scale. The authors conclude that their findings support the use of the SF-36
survey across the diverse populations studied15.
Normative data for individuals with various disease conditions, including heart failure, have
been estimated from the general US population and M.O.S. patient population. We recognize
that the relatively small sample size (n=216) for heart failure and the fact that the norms are not
adjusted for sociodemographics and comorbid conditions. However, it is clear from the currently
available data that patients with heart failure exhibit markedly worse physical, role, and social
functioning; mental health; health perceptions; and/or bodily pain compared with individuals
with no chronic conditions.
In the present study the SF-36 scores for each specific concept are significantly lower for the
patients compared to age-matched controls. This indicates reduced perception of quality of life.
Despite our small sample size, these results are very similar to the national norms established by
Ware9. Furthermore, these data reveal a direct relationship between maximum walking distance
and quality of life scores. These results confirm previous reports by Havranek et al.16, suggesting
the meaningfulness of these measures for the evaluation of heart failure interventions.
•

Effect of 4 Month of Care-Managed Exercise Program
The pattern of speed changes during the walking tests from start to finish for the heart failure

patients who completed a 4 month care management program are depicted in Figure 2. As can be
seen from these data patients selected higher speeds in the first minute of the test and were able
to maintain these speeds throughout the 6-min walk test following the intervention period.
Consequently, the maximum walk distance improved by 19%, from 241.43+88.06m to 285.65+
99.69m, p=0.06. The observed improvements in maximum walking distance in our pilot study
are less than previously reported following a 3-week exercise training program17. However, our
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findings are similar to Rector et al. (1996) who showed increases in maximum walking distances
(390+91 versus 422+86 m, p<0.05) in a study to determine whether supplemental oral L-arginine
augment peripheral blood flow and improve functional status in patients with moderate to severe
heart failure18. Recognizing the limitations of a pilot study, these data do support the idea that a
carefully managed program for heart failure patients may contribute to improvements in 6minute walk test performance.
The preliminary findings on the effects of the 16-week Care-Managed Heart Failure Program
on quality of life indicate a significantly higher score on the physical functioning (PF)
component of the SF-36 in those subjects who completed the exercise arm of the pilot-study.
2.5. Conclusion
In conclusion, this study indicates that despite the overwhelming evidence of the benefits of
exercise for patients with heart failure, there appears to be a lack of evidence to suggest that
these patients are receiving adequate information regarding physical activity. Second, both the
maximum walking distance on a 6-min walking test and the SF-36, a quality of life survey,
clearly differentiate between patients with heart failure and age-matched controls. Third, the oneweek stability in the hemodynamic measures and the distance walked on the 6-minute walking
test on a treadmill were adequate. Finally, home exercise with frequent patient contact resulted in
modest improvements in exercise tolerance and perceived quality of life.
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CHAPTER 3. IMPROVED EXERCISE TOLERANCE AND QUALITY OF LIFE
FOLLOWING A HEART FAILURE PROGRAM IN FAMILY PRACTICE
3.1 Introduction
Heart failure is defined as "the pathophysiological state in which an abnormality of cardiac
function is responsible for failure of the heart to pump blood at a rate commensurate with the
requirements of the metabolizing tissues and/or to be able to do so only from an elevated filling
pressure" 1. The alteration in the normal physiological pumping capacity of the heart is
principally due to three distinct etiologies: (1) intrinsic myocardial disease including coronary
heart disease, cardiomyopathy, and infiltrative disease; (2) excess work load due to increased
resistance to ejection (pressure load) secondary to hypertension and hypertrophic
cardiomyopathy or increased stroke volume (volume load) secondary to aortic and/or valvular
insufficiency; (3) iatrogenic myocardial damage from drugs or radiation therapy 2.
The National Health and Nutrition Examination Survey reports an estimated 4.8 million
Americans have heart failure. Each year approximately 400,000 new cases are diagnosed, and
36,387 Americans died from heart failure in 1992 3. This represents a significant rise in the
number of deaths from heart failure since 1968. In addition to the cost of human life, heart
failure poses an enormous financial burden on American society. The management of heart
failure generally exceeds $5 billion 4. It is expected that this cost to society will only rise in the
future, as it is estimated that by the year 2020, the number of persons over 65 years of age
population will represent over 20% of the general populous. This will undoubtedly result in a
significant increase in the number of people with chronic conditions including heart failure.
The treatment of heart failure is aimed at correcting the underlying cause and/or controlling
the heart failure state. The management of the heart failure patient generally includes a
combination of pharmacological compounds aimed to relieve clinical symptoms and prolong life
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5

. Numerous pharmacological agents are available which help improve central hemodynamics

by reducing cardiac afterload or enhancing myocardial contractility. Additional pharmacological
agents are used to reduce excessive fluid retention. Following initiation of such therapy
mortality is reduced, and many patients experience resolution of their symptoms at rest 5-7.
However, most patients continue to experience activity-related symptoms, including shortness of
breath, muscle fatigue, and weakness. As a result, patients with heart failure often complain of
chronic fatigue and are unable to perform many of their normal activities of daily living. Thus,
despite traditional pharmacological treatment, the clinical phase of heart failure includes a
marked decline in functional status, as defined by exercise tolerance with a subsequent decrease
in quality of life.
Modifications of lifestyle can be helpful in controlling the symptoms of heart failure and
maintaining clinical stability. For example, it has been suggested that basic habits of moderate
sodium restriction, weight monitoring, exercise, and adherence to medication schedules may aid
in avoiding fluid retention or alerting the patient to its presence 8. Multiple studies have shown
that patients who are educated and knowledgeable about their disease process and understand
how their medications work and the importance of compliance have fewer hospital readmissions
and experience an increase in exercise tolerance and quality of life 9-11. For example, in a review
of the literature from 1966 to 1993 12, counseling and health education increased life expectancy
and quality of life, and reduced hospitalization of patients with heart disease.
In an effort to address this major public health concern, the Agency for Healthcare Policy and
Research (AHCPR) published guidelines for the evaluation and care of patients with HF 13.
These guidelines include recommendations for patient and family education and counseling, diet,
physical activity, nursing and social services intervention, support groups, and specific measures
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to improve compliance. It is noteworthy that the vast majority of patients with heart failure are
managed in the primary care setting, yet few studies have examined the efficacy of
comprehensive care as outlined by the AHCPR in this setting. In fact, one of the key areas for
future research suggested by the AHCPR is to determine the efficacy of their guidelines in
different practice environments and with diverse populations (i.e. gender, race, socioeconomic
status, level of education and etiology of heart failure). Consequently, the purpose of the second
study was to determine whether a tailored heart failure educational program as outlined by the
Agency of Health Care Policy and Research (AHCPR) could be effectively implemented in a
primary care setting. Specifically, this study examined the effects of a 3-month care-managed
program on exercise tolerance and measures of perceived quality of life in patients with heart
failure in a family practice setting.
3.2 Methods
•

Participants
All patients were recruited from the Family Medicine Residency Program/ Baton Rouge

General Medical Center. Men and women over the age of 18 years with diagnoses of heart
failure (regardless of etiology) were eligible for the study. In addition, participants had to have
the ability to read and write English. The duration of heart failure in all patients was no less than
4 months and patients were optimally managed as deemed by the participant’s primary care
physician. Participants were not excluded on the basis of gender, race, and/or etiology of heart
failure. However, those patients with acute unstable myocardial ischemia and/or angina, other
non-cardiac diseases that would interfere with the completion of the study (uncontrolled
hypertension, severe chronic obstructive pulmonary disease, or severe arthritis), and those
recovering from a recent medical emergency resulting in hospitalization (e.g. acute myocardial
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infarction, coronary bypass graft surgery, radiation therapy, etc.) were excluded from
participation.
•

Recruitment Strategies
In an effort to maximize the ability to recruit from a pool of approximately 350 patients, a

dedicated nurse clinician was hired. A major portion of the nurse clinician’s job responsibilities
was to identify all potential candidates and contact both patients and physicians in terms of their
potential participation. The first strategy involved identification of the candidates through
medical and computer records. The second strategy involved telephone contact and subsequently
a direct meeting when the patient was scheduled for an appointment. Finally, each physician (a
total of 6) was constantly reminded about the program to help in remind them about the study.
•

Study Design and Experimental Measures
This study was a prospective, randomized controlled trial aimed at examining the effects of a

multifaceted, care-managed program as outlined by the AHCPR in patients with heart failure in a
family practice setting 13. Changes in exercise tolerance and perceived quality of life were
followed over a 3-month period and patients were randomly assigned to one of two groups:
Usual Care and Care-managed. Exercise tolerance was measured as the maximum distance
(MWD) achieved on a six-minute walk test. Perceived quality of life (QOL) was evaluated using
the short-form 36 health survey (SF-36). Patients in both the usual care and care-managed groups
received an initial education session including general information about heart failure, followed
by weekly telephone calls to monitor compliance and clinical status.
Additionally, patients randomized to the care-managed group received education guided by
an extensive heart failure patient workbook. The workbook included recommendations about
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physical activity, medications, nutrition, and other pertinent issues as outlined by the AHCPR
guidelines 13. Figure 3.1 displays an example of chapter outlines from the patient workbook.

Figure 3.1. Heart Failure Disease Management Patient Workbook Sample
Table 3.1 provides an overview of the specific topics that were addressed and monitored
throughout the course of the study. These topics were specifically recommended by the AHCPR
for patient and family education and counseling. Furthermore the decision to use these topics
was based on the available literature which indicates the use of these strategies to be effective in
heart failure patients in tertiary settings 14,15.
•

Baseline Visit One
Upon arrival to the clinic all participants received a comprehensive explanation of the

proposed study, its benefits, inherent risks and expected commitments with regard to time and
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patient responsibilities. Each individual was required to complete an informed consent
document approved by the Baton Rouge General and Louisiana State University Institutional
Review Board prior to any testing procedures. All patients underwent a medical evaluation
performed by the Medical Director of the study, which included a medical history, review of
symptoms, and routine examination of the major organ systems.
Table 3.1. Topics for Patient, Family, and Caregiver Education and Counseling
General Counseling
Explanation of Heart Failure and the Reason for Symptoms
•
Cause or probable cause of heart failure
•
Expected symptoms
•
Symptoms of worsening heart failure
•
What to do if symptoms worsen
•
Self-monitoring with daily weights
•
Explanation of treatment/care plan
•
Clarification of patient's responsibilities
•
Importance of cessation of tobacco use
•
Role of family members or other caregivers in the treatment/care plan
•
Availability and value of qualified local support group
•
Importance of obtaining vaccinations against influenza and pneumococcal disease
Prognosis
•
Life expectancy
•
Advance directives
•
Advice for family members in the event of sudden death
Activity Recommendations
•
Recreation, leisure, and work activity
•
Exercise
•
Sex, sexual difficulties, and coping strategies
Dietary Recommendations
•
Sodium restriction
•
Avoidance of excessive fluid intake
•
Fluid restriction (if required)
•
Alcohol restriction
Medications
•
Effects of medications on quality of life and survival
•
Dosing
•
Likely side effects and what to do if they occur
•
Coping mechanisms for complicated medical regimens
•
Availability of lower cost medications or financial assistance
Importance of Compliance with the Treatment/Care Plan

33

Exercise tolerance was assessed using a 6 minute walking test on a motor driven treadmill 16.
Prior to testing the patients were instructed to walk at a self-selected speed, avoiding chest pain
or marked dyspnea. The grade of the treadmill was set at 0%. Patients controlled the treadmill
speed and were allowed to change it at any time. The speed could be altered in increments of 0.1
km/hr, allowing precise measurement of walking distance. Heart rate and blood pressure were
monitored during the test. To standardize the protocol, participants were not coached during
testing but all participants were made aware of the time remaining to completion.
Finally, patients' perceived quality of life, defined for the present study as the subjective
appraisal of general physical and emotional well-being, was assessed with the Short-Form 36
(SF-36) questionnaire 17. The SF-36 is comprised of 36 items that describe health related
physical and psychosocial dysfunction in 8 areas to include physical function, social function,
role-limitation-physical, role limitation-emotional, mental health, vitality, bodily pain, and
general health. A single item evaluates the patient’s perception of change in health. Scores range
from 0% to 100% with higher scores consistent with better health status.
•

Baseline Visit Two
To ensure stability of the measure, the six minute walk test was repeated one week after the

initial test. Therefore, upon arrival to the clinic participants were prepared for assessment of
exercise tolerance. After a 15 minutes rest period, resting heart rate and blood pressure were
obtained from the dominant arm, using standard auscultation procedures and a Trimline mercury
sphygmomanometer (Pymah Co., Somerville, NJ). Subsequently, exercise tolerance was again
assessed using the 6 minute walking test on a motor driven treadmill as described in the previous
section.

34

Following these procedures, all patients received a general educational session with the nurse
educator. The purpose of this session was to educate the patient about the serious implications of
their diagnosis, an explanation of what patients can expect to experience during activities of
daily living, typical symptoms of worsening heart failure, and who to contact if such symptoms
develop. Furthermore the nurse educator discussed medication compliance, low salt-diet and
encouraged regular physical activity. In addition, patients randomized to the care-managed group
received an educational workbook that included information regarding physical activity, diet,
medications, and other pertinent issues as recommended by the AHCPR 13.
•

Follow-up
All patients received weekly telephone follow-up to monitor clinical status. Additionally,

patients randomized to the care-managed group received intensive education regarding specific
topics as outlined by the AHCPR and individualized program modification. Furthermore, these
patients were scheduled for monthly group visits for additional education on selected topics.
•

Three Month Follow-up
At the end of the 3 month period, all patients were scheduled to undergo the same series of

assessments as described for the baseline visits (Physical examination, quality of life survey, and
the 6-minute walking test). In order to control for the possible confounding effects of
pharmacotherapy, circadian rhythms, and other external sources of variability the tests were
performed by the same team of investigators at approximately the same time of day.
•

Statistical Analysis
All statistical analyses were conducted using the latest version of the SPSS statistical

package for windows. To examine the influence of the intervention on exercise tolerance and
hemodynamic measures a 2 (intervention and usual care group) by 2 (Pre versus Post) ANOVA
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was conducted. To examine the influence of the intervention on quality of life a 2 (intervention
and usual care group) by 2 (Pre versus Post) ANOVA was conducted. The stability of the 6-min
walking test was examined using an ANOVA with repeated measures, and intraclass correlation
coefficients. Alpha levels were set at 0.10.
3.3 Results
•

Patient Characteristics
Of a possible 350 patients, only 18 patients with HF (NYHA class II or III) were taken

through the program. From the 18 patients, ten were randomized to the care managed group
(n=10; age=57+13) and eight to the usual care group (n=8; age=53+14). The main etiology of
heart failure for the patients was ischemic heart disease followed by hypertensive heart disease.
There were no differences between the groups prior to the intervention for age, height, weight,
BMI, or any hemodynamic measures (see Table 3.2).
Table 3.2. Participant Characteristics
Participant Characteristics
Intervention
Usual Care
(n=10)
(n=8)
Age (yrs)
57±14
53±13
Height (cm)
167±7
167±10
Weight (kg)
98.44±15.50 98.80±38.61
BMI (kg/m2)
34.67±5.35
37.51±15.85
HRrest (b/min)
66±14
80±15
SBPrest (mmHg) 143±17
132±14
DBPrest (mmHg) 80±10
82±11
Co-Morbidity
5±3
3±2
•

Six-minute Walk Test
The test-retest values for the 6 minute walk test prior to training are presented in Figure 3.2.

As previously reported the reproducibility and stability of the test is adequate. For the purpose of
comparing the pre and post training values the second test was used as the true baseline value.
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Six-minute walking distances at baseline and three months are depicted in Table 3.3. Patients
in the care-managed group walked significantly farther at 3-months as compared to baseline for
each minute of the test; consequently, maximum walking distance improved by 24% (199.7+26
to 247.1+92; p=0.014). Maximum walking distance did not significantly improve for patients in
the usual care group.
Table 3.3. Six Minute Walking Distance at Baseline and 3 months
Six-Minute Walk Test
(Walking Distance)
Intervention(n=10)
Usual Care (n=8)
Baseline
Baseline
3-Months
3-Months
Min 1(m/min)
Min 2(m/min)
Min 3(m/min)
Min 4(m/min)
Min 5(m/min)
Min 6(m/min)
MWD(m)

30.25±15.80
32.48±14.03
34.87±14.51
36.66±14.75
36.66±14.75
36.66±14.75
199.70±29.00

35.76±17.54*
38.74±17.34*
42.31±15.51*
42.91±15.29*
42.32±15.86+
42.32±15.86+
247.10±92.00*

15.71±5.04
16.86±5.47
18.78±6.90
20.69±9.09
20.69±9.09
21.46±9.96
114.19±45.43#

19.93±3.94
21.27±5.15*
22.22±6.24
24.14±8.43
24.72±9.09
24.52±8.87
136.79±41.38

Table 3.4 shows the hemodynamic measures immediately after the 6th minute on the walk
test. No significant differences between the periods or the groups were noted.
Table 3.4 Hemodynamic and Perceived Exertion in the Last Minute of the Walk Test
Six-Minute Walk Test
(Hemodynamics and Perceived Exertion @ 6 min)
Intervention(n=10)
Usual Care (n=8)
Baseline
3-Months Baseline
3-Months
Heart Rate (Bts/min)
Systolic Blood Pressure (mmHg)
Diastolic Blood Pressure (mmHg)
RPE
•

103±13
144±23
81±16
9.33±1.63

96±17
165±12
77±8
10.44±1.51

108±17
167±15
100±8
8.43±1.06

110±18
159±12
88±12
9.57±1.67

Quality of Life
The results of the effects of the 3-month Care-Managed Heart Failure Program on the

perceived quality of life measured using the SF-36 Health Survey are shown in Table 3.5.
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Table 3.5. Perceived Quality of Life before and after the intervention
Perceived Quality of Life(SF-36)
Intervention(n=10)
Usual Care (n=8)
Baseline
3-Months Baseline
3Months
+
Physical Function
40±25
40±38
50±27
65±25
Role Physical
39±42
50±45
44±42
70±36
Bodily Pain
63±30
65±27
80±16
79±25
General Health
48±23
55±19
21±10
24±12
*
Vitality
39±19
37±19
42±23
62±24
Social Function
67±38
64±31
75±18
97±6
Role Emotional
59±32
78±24
58±32
67±47
+
Mental Health
59±31
64±30
66±21
75±26
Physical Component Score
37±11
40±9
37±9
39±10
Mental Component Score
46±12
50±10
45±13
51±12
*
+
p<0.05 vs. Baseline; p<0.10 vs. intervention
The data indicate that following the 3-month intervention, physical function (PF), vitality (VT),
and mental health (MH) scores improved by 29% (50+27 to 64.5+25), 46% (42+23 to 61.5+24),
and 13% (66.4+21 to 75.2+26), respectively (p<0.10), in patients randomized to the caremanaged group.
3.4. Discussion
The present study indicates it is feasible to implement a multifaceted, care-managed program
for individuals with heart failure in a family practice setting. However, a significant barrier to its
success was the inability to effectively recruit patients from the pool of candidates. Despite this
failure, the present data indicate moderate improvements in exercise tolerance and perceived
quality of life in heart failure patients following a care-managed program in a family practice
setting.
•

Reproducibility of the 6-minute Walk Test
The present study clearly shows that the 6-minute walking test differentiates between a

healthy and heart failure population. In fact, the reported maximum walking distance for the
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heart failure patients in this study was quite consistent with previous reports10. Guyatt et al. 16
were one of the first to study the potential value of the 6-minute walk as an objective measure of
exercise capacity in patients with chronic heart failure. They administered the 6-minute walking
test six times over 12 weeks in 18 patients with chronic heart failure and 25 with chronic lung
disease. The subjects also underwent cycle ergometer testing, and their functional status was
evaluated by means of conventional measures. The walking test proved highly acceptable to the
patients, and stable, reproducible results were achieved after the first two walks16. The results
correlated with the conventional measures of functional status and exercise capacity. The authors
concluded that the 6-minute walk is a useful measure of functional exercise capacity and a
suitable measure of outcome for clinical trials in patients with chronic heart failure16. The present
study is somewhat unique in that the stability of the measures was found using a treadmill test
rather than the traditional hallway test. Recognizing the importance of using the same approach
when conducting repeat measures the present data clearly show the usability of a treadmill for
the purpose of obtaining the maximum walking distance on the 6-minute walking test. The
present data do support research by Guyatt et al. 16, who recommends at least a practice walks be
performed. If the difference between the first and second walk is greater than 10% a third walk
should be undertaken and used as the baseline measure. In this study the magnitude of the
difference did not exceed 10% in any of the participants.
•

Effect of 3 Month Intervention
Exercise tolerance as defined by the maximum walking distance achieved on a six-minute

walk test improved in the patients randomized to the care-managed group. The pattern of speed
changes during the walking tests from start to finish indicated patients in the care-managed group
selected higher speeds in the first minute of the test and were able to maintain these speeds
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throughout the 6-min walk test following the3-month intervention period. Consequently, the
maximum walk distance improved by 24%, from 199.7+26 to 247.1+92 (p=0.014). The observed
improvements in maximum walking distance in this study are slightly better than our pilot study
(19%, 241.43+88.06m to 285.65+ 99.69m (p=0.06).These findings are also similar to Rector et
al. 18 who showed increases in maximum walking distances (390+91 versus 422+86 m, p<0.05)
in a study to determine whether supplemental oral L-arginine augment peripheral blood flow and
improve functional status in patients with moderate to severe heart failure. Recognizing the
limitations of this study, these data support the idea that a carefully managed program for heart
failure patients may contribute to improvements in 6-minute walk test performance.
In addition, data from the present study indicate a significantly higher score on three
components of the SF-36. These included physical function, vitality, and mental health scores,
which improved by 29%, 46%, and 13%, respectively (p<0.10). These improvements were only
evident in the patients randomized to the care-managed group. The improvements are somewhat
modest in comparison to another study that reported significant improvements in energy (80%),
physical mobility (74%), and emotional reactions (83%) in heart failure patients 3 months
following cardiac transplantation 19. Obviously such changes are difficult to compare as the
present study did not involve transplantation. The present changes are also less than those
reported by Kavanagh et al. 20, although they reported their improvements after one year of
training.
•

Recruitment Failures
The greatest failure of this study was the inability to effectively recruit, despite a dedicated

nurse clinician, a committed medical director, and a large enough candidate pool. It is certainly
not easy to pin-point the reasons for the lack of success but a few barriers are presented in an
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effort to aid future attempts to overcome these more quickly. A major reason appeared to be a
general lack of interest by many patients with heart failure. The reasons for the lack of interest
are unknown but it is not uncommon to see this problem in populations with similar
demographics. It has been suggested that some patients may be somewhat fearful, in greater
denial, or mistrusting of a particular program that is not directly associated with their physician.
Other issues could certainly include a lack of perceived benefits, transportation problems, a lack
of education or other socioeconomic factors. Many of these factors have previously been
identified and should become a greater part of the planning stages of these sorts of efforts 21-23.
Another issue that may have affected the recruitment was the fact that the clinic was undergoing
a major transition in leadership. It appeared the physicians were somewhat distracted by these
issues which may have affected their attention to this study.
A second issue that requires a lot more thought and planning is the fact that it appeared many
patients were just not ready to engage, regardless of a specific reason. Given this lack of
readiness, it is not realistic to expect such patients to make changes that they are not prepared to
make. Thus it would appear greater attention to assessing the motivation and readiness of
patients with heart failure could be an important factor prior to forcing or implementing
behavioral changes24. In fact clinicians have been encouraged to examine theoretically based and
practically important behavioral strategies that might be useful for encouraging and supporting
behavior changes (e.g. exercise initiation and/or maintenance) among individuals with chronic
heart failure13, 25, 26. Application of behavioral theories, such as the Transtheoretical model
(TTM) of behavior change may be useful in designing effective intervention programs for
patients with heart failure26. These approaches could be used to guide strategies that go beyond
traditional patient educational approaches27. For example, with the appropriate activities to meet
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the patient’s stage of readiness for change, healthcare providers may facilitate a patient’s
movement along the continuum of change to alter lifestyle behaviors, such as physical activity,
that can result in improved outcomes 24,26,28. Therefore, the TTM offers an opportunity to
improve compliance with published guidelines by individualizing the change process to meet the
needs of each patient.
•

Educational Workbook
A major effort of this study was the development of an educational workbook that was

specifically tailored to the patients’ level of education and disease. The workbook was designed
to allow patients gain a greater understanding of their condition and teach them the importance
of adhering to their program and recognizing early warning signs that may lead to congestive
heart failure. Perhaps somewhat surprising few patients had any awareness of their condition and
the steps needed to protect them from deteriorating. The workbook appeared to raise the patients’
awareness about their condition, which according to other researchers is a necessary component
in the successful management of the patient 15.
Clearly more work is needed. On the basis of the data from this study it would be important
to modify the workbook to include strategies that may help individuals become more motivated
and prepared to engage in these important behavioral strategies such as exercise, weighing, and
careful adherence to diet and medications.
3.5 Conclusion
The present study indicates it is feasible to implement a multifaceted, care-managed program
for individuals with heart failure in a family practice setting. The present data indicate moderate
improvements in exercise tolerance and perceived quality of life in heart failure patients
following a care-managed program in a family practice setting. A greater appreciation of factors
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that may prevent patients from participation in these intervention programs is necessary. One
such factor may include pre-intervention assessments of the motivation and readiness of patients
with heart failure to make behavior changes.
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CHAPTER 4. EXAMINATION OF THE CONSTRUCTS OF THE
TRANSTHEORETICAL MODEL IN PATIENTS WITH HEART FAILURE: A FOCUS
ON PHYSICAL ACTIVITY READINESS
4.1 Introduction
Chronic heart failure remains a significant health problem in the United States, with frequent
hospitalizations, widespread functional impairment, and a high mortality rate. Recent studies
have shown the significant value of the use of a multidisciplinary approach in the management of
the heart failure patient. These programs emphasize the importance of close monitoring and
patient education1, 2. Despite positive outcomes from these programs, including fewer
readmissions and hospital days, decreased costs, and improved functional status and quality of
life, patient participation and adherence remain suboptimal1, 3.
A major component of the management of the heart failure patient is planned physical
activity. Such programs have shown great promise as studies have revealed dramatic
improvements in functional ability and quality of life and a reduction in healthcare costs and
mortality in patients engaged in exercise programs1, 4. Consequently, current recommendations
on the management of heart failure patients strongly emphasize an active lifestyle, and if
possible, participation in a moderate exercise training regimen5, 6. However, despite the benefits
of physical activity for patients with heart failure, research indicates that few individuals with
heart failure actually engage in regular physical activity7. Numerous studies have revealed that
traditional methods of promoting physical activity have been only marginally successful in heart
failure patients, citing failure to adhere to recommendations as a predominant factor8, 9.
Given the importance of physical activity, and the high levels of inactivity among individuals
with chronic heart failure, clinicians have been encouraged to examine theoretically based and
practically important behavioral strategies that might be useful for encouraging and supporting
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exercise initiation and/or maintenance among individuals with chronic heart failure5, 10, 11.
Literature suggests that it is not realistic to expect patients to make changes that they are not
prepared to make and little attention has been given to assessing the motivation and readiness of
patients with heart failure to make necessary behavioral changes7. Application of behavioral
theories, such as the Transtheoretical model (TTM) of behavior change may be useful in
designing effective intervention programs for patients with heart failure10. These approaches
could be used to guide strategies that go beyond traditional patient educational approaches12. For
example, with the appropriate activities to meet the patient’s stage of readiness for change,
healthcare providers may facilitate a patient’s movement along the continuum of change to alter
lifestyle behaviors, such as physical activity, that can result in improved outcomes 10, 13, 14.
Therefore, the TTM offers an opportunity to improve compliance with published guidelines by
individualizing the change process to meet the needs of each patient. To date, no studies have
examined the full TTM among patients with heart failure. Therefore, the specific aims of this
research were three-fold:
1. To examine the associations of TTM behavior change constructs (behavioral and
cognitive processes of change, decisional balance, and self-efficacy) by stage of change
for planned regular physical activity among individuals with chronic heart failure.
2.

To determine the most important predictors of physical activity stages of change
utilizing the constructs of the TTM among individuals with chronic heart failure

3. To examine the association of the stage of change construct for daily physical activity
and maximum walking distance achieved on a 6 minute walk test.
In regards to specific aim one, the following hypotheses were tested:
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Hypothesis I:

Self-efficacy will increase in linear fashion from precontemplation to
maintenance

Hypothesis II:

Perceived pros will increase across the stages from precontemplation to
maintenance; whereas, perceived cons will decrease across the stages. The
crossover point in decisional balance scores will be observed in the preparation
stage.

Hypothesis III: Experiential and behavioral processes will increase across the stages of change.
In regards to specific aim two:
The predictive power of the TTM constructs to the stage of change is unknown in
patients with heart failure; therefore, no specific hypothesis is stated.
In regards to specific aim three, the following hypothesis was tested:
Hypothesis IV: Both maximum walking distance and daily physical activity scores will be
higher in the action and maintenance stages as compared to the previous stages.
•

Background and Significance
Heart failure is defined as the pathophysiological state in which an abnormality of cardiac

function is responsible for failure of the heart to pump blood at a rate commensurate with the
requirements of the metabolizing tissues, or to do so only from an elevated filling pressure15.
Despite traditional pharmacological treatment, the clinical phase of heart failure includes a
marked decline in functional status, defined by exercise tolerance and capacity with a subsequent
decrease in quality of life.
An estimated 4.9 million Americans have heart failure, a chronic condition associated with
frequent hospitalizations, widespread functional impairment, and a high mortality rate. Each
year, approximately 550,000 new cases are diagnosed and nearly 300,000 patients die of heart
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failure as a primary or contributory cause16. Elderly individuals are particularly at risk for
developing heart failure. In fact, heart failure is the most common hospital discharge diagnosis
for patients over 65 years. The syndrome is the underlying reason for 12 to 15 million office
visits and 6.5 million hospital days each year17. Furthermore, during the last 10 years, the annual
number of hospitalizations has increased from approximately 550,000 to nearly 900,000 for heart
failure as a primary diagnosis and from 1.7 to 2.6 million for heart failure as a secondary
diagnosis18. In addition to the substantial morbidity and mortality associated with this condition,
there is a significant financial impact on our society. In fact, heart failure is now the single most
costly cardiovascular illness in the United States, with total treatment costs estimated at $24.3
billion16. The cost to society is expected to increase due to an aging population and prolonged
survival rates of individuals with cardiovascular disease, therefore imposing a large burden on
individuals and the healthcare system18.
Research indicates that a multidisciplinary approach to heart failure management may be
associated with important clinical benefits, including fewer readmissions and hospital days,
decreased costs, improved functional status and quality of life1,3,19. An important component of
such programs focuses on the promotion of behavior modification, including proper diet,
adequate exercise and rest, and other lifestyle changes. Unfortunately, adherence to heart failure
programs is generally low, and noncompliance remains a serious problem8. In fact, failure to
adhere to recommendations continues to be a primary reason for hospital readmission for
patients with decompensated heart failure8, 9. The reasons behind the noncompliance are poorly
understood. Clearly, a better understanding of factors that may contribute to noncompliance may
lead to better strategies for the clinician to engage the patients in their disease management.
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The use of appropriate and adequate physical activity may be of particular importance in the
management of the heart failure patient. Arguably, there is no single intervention with greater
promise than physical activity in the management of the heart failure syndrome20. Not only does
physical training improve measures of exercise tolerance and capacity, but exercise training also
reverses a number of maladaptations in the vasculature, skeletal muscle, neuroendocrine systems,
and metabolism in heart failure patients. Moreover, patients’ functional ability and quality of life
improve dramatically. Lastly, a recent meta-analysis reveals a significant reduction in mortality
in patients engaged in exercise programs4. Consequently, the current recommendations on the
management of heart failure patients strongly emphasizes an active lifestyle, and if possible,
participation in a moderate exercise training regimen5, 6. However, as previously stated, few
individuals with heart failure actually engage in regular physical activity7. In fact, Sneed & Paul7
reported only 38% of patients with heart failure (age=56+12) exercise regularly (at least 3 days
per week for at least 20-minute intervals).
Traditional strategies to alter behaviors such as physical activity patterns include educational
classes, videos, and written materials. These materials are generally presented to all patients in
the same manner. More recently, there is clear evidence that education will only work if the
patient is willing to engage in the process14. For example, despite the use of an individualized
intervention focused on preventing exacerbations of heart failure through symptom recognition,
medication, dietary education, and modification of poor health behavior, a 33% readmission rate
was noted within the first 6 months after hospital discharge8. The authors attributed the high
readmission rates to lack of social support and individual motivation to learn and manage health
behavior8.
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The problems with motivating individuals to change health-related behaviors are similar in
other populations. For example, Marcus et al.21 revealed that population-based interventions such
as media-based campaigns, aimed at increasing the public’s interest in initiating physical activity
have been ineffective in reaching large numbers of people. The authors speculate that the failures
are in part due to the educational rather than behavior and motivational focus of many
campaigns21. Furthermore, many exercise programs are designed for people who have decided to
begin exercise, yet a large proportion of individuals are simply not interested or ready to engage
in physical activity programs22. A general rule of thumb is that at any given moment, only about
20% of at-risk populations are ready to take meaningful action to change a health behavior and
40% of those with a problem are in a stage of change marked by denial and resistance23. This
reflects a mismatch between what is currently offered (action-oriented programs) and where
individuals might be regarding their readiness to change (i.e., sedentary and not interested in
exercise)24. Consequently, interventions should be tailored to the specific needs of the population
of interest. The following section will describe a theoretical framework for understanding
behavioral change.
•

The Transtheoretical Model of Health Behavior Change
The TTM provides a theoretical framework for assessing and addressing readiness for

changes in behavior. A strength of the model is its focus on the dynamic nature of health
behavior change, or understanding behavior change as a process rather than a single event23. The
use of the TTM originated in studies to treat addictive behaviors25, but has since been offered as
a coherent framework to help understand readiness to begin physical activity24. Additionally, the
TTM has been applied successfully to a wide variety of populations in the physical activity
domain26, 27, 28. Although only one study has utilized the TTM to assess readiness for behavior
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change in patients with heart failure7, currently there are no studies that have specifically
addressed physical activity behaviors using the TTM in patients with heart failure.
Understanding how the model works in patients with heart failure may yield insight into why
some patients are ready to engage in physical activity programs and others are not. Furthermore,
once the correct stage of an individual is identified more appropriate interventions can be
implemented to move a person along the continuum of physical activity behavior change.
The framework of the TTM consists of four core constructs (see Table 4.1): the stages of
change, processes of change, decisional balance, and self-efficacy23. It has been recommended
that interventions to increase physical activity participation be designed utilizing these
constructs29. Each construct will be briefly discussed in the following sections. Particular
attention will be given to the need to use these constructs in the heart failure population.
Table 4.1. Transtheoretical Model: Core Constructs
Construct

Description

Stages of Change

The five sequential stages involved in any behavior change

Processes of Change

Strategies and techniques that support the change process

Decisional Balance

The balance between perceived advantages and disadvantages of
behavioral change

Self-efficacy

Self-confidence in ability to perform and maintain new behavior in the
face of temptation

Stages of Change
The central construct of the TTM is the stages of change. The stage construct was developed
to reflect the temporal dimension of health-behavior change23. A change in behavior is viewed as
a 5-stage process that may progress in a linear fashion, but most often progresses in a cyclical
pattern, including relapse to previous stages, before the change becomes stable23. Five stages that
have been proposed within the TTM include: 1) Precontemplation; individuals in this stage are
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not intending to take action in the foreseeable future, usually measured as the next 6 months; 2)
Contemplation; reflects the intent to change within the next 6 months; 3) Preparation; indicates
the intent to change in the immediate future, usually measured within the next 30 days; 4)
Action; during which specific, overt modification in lifestyle has occurred within the past 6
months; and 5) Maintenance; maintenance of an overt behavior change for more than 6 months23.
Studies that have used the stage of change construct generally report greater success in terms
of adopting targeted behaviors. More specifically, research suggests physical activity
interventions targeted to stage of change are more effective than interventions not tailored to
stage of change21, 30. Currently, clinicians typically provide generic health advice to patients with
heart failure. Although literature suggests that it is not realistic to expect patients to make
changes that they are not prepared to make, little attention has been given to assessing the
motivation and readiness of patients with heart failure to make necessary behavioral changes7.
Therefore, knowledge of a person’s stage of readiness to begin regular physical activity could be
used to assist clinicians in developing targeted, effective behavior change interventions and to
guide strategies that go beyond traditional patient educational approaches12.
Self-efficacy
The self-efficacy construct originated with Bandura’s theory that successful change is based
on the degree of confidence an individual has in his/her ability to be physically active under a
number of specific circumstances31. Self-efficacy is positively associated with physical activity
behavior21 and motivational readiness for physical activity adoption27, 32. Additionally, many
studies have found that self-efficacy is the best predictor of physical activity behavior,
suggesting that improved self-efficacy leads to higher levels of physical activity26. Although
there have been no studies that have addressed this construct in heart failure patients, Hellman13
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utilized the TTM to determine that perceived self-efficacy was an important predictor of stage of
change and exercise adherence in a cardiac rehabilitation population.
The self-efficacy construct may be particularly important in the heart failure patient. Many
patients are somewhat fearful in engaging in activities that may bring on symptoms associated
with their condition. Thus information about their perceived self-efficacy for regular physical
activity may be particularly important for the clinician.
Decisional Balance
The decisional balance construct is based on the theoretical model of decision-making
developed by Janis and Mann33 and reflects an individual’s relative weighing of the pros and
cons, or benefits and costs, of changing behavior. The underlying assumption is that a person
will not decide to change behavior to begin an activity unless the pros of changing exceed the
costs of changing the behavior. Differences in decisional balance tend to correspond to different
stages of motivational readiness23. People in precontemplation stage perceive more barriers
(cons) than benefits (pros) to change, while those in the action stage perceive more benefits than
barriers34. Prochaska and colleagues34 studied twelve problem behaviors and noticed that for all
twelve behaviors, the cons of changing are more important than the pros for people in the
precontemplation stage. The opposite is true for people in the action stage in eleven out of twelve
behaviors. Additionally, across all twelve behaviors, the pros of changing always increase from
precontemplation to contemplation, whereas, the cons of changing always decrease from
contemplation to action35. Furthermore, the cross-over point for pros and cons for exercise
behavior was observed in the preparation stage34, and this finding has been replicated in recent
studies27, 28. Once more, there are currently no data available regarding decisional balance for
any behavior (including physical activity) in the heart failure patient.
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Processes of Change
Processes of change include strategies and techniques used to support efforts to progress
through the stages of change23. Ten distinct processes can be divided into 5 experiential
processes that are internally focused on emotions, values, and cognitions; and 5 behavioral
processes that are focused on behavioral changes23. Experiential processes include
consciousness-raising, dramatic relief, environmental reevaluation, social liberation, and selfreevaluation. Behavioral processes include counter-conditioning, helping relationships,
reinforcement management, stimulus control, and self-liberation (Table 4.2).
Table 4.2. Process of Change Descriptions for Physical Activity Behaviors
Experiential Processes
Consciousness raising
Dramatic relief
Environmental re-evaluation
Self re-evaluation
Social-liberation
Behavioral Processes
Counter-conditioning
Helping relationships
Reinforcement management
Self-liberation
Stimulus control

Description
Seek new information about exercise
Experience and express intense feelings about being inactive
Assess how being inactive affects physical and social environment
Re-appraise values regarding inactivity
Develop awareness and acceptance of active lifestyle
Description
Substitute alternative behaviors for sedentary activities
Use support from others to be more active
Changes contingencies; reward physical activity
Choose and commit to being more active; believe that change is
possible
Control situations and cues that support inactivity

The TTM posits that the use of specific processes varies by stage of change23. In general,
sedentary individuals, those in the earlier stages of motivational readiness (precontemplation,
contemplation), tend to place greater emphasis on cognitive processes, while regularly active
individuals, those in later stages of physical activity adoption tend to endorse more behavioral
processes26, 35. Moreover, use of behavioral processes of change has been shown to significantly
predict physical activity behavior36, and stage of motivational readiness for physical activity28.
Kosma and colleagues28 utilized the TTM constructs to examine the most important physical
activity stage of change predictors for mostly inactive adults with physical disabilities. Results
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revealed that the most important predictors were the behavioral (r2 = .88) and cognitive processes
(r2 = .50), followed by self-efficacy (r2 = .33), and decisional balance (r2 = .13). . These results
are consistent with findings for other populations26.
Furthermore, research has demonstrated that an integration of the stages and processes of
change can provide a useful guide for interventions21, 32. Once an individual’s stage has been
assessed, interventionists have a better idea of which processes to emphasize in order to facilitate
progress to the next stage of change24.
Table 4.3. Stages of Change in which Processes are most emphasized.
Stages of Change
Precontemplation Contemplation Preparation Action Maintenance
Processes
Consciousness Raising
Dramatic relief
Environmental
reevaluation
Self-reevaluation
Self-liberation
Contingency management
Helping relationships
Counter-conditioning
Stimulus control

With the appropriate activities to meet the heart failure patient’s stage of readiness for change,
healthcare providers may facilitate a patient’s movement along the continuum of change to alter
lifestyle behaviors, such as physical activity, that can result in improved outcomes13.
Summary of the Transtheoretical Model
The TTM consists of 4 distinct constructs. Careful examination and appreciation of these
constructs generally results in greater success in adoption of a targeted behavior, such as planned
physical activity. In a meta-analysis of eighty studies using the TTM in the physical activity
domain, no study was included that examined the TTM’s constructs among individuals with
heart failure26. Interestingly the majority of the guidelines for management of the heart failure
syndrome emphasize the need for using targeted behavioral strategies5, 6, 11. Therefore,
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considering the lack of data regarding the full TTM in patients with heart failure, and given the
success of the TTM for understanding physical activity behaviors in other populations, the TTM
has been identified as a potentially useful model for understanding the exercise behavior of
individuals with chronic heart failure10, 14. However, before the TTM is widely used for
intervention studies, its utility and relevance must first be examined within this population
segment.
•

Measure of Physical Activity
As stated above, a patient’s perception of his or her stage of readiness might not always

match the patient’s actual behavior14. Therefore, an actual assessment of physical activity should
also be included in order to compare the results of such assessments with the individual’s stage
of change27. The measurement of actual physical activity or exercise tolerance is difficult in
patients with heart failure. Numerous tools are available, for assessment of actual exercise
behavior such as activity logs or journals, accelerometers, symptom limited graded exercise tests,
and submaximal tests such as the 6-minute walk37. Each of these assessments has limitations and
flaws and may not be very representative of the patient’s actual physical activity behavior. One
of the better predictors of a patient’s functional ability, exercise tolerance and physical activity
behavior may be the maximum distance an individual can travel on a 6-min walk test37, 38.
Moreover, the 6-min walk test provides prognostic information about the heart failure patient and
appears to be sensitive to interventions such as exercise training. A recent review37 revealed that
the 6-min walk test is recommended as a useful, simple, noninvasive alternative for assessing
physical activity in patients with heart failure. There currently are no studies that have examined
the TTM constructs for physical activity behavior to an actual measure of exercise tolerance in
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patients with heart failure. Such data could potentially provide a better understanding of the links
between the TTM constructs and the patient’s physical activity behavior.
•

Clinical Relevance
There is clear evidence that implementation of a tailored heart failure educational program as

outlined by the Agency of Health Care Policy and Research is effective in improving
physiological and functional outcomes, as well as reduces hospitalization and associated health
care costs39. Despite this evidence a significant number of patients with heart failure do not
participate in such programs even when accessible. For example, our experience shows that from
a pool of approximately 250 heart failure patients we were only able to recruit 20 patients. This
is particularly disappointing given the fact we had an active recruiting program in place, which
was coordinated by a dedicated nurse clinician. Moreover, a major criticism of many large-scale
therapeutic trials in heart failure is that the characteristics of the heart failure population at large
are quite different from those being studied. This suggests there is a tremendous number of
patients with heart failure who are currently not being reached. Knowledge regarding factors that
may provide a better understanding of reasons that may prevent a patient from participation will
ultimately contribute to the development of improved strategies for inclusion.
4.2 Methods
•

Participants
One hundred and forty-eight patients with a diagnosis of heart failure were recruited from the

Baton Rouge, LA and Jackson, MS areas. Participants had to be at least 18 years of age, and be
on stable and optimal pharmacotherapy for their heart failure condition as determined by their
physician. In addition, participants had to have the ability to read and write English. Participants
were not excluded on the basis of gender, race, and/or etiology of heart failure. Exclusion criteria
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included individuals with acute medical conditions related or independent of the primary
diagnosis (e.g. congestive heart failure requiring hospitalization, unstable angina, active
infections etc.). Prior to participation, each individual was required to complete an informed
consent approved by the area Institutional Review Board.
•

Study Design
The study was a cross-sectional design aimed at examining the application of the full TTM

for physical activity in a group of individuals with chronic heart failure. Upon arrival to a
scheduled Cardiology appointment, each participant was asked at check-in if they would mind
completing information regarding physical activity behaviors and beliefs. If willing to
participate, the individual was given a folder containing all questionnaires to be completed for
the study, including stage of change, decisional balance, processes of change, self-efficacy, and
Daily Activity in Heart Failure Questionnaire (DAIHFQ). Additionally, each participant
underwent a six minute walk (6MW) test and a review of medical history and demographics.
Data were collected in one visit.
•

Experimental Measurements
Stage of Change
Each participant’s stage of change for physical activity adoption was assessed by the Stages

of Change for Physical Activity Questionnaire, using the algorithm recommended by Reed and
colleagues40. Specifically, participants were asked to indicate their present levels of physical
activity behavior. Regular physical activity or exercise was defined as “any planned physical
activity of moderate intensity (e.g., brisk walking, cycling, jogging, swimming, aerobics, etc.)
aimed at improving/ maintaining your health. The activity does not have to be painful to be
effective but should be done at a level that increases your breathing rate and causes you to break
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a sweat. For activity to be regular it must add up to a total of 30 or more minutes per day,
and be done at least 5 days per week. For example, you could take a 30 minute walk or take 3
ten minute walks each day.” Participants were asked to indicate whether they engage in planned
regular physical activity, according to the above definition, by marking one out of five
statements, each of which reflects one of the five stages: precontemplation: “I do NOT plan to
start regular physical activity in the next 6 months ”; contemplation (C): “I am planning to start
regular physical activity in the next six months”; preparation (P): Not regularly, but I engage in
such activities occasionally and plan to start on a regular basis within the next month; action (A):
“I have been physically active for LESS than six months”; and, maintenance (M): I have been
physically active for MORE than six months”. This staging measure is recommended as the
most accurate estimate for adults45, and the construct validity and test-retest reliability of this
methodology has received strong support in previous research41.
Processes of Change
The processes of change were assessed using a 30-item, five-point Likert scale designed
specifically for exercise36. Fifteen items assessed the behavioral processes of change (i.e.,
counter-conditioning, contingency management, helping relationships, self-liberation, and
stimulus control) and fifteen items assessed the cognitive processes of change (i.e.,
consciousness raising, dramatic relief, environmental reevaluation, self-reevaluation, and social
liberation). An example of a behavioral process is “Instead of relaxing by watching TV or
eating, I take a walk or do physical activity”; whereas, an example of a cognitive process is “I
read articles to learn more about physical activity”35.
Self-efficacy
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Self-efficacy was assessed using a six-item survey designed to measure confidence in one’s
ability to persist with exercising in various situations32. A sample item is, “I am confident I can
participate in regular physical activity when I am tired.” Participants responded to each item
using a five-point Likert scale (1 = “not at all confident,” 2 = “somewhat confident,” 3 =
“moderately confident,” 4 = “very confident”, and 5 = “completely confident”). Prior studies
have shown an alpha coefficient of this scale is 0.82 and scores have been shown to significantly
differentiate individuals at most stages of motivational readiness for physical activity
adoption26, 32.
Decisional Balance
Decisional balance was measured using a 10-item inventory assessing five perceived benefits
(pros) and five perceived barriers (cons) to physical activity participation42. Items were rated
using a five-point Likert scale with 1 being “not at all important” and 5 being “extremely
important”. This measure has been shown to have good internal consistency for both pros and
cons of physical activity participation, at .82 and .72, respectively42. The actual decisional
balance score was determined by subtracting the participant’s con score from the pro score (i.e.
pros-cons).
Six-Minute Walk Test
Exercise intolerance is defined as the reduced ability to perform activities that involve
dynamic movement of large skeletal muscles because of dyspnea or fatigue38. Exercise tolerance
was measured as the maximum walking distance achieved on a 6-min-walk test38. The sixminute walk test is recommended as a useful, simple, noninvasive alternative for assessing
physical activity in patients with heart failure. The test was performed in a corridor and
participants were instructed to walk as far as possible in 6 minutes, avoiding chest pain, marked
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dyspnea, or other symptoms44. To standardize the protocol, the participants were not coached
during the test, but made aware of time remaining to completion. The use of the six-minute walk
test has received a lot of attention recently, due to its relative ease of administration. The test is
also thought to reflect a realistic effort as performed in daily life, and appears highly acceptable
to patients38. Furthermore, several studies have reported the prognostic significance of the 6minute walk test in patients with heart failure43, 44.
Physical Activity Questionnaire
Garet et al. (2004) recently published a detailed self-administered questionnaire of daily
energy expenditure dealing with 7 dimensions of everyday life to better reflect habitual activities
in patients with heart failure45. To validate this questionnaire the investigators45 measured actual
VO2peaks and found it to be a valid and reliable reflection of physical activity status. The
original questionnaire was in French; therefore, in the present study a translation of the French
questionnaire was used. The translation was made with help of the original investigators of the
questionnaire. The questionnaire considers seven main areas including sleeping and resting,
basic everyday activities (e.g. eating and washing), housework activities, leisure time physical
activities, physical activity in salaried or voluntary work, moving about, and miscellaneous
activities. Subsequently, activities could be classified in terms of intensity, i.e. activities below 3
METs, between 3 and 5 METs, and above 5 METs, as well as duration (minutes performed)45.
Three response models were applied depending on the item. For example, participants reported
information pertaining to time spent on each activity, quantifying the number of times the
activity is done per week or day, and reported whether help or interruption was needed
systematically, sometimes, or never during an activity45. Detailed scoring instructions are
provided elsewhere64.
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•

Statistical Analysis
The Statistical Package for the Social Sciences (SPSS version 12.0, SPSS Inc., Chicago, IL)

was used for all data analysis. Descriptive statistics were performed to provide demographic
characteristics of the study participants. The first specific aim and respective hypotheses were
examined using a one-way MANOVA with Univariate F-tests to describe the general trend of the
associations among the constructs of the Transtheoretical model. Specifically, this includes the
associations between the stages of change (independent variable) and the other constructs of the
TTM (i.e., self-efficacy, decisional balance, and the cognitive and behavioral processes), which
serve as the dependent variables.
In terms of the second specific aim, a direct discriminant function analysis (DDF) was
conducted from which a classification matrix was generated46 to identify the most influential
predictors of exercise stage of change as well as overall prediction accuracy. Criterion for a
significant relationship between predictors and discriminant functions is >.3346. Finally, the
hypothesis associated with the final aim was tested using a univariate general linear model with
the maximum walking distance as the dependent measure and the stage of change constructs as
the independent measures. In addition, to examine the concurrent and construct validity between
the physical activity questionnaire and the six-minute walk test, simple correlation coefficients
and a multivariate general linear model with the categories of activity as the dependent measures
and stages of change as the fixed factor were used.
4.3 Results
•

Patient Characteristics
Patient characteristics are presented in Table 4.5 through 4.9. A total of 148 patients were

studied. Ninety eight participants were men, and fifty women. The mean age for the total group
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was 52±13 (years), the average left ventricular ejection fraction (LVEF) for the group was
31±11%. Etiology of heart failure included: ischemic heart disease (18.5%), non-ischemic
cardiomyopathy (20.0%), hypertensive heart disease (16.9%), pregnancy induced heart failure
(3.1%), viral induced heart failure (3.1%), heart failure related to cancer treatments (1.5%),
idiopathic cardiomyopathies (32.3%), and congenital heart failure (4.6%). The duration of heart
failure averaged just over 6 years, ranging from 2 months to 35 years. The majority of patients
were classified as New York Heart Association (NYHA) Class II (61%) and III (38%). One
patient was considered between a Class III and IV, and was included in the analyses. Forty-six
percent of the patients were married, 26% were separated/divorced or widowed, and the
remaining 28% of the participants were single or engaged. Sixty-five percent of the participants
were Caucasian, 34% were African-American, and 1% Hispanic. In regards to the level of
education 26% of participants did not have a high-school diploma, 57% did have at least a high
school diploma or equivalent, 13% had an earned bachelor’s degree, and 4% had an earned postbaccalaureate degree.
The majority of participants reported being in the preparation stage of change (n = 41,
27.7%), followed by contemplation (n = 33, 22.3%), maintenance (n = 29, 19.6%), action (n =
23, 15.5%), and precontemplation (n = 22, 14.9%). In regards to the stage of change
classification, no significant differences were noted for age, LVEF and heart failure duration (see
Table 4.5 and 4.6). Furthermore, as depicted in Tables 4.7 and 4.8, no differences in the stage
classifications for race, employment status, income level, education level, heart failure diagnosis,
number of co-morbidities and medications were observed. Therefore, these demographic
variables were not treated as moderators in subsequent analyses. However, there was a tendency
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for a greater percentage of women (75%) than men (60%) to be in the precontemplation and
contemplation stages of readiness (p=0.06).

Table 4.5 Descriptive Statistics (Age, Height, Weight, BMI)
Stage of Change

Age (yrs)

Height (m)

Weight (kg)

BMI (kg/m2)

Mean

SD

Mean

SD

Mean

SD

Mean

SD

Precontemplation

55

13

1.72

0.10

98.49

33.56

34

11

Contemplation

52

16

1.72

0.08

88.52

27.38

30

8

Preparation

50

13

1.74

0.09

105.14

32.99

35

11

Action

55

9

1.77

0.09

93.13

13.65

29

3

Maintenance

50

15

1.76

0.08

91.96

16.64

31

7

Total

52

13

1.75

0.10

95.28

26.43

31

10

Table 4.6 Descriptive Statistics (Hemodynamics)
Stage of Change

LVEF (%)

HR (bts/min)

SBP (mmHg)

DBP (mmHg)

Mean

SD

Mean

SD

Mean

SD

Mean

Precontemplation

35.58

12.83

74

12.74

130

22.91

73

14.93

Contemplation

29.80

12.55

75

19.37

115

26.99

71

18.99

Preparation

29.16

10.26

78

13.99

117

18.50

68

10.17

Action

31.35

7.07

74

11.70

110

15.90

70

6.85

Maintenance

29.84

11.79

76

11.42

121

8.51

69

6.69

Total

30.70

11.03

76

13.98

118

19.59

70

12.09

65

SD

Table 4.7 Test for Differences between Stages of Change: One Way ANOVA
Age (yrs)
Height (m)
Weight (Kg)

Sum of Squares
435.585
.039
3646.859

df
4
4
4

Mean Square
108.896
.010
911.715

F
.597
1.196
1.324

Sig.
.665
.318
.267

BMI
LVEF (%)
RHR (b/min)
SBP (mmHg)
DBP (mmHg)

476.563
377.627
122.191
1774.276
133.878

4
4
4
4
4

119.141
94.407
30.548
443.569
33.469

1.690
.769
.146
1.171
.215

.160
.548
.964
.335
.929

Table 4.8 Test for Differences between Stages of Change: Kruskal Wallis Test
Gender

Race

NYHA

Employ
Status

Income

Educ.

CHF

level

Level

Diagnosis

Comorbidities (#)

Med (#)

X2

9.027

2.157

5.204

.297

1.475

1.237

9.320

3.433

1.273

df

4

4

4

4

4

4

4

4

4

Sig

.060

.707

.267

.990

.831

.872

.054

.488

.866

Grouping Variable: Stage of Change
•

Hypotheses I-III
The MANOVA, used to examine the associations between the stages of change and the TTM

constructs, revealed a statistically significant relationship (F(20, 461) = 26.4; p < .001, η2 = .47)
between the stages of change (independent variable) and other constructs of the TTM (selfefficacy, decisional balance, behavioral and experiential processes) that served as the dependent
variables. The means, standard deviations, F-tests, variance explained (η2), and Tukey post hoc
contrasts of the follow-up ANOVAs for self-efficacy, decisional balance, and the cognitive and
behavioral processes of change across the five stages are shown in Table 4.9. Based on these
results, the behavioral processes of change explained most of the variance (η2 = .83), followed by
self-efficacy (η2 = .77), perceived pros (η2 = .62), perceived cons (η2 = .54), and experiential
processes (η2 = .53).
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Table 4.9 Descriptive Associations between the Constructs of the Transtheoretical Model
across the Stages of Change
Variable
N=148
N=

PC

C

PR

Stage of Change1
A
M
F4,143

22

33

41

23

η2

Tukey Contrasts

29

Perceived
Pros
M
SD

12.77
2.29

17.09
3.24

19.90
3.95

22.78
2.22

23.83
1.44

57.28*

.62

PC<C<PR<A,M

Perceived
Cons
M
SD

13.95
3.40

12.30
2.94

10.07
3.37

6.04
1.14

6.34
1.65

41.63*

.54

PC,C>PR>A,M

Experiential
Processes
M
SD

30.91
7.83

42.06
8.51

50.41
7.49

50.65
6.82

55.00
6.62

40.22*

.53

PC<C<PR,A,M

Behavioral
Processes
M
SD

22.32
5.07

30.91
7.18

40.17
5.99

57.39
5.75

60.59
7.42

170.72*

.83

PC<C<PR<A,M

8.50
2.55

11.55
3.42

14.83
3.58

22.39
2.14

23.52
2.74

120.92*

.77

PC<C<PR<A,M

Self-Efficacy
M
SD
1

PC = precontemplation, C = contemplation, PR = preparation, A = Action, M = maintenance
*p < .001
As depicted in Table 4.9, the general trend of the scores for the dependent variables
illustrates an increase from the lower to the higher stages in all variables except for perceived
cons. Specifically, individuals in the precontemplation stage had the lowest scores for selfefficacy, showed minimal use of the behavioral and experiential processes of change, and
perceived relatively fewer pros and higher cons than any other stage. Whereas, the participants in
the contemplation stage reported higher self-efficacy scores as compared to those in
precontemplation, were clearly using some experiential strategies, yet continued to report
relatively high perceived cons for exercise. In the preparation stage, individuals reported using
the behavioral processes of change more so than in the previous stages, along with advances in
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the use of the experiential processes of change, higher self-efficacy scores, the perception of
more pros to exercise, along with significantly fewer perceived cons to exercise as compared to
previous stages. Those individuals in the action stage reported higher self-efficacy scores and
extensive use of behavioral processes, whereas, the scores for experiential processes were similar
to those in the preparation stage. Decisional balance clearly favored the pros, with higher pros as
compared to previous stages and the cons diminishing to a lower level than any previous stage.
In the maintenance stage, participants continued to use the behavioral processes extensively, selfefficacy scores and perceived pros also remained high, experiential processes remained similar to
those in preparation and action stages, and perceived cons remained low and were similar to
those in the action stage.
In summary, based on the results of the general linear model multivariate procedure, the
hypotheses were generally supported. First, self-efficacy scores were lowest in the
Precontemplation stage and increased in linear fashion to maintenance (PC<C<PR<A, M).
Secondly, decisional balance shifted from greater perceived cons and lower perceived pros in the
precontemplation and contemplation stages to lower perceived cons and higher perceived pros in
the action and maintenance stages (Cons: PC,C>PR>A,M; Pros: PC<C<PR<A,M). Furthermore,
although both experiential and behavioral processes increased from lower to the higher stages, it
should be noted that scores for experiential processes were higher than behavioral processes in
precontemplation, contemplation, and preparation stages; whereas, the opposite was true for the
action and maintenance stages.
•

Predictors of the Stage of Change
A direct discriminant function analysis (DDF) was conducted to identify the most important

stage-of-change predictors based on the TTM constructs (perceived pros and cons, self-efficacy,
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and behavioral and experiential processes of change), which served as the independent variables.
The structure matrix for each discriminant function, along with canonical correlations,
eigenvalues, and % variance are shown in Table 4.11. Of the four discriminant functions
produced in the DDF analysis, the predictor variables were found to differentiate the stages of
change with two significant functions, which accounted for 95.0% (Wilks’ λ = .080, X2(20) =
358.76, p<.001) and 4.8% (Wilks’ λ = .705, X2(12) = 49.62, p<.001), respectively, of the
between-group (stage of change) variability. The a priori criterion for an accepted canonical
correlation was >.33 46. Thus, the third and fourth functions were neither statistically (p=.87 and
p=.72) nor practically (r2= .11 and r2 =.07) significant, respectively. Therefore, the focus was on
the first two discriminant function analyses and the other two were discounted.
As depicted in Table 4.10, the structure coefficients (i.e., correlation between each predictor
and the first discriminant function) revealed that the most important stage of change predictors
were the behavioral processes (r2= .78) and perceived self-efficacy (r2= .66), followed by pros
(r2= .44), cons (r2= -.38), and experiential processes (r2= .33). According to the functions at
group centroids (mean discriminant scores for each stage of change) (see Table 4.11 and Figure
4.1), these predictors contributed mostly in the discrimination between precontemplation and the
other four stages, as well as in discriminating contemplation and preparation from action and
maintenance. Furthermore, the second function revealed that the experiential process of change
(r2= .80) and the pros of decisional balance (r2=.48) distinguished those in the precontemplation
stage from contemplation and preparation, as well as those in the preparation stage from action
and maintenance.
The number & corresponding percentages of correctly classified cases within the five stages,
on the basis of predictors, and after weighing for different group sizes are shown in Table 4.14.

69

Table 4.11 Discriminant Function Structure Matrix
Predictor Variable
Function
1
2
3
.781*
.010
.245
Behavioral Processes
.657*
-.143
.234
Self-efficacy
.334
.800*
.417
Experiential Processes
-.384
- .002
.861*
Cons
.439
.476
.098
Pros
.78
.39
.01
Eigenvalue
95.0
4.8
.20
% Variance
95.0
99.8
99.9
Cumulative %
.94
.53
.11
Canonical correlation
.000
.000
.87
P
* Largest absolute correlation between each variable and any
discriminant function.
Table 4.12 Functions at Group Centroids
Function
Stage of Change
1

2

Precontemplation

-3.98

- .97

Contemplation

-2.19

.17

Preparation

- .42

.82

Action

3.13

- .52

Maintenance

3.62

- .20

6

Function 2

4

2

2
0

3

Group Centroids

45

1

M aintenance
Action
Preparation

-2

Contemplation
-4

Precontemplation
-6

-4

-2

0

2

4

6

Function 1

Figure 4.1 Canonical Discriminant Functions
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4
-.444
-.138
-.255
.290
.740*
.01
.10
100
.07
.72

Table 4.13 Correlation Matrix among the Predictor Variables for the Discriminant
Function Analysis

Pros
Cons
Experiential Processes
Behavioral Processes
Self Efficacy

Pros

Cons

1.00
.15
.39
.09
.04

1.00
.17
- .16
- .20

Experiential
Processes

Behavioral
Processes

Selfefficacy

1.00
.52
.17

1.00
.38

1.00

Results revealed that 34 individuals (82.9%) were correctly classified in preparation, 18 (81.8%)
in precontemplation, and 25 (75.8%) in contemplation, followed by 18 (62.1%) in maintenance
and 11 (47.8%) in the action stage. Overall, the probability of correct stage classification was
71.6%.
Table 4.14. Classification Results

Count

%

SOC
Precontemplation
Contemplation
Preparation
Action
Maintenance
Precontemplation
Contemplation
Preparation
Action
Maintenance

Predicted Group Membership
1
2
3
4
5
18
4
0
0
0
2
25
6
0
0
1
4
34
2
0
0
0
0
11
12
0
0
0
11
18
81.8
6.1
2.4
.0
.0

18.2
75.8
9.8
.0
.0

.0
18.2
82.9
.0
.0

.0
.0
4.9
47.8
37.9

.0
.0
.0
52.2
62.1

Total
22
33
41
23
29
100.0
100.0
100.0
100.0
100.0

a 71.6% of original grouped cases correctly classified.
•

Hypothesis IV
A total of 111 subjects were available to examine if the 6 minute walk distance is capable of

distinguishing the action and maintenance stages from the previous stages of readiness. No
significant differences were noted between the groups according to age, height, weight, and
LVEF. As indicated in Table 4.15, the average walking distance for the entire group was
349±118meters. The walking distance appears to increase dependent on the stage of change
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category. Indeed, as indicated in Table 4.16, the univariate general linear model analyses with
the 6 minute walk distance as the dependent measure and stages of change as the fixed factor,
revealed a significant main effect. Post hoc examination, using a Tukey test, indicates the
following differences (see Figure 4.2): The 6-minute walk distance for individuals in
precontemplation, contemplation and preparation stages appear to be similar, whereas the 6minute walk distance for the action and maintenance groups are significantly higher. Finally,
there does not appear to be a significant difference between the action and maintenance groups.
These findings suggest the 6-minute walk distance is capable of distinguishing the action and
maintenance stages from the previous stages of readiness and is in support of the stated
hypothesis.
Table 4.15 Descriptive Statistics: Maximum Walking Distance (Meters) on the 6-minute
Walk Test
Stage of Change
Mean Std. Deviation
n
297
137
12
Precontemplation
276
108
29
Contemplation
323
80
30
Preparation
401
87
20
Action
472
73
20
Maintenance
Total
•

349

118

111

Validity of the 6-minute walking distance
Stage of Change according to Estimated Exercise Capacity

To further examine the influence of the stage of change categories on exercise
tolerance/capacity, an estimated VO2peak was calculated from the 6-minute walking distance,
using a regression equation 47. The equation: VO2peak = 0.03 * 6-minute walking distance +
3.98 (r2 = 0.42 vs. actual VO2peak measures) was validated against actual VO2peak measures
and is based on the fact that the 6-minute walking distance is the best predictor of VO2peak47.
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Table 4.16 Tests of Between-Subjects Effects: Dependent Variable: 6-minute Walk
Distance
Source
Corrected
Model
Intercept
Stage of
Change

Type III
Sum of
Squares

Df

Mean
Square

F

Sig.

Partial
Eta
Squared

Noncentral
Parameter

Observed
Power

567212

4

141803

16

0.0001

0.371

63

1.000

12450284

1

12450285

1374

0.0001

0.928

1374

1.000

567212

4

141803

16

0.0001

0.371

63

1.000

Error

960766

Total

15016475

Corrected
Total

1527978

10
6

9064

11
1
11
0

Computed using alpha = .05; b r2 = 0.371 (Adjusted r2 = 0.347)

p

g y

6-minute walk distance (m)

600

*

500

*

400

300

200
Precontemplation

Preparation

Contemplation

Maintenance
Action

Stage of Change
Figure 4.2 Six-Minute Walk Distance per Category
Means and standard deviations for the estimated VO2peak are presented in Table 4.17 and
depicted in figure 4.3. Consistent with the analysis for the 6-minute walk distance there was a
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significant main effect for stage of change category (p=0.0004), and significant differences in the
means for VO2peak between the Action and Maintenance categories vs. the remaining three
categories. Importantly, the average estimated VO2peak for the Action and Maintenance groups
is above the prognostically relevant 14 ml/kg/min threshold (as indicated by the dashed line on
figure 4.3).
Table 4.17 Estimated VO2peak (ml/kg/min) per category
Stage of Change
Mean Std. Deviation
12.90
4.11
Precontemplation
12.24
3.22
Contemplation
13.66
2.40
Preparation
16.01
2.60
Action
18.15
2.199
Maintenance
14.44
3.54
Total

n
12
29
30
20
20
111

Stage of Change according to Daily Physical Activity
To examine the criterion validity between the physical activity questionnaire and the sixminute walk test, 78 data sets were available which allowed for simple correlation coefficients
and a multivariate general linear model with the categories of activity as the dependent measures
and stages of change as the fixed factor.
19

*

VO2peak (ml/kg/min)
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Stage of Change

Figure 4.3 Estimated VO2peak per Category
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Minutes of activity over 5 METs

100
80
60

Maintenance
Action

40

Preparation
20

Contemplation
Precontemplation

0

Total Population
Rsq = 0.3155

-20
0

100 200 300 400 500 600 700

Six-Minute Walk Distance (m)
Figure 4.4 Estimated Minutes of Physical Activity above 5 METs vs. 6-minute Walk Distance
Simple correlation coefficients revealed significant associations between the 6-minute walk
test and self-reported amount of minutes spent at rest (r = -0.27, p = 0.02), performing activities
between 3 and 5 METs (r = 0.52, p = 0.0009), and activities over 5 METs (r = 0.56, p = 0.0001).
A significant association was also seen between total minutes of daily physical activity and the
6-minute walk test (r = 0.32, p = 0.005). Interestingly, it appears from the scatterplot (see figure
4.4), that the amount of activity may be dependent on the patients stage of change.
On the basis of a multivariate general linear model with the categories of activity as the
dependent measures and stages of change as the fixed factor, a significant main effect was found
(p = 0.0005). Subsequent univariate tests revealed no differences between minutes at rest and
stage of change category, but significant differences for the other measures as indicated in Table
4.18 and 4.19. Figures 4.5a and b further highlight the observed differences between the stages
of change categories.
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Table 4.18 Minutes of Rest and Various Intensities of Physical Activity per Day
Variable

Mean

Std. Deviation

n

Rest Precontemplation
Contemplation
Preparation
Action
Maintenance

613
604
531
573
551

108
111
137
126
192

14
23
24
15
15

Total
Precontemplation
Contemplation
Preparation
Action
Maintenance
Total
Precontemplation
Contemplation
Preparation
Action
Maintenance
Total
Precontemplation
Contemplation
Preparation
Action
Maintenance
Total
Precontemplation
Contemplation
Preparation
Action
Maintenance
Total

572
820
995
1030
1133
1041
1008
684
879
907
927
824
855
73
107
111
186
180
128
2
8
13
20
37
15

137
224
223
339
341
393
315
230
201
277
312
299
269
86
61
101
86
121
99
7
13
14
14
27
19

91
14
23
24
15
15
91
14
23
24
15
15
91
14
23
24
15
15
91
14
23
24
15
15
91

Total Activity (min)

Minutes up to 3 METs

Minutes between 3 to 5 METs

Minutes above 5 METs

Stage of Change

Table 4.19: Univariate Tests for Activity categories and Stage of Change
Dependent
Variable
Rest
Total Activity
(min)
Minutes up to 3
METs
Minutes between 3
to 5 METs
Minutes above 5
METs

Sum of
Squares
95549
763952

df

F

Sig.

4
4

Mean
Square
23887
190988

0.281
0.100

Partial Eta
Squared
0.057
0.086

Noncent.
Parameter
5.155
8.041

Observed
Power
0.387
0.580

1.29
2.01

579684

4

144921

2.09

0.089

0.089

8.374

0.600

150391

4

37598

4.47

0.003

0.172

17.872

0.928

11267

4

2817

11.12

0.000

0.341

44.461

1.000
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Figure 4.5a Estimated Minutes of Physical Activity above 5 METs according to Stage of Change
*p < 0.05 vs precontemplation, contemplation, preparation, and action; †p < 0.05 vs.
precontemplation, contemplation, and maintenance; +p < 0.10 vs. precontemplation
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Figure 4.5b Estimated Minutes of Physical Activity between 3 and 5 METs according to Stage of
Change. *p < 0.05 vs. precontemplation, contemplation, and preparation
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•

Summary Section 4
In summary, these data indicate that the 6-minute walking distance is capable of

distinguishing individuals in the action and maintenance stages from the pre-action stages of
readiness. Furthermore, the data clearly indicate differences in the means for estimated VO2peak
between the action and maintenance categories vs. the remaining three categories. Uniquely, the
average estimated VO2peak for the action and maintenance groups is above 14 ml/kg/min, and
perhaps more importantly the estimated VO2peak is below this powerful prognostic indicator for
the pre-action stages. These data reveal significant associations between self-reported physical
activity and the 6-minute walk distance. Finally, the number of minutes at higher intensities of
physical activity is greater in individuals in the action and maintenance stages compared to the
pre-action stages of readiness.
4.4 Discussion
•

Patients Characteristics
Review of the available literature reveals very few studies, which have attempted to examine

the readiness for behavioral changes in patients with heart failure7,14. Consequently, it is difficult
to compare the patient characteristics in the present study to other studies. Perhaps the only study
of comparison is by Sneed and Paul (2003). In this study a mail survey was sent to patients with
heart failure7. Respondents were asked to select the stage of readiness for change in 6 lifestyle
behaviors important in management of the heart failure syndrome. Unfortunately, Sneed and
Paul (2003) did not examine the full TTM model among individuals with heart failure7. Despite
that, it is interesting to note the patient population in that study was remarkably similar to the
present study7. In general, their subjects were also relatively young (mean 55.6 years vs.
52±13yrs). Fifty-nine percent of the participants were Caucasian and 40% were African-
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American as compared to 65% Caucasian, 34% African American, and 1% Hispanic in our
study. Sixty-two percent were men and 38% women compared to sixty-six percent men and 34%
women in the present study. Fifty-nine percent of the patients were married and most had a high
school education; whereas, in the present study forty-six percent of the patients were married and
57% did have at least a high school diploma or equivalent. The duration of heart failure was
virtually the same as the present study (mean 6.5 years, range: 6 months to 35 years vs. 6 years,
range: 2 months to 35 years in our study).
Unfortunately the authors did not report the patients LVEF, etiology of heart failure, or
NYHA class, although it appears from a Specific Activity Scale that the patients ranged from a
Class I to IV, which appears to be a little more diverse than the patients in the present study.
However, it is not known how the Specific Activity Scale compares to the more widely used
NYHA classification.
Considering the present study also examined the association of the stage of change construct
for physical activity with actual measures of exercise tolerance (six minute walk test), and selfreported daily physical activity, a second comparison study is offered by Garet et al.(2004)45.
These investigators assessed the reproducibility, sensitivity, and concurrent validity of selfreported daily energy expenditure in a population of stable patients with heart failure. Their
population consisted of 105 Caucasian participants (mean age: 55.8±12.4 yr, range 31–80 years).
Mean left ventricular ejection fraction was nearly exactly as reported in the present study (LVEF:
33.2±6.1%). Interestingly the majority of the patients in the comparison study suffered from
dilated cardiomyopathy (66 patients) and ischemic cardiomyopathy (39 patients), which is
somewhat higher than the major etiology in the present study45.
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In summary, although few comparison studies are available, the present population
characteristics appear to be similar to published studies. Moreover, based on the available
guidelines for the management of heart failure, it would appear that the participants in this study
would be excellent candidates for heart failure intervention programs including exercise training.
Classification according to the TTM for stage of change reveals the majority of participants
in this study were in the preparation stage of change (n = 41, 27.7%), followed by contemplation
(n = 33, 22.3%), maintenance (n = 29, 19.6%), action (n = 23, 15.5%), and precontemplation (n
= 22, 14.9%). These findings are somewhat similar to a previous which examined the predictors
of exercise adherence and the validity of the Stages model among older adults (N = 349) with a
cardiac diagnosis (not heart failure) after discharge from a cardiac rehabilitation inpatient
program13. In that study, 16% of the patients were in precontemplation, 16% in contemplation,
22% in preparation, and 23% in both the action and maintenance stage13. In yet another study,
the theorized associations of the TTM of behavior change constructs were examined along with
exercise barriers, by stage of change for exercise behavior among individuals with physical
disabilities 27. In that study the majority of participants reported being in the maintenance stage
of change (53.7%), followed by precontemplation (18.9%), action (11.8%), contemplation
(9.0%), and preparation (6.5%) 27. One possible explanation for the greater number of
individuals classified in the maintenance stage in this comparison study 27 is the passive
recruitment method used by the authors, which tends to over-represent those individuals with an
interest in the subject matter. Other than differences in recruiting strategies, it is difficult to
reconcile the differences among studies, given the vast differences in terms of populations,
geographical location, and overall subject number. However, it is important to appreciate that in
the current study 65% of patients were in the pre-action stages of readiness to engage in a

80

treatment strategy known to be critical in the management of their disease. In fact, the present
data falls very much in line with the study by Sneed & Paul7 who reported only 38% of patients
with heart failure exercised regularly.
•

Hypotheses I-III
This study was unique in that it was the first study to examine the full TTM among

individuals with chronic heart failure. The first purpose of this study was to examine the
associations of TTM behavior change constructs (behavioral and cognitive processes of change,
decisional balance, and self-efficacy) and stage of change for planned regular physical activity
among individuals with chronic heart failure. It was hypothesized that 1) self-efficacy would
increase in linear fashion from precontemplation to maintenance; 2) the crossover point in
decisional balance scores would be observed in the preparation stage; and 3) experiential
processes would be utilized in the earlier stages; whereas, behavioral processes would be utilized
in the latter stages of change.
Based on the results of the one-way MANOVA, the hypotheses were generally supported.
First, self-efficacy increased across the stages of change in linear sequence, although differences
were not significant between the action and maintenance groups. These results suggest that
confidence to be active increases with advances in stage of change, as proposed by the TTM26.
Similar findings have been reported among individuals with a cardiac diagnosis13, and those
with27 and without26 disabilities. Thus, the conclusion from various studies and narrative reviews
that self-efficacy differentiates between individuals at most stages appears supported13, 24, 48, 49.
This is an important finding because the self-efficacy construct may be particularly relevant in
the heart failure patient. Many patients are somewhat fearful in engaging in activities that may
bring on symptoms associated with their condition. Thus, information about a patient’s perceived
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self-efficacy for regular physical activity may be particularly important for the clinician to guide
strategies for physical activity adoption.
Secondly, decisional balance shifted from greater perceived cons and lower perceived pros in
the precontemplation and contemplation stages to lower perceived cons and higher perceived
pros in the action and maintenance stage, which is consistent with TTM theory34 and previous
research49. Once again, this research is unique in that prior to this study there was no data
available regarding decisional balance for any behavior (including physical activity) in the heart
failure population. The underlying assumption of TTM theory is that a person will not decide to
change behavior unless the benefits (pros) of change exceed the costs (cons)23. Differences in
decisional balance tend to correspond to different stages of motivational readiness23, 34. Results
of this study support previous research which suggests that people in the precontemplation stage
perceive more barriers (cons) than benefits (pros) to change, while those in the action stage
perceive more benefits than barriers34. For example, patients in the early stages
(precontemplation and contemplation) endorsed such items as “I am too tired to get regular
physical activity because of my other daily responsibilities.” Additionally, these patients
perceived physical activity would take too much time, cost too much, or they would worry about
looking awkward. In contrast, patients in the advanced stages (action and maintenance) indicated
that physical activity would help them have a more positive outlook, control their weight, sleep
better, reduce tension or manage stress, and feel more confident about their health. These
findings are in line with Prochaska and colleagues34 who studied twelve problem behaviors and
noticed that for all twelve behaviors, the cons of changing were more important for people in the
precontemplation stage than the pros. The authors34 concluded the opposite was true for people in
the action stage in eleven out of twelve behaviors. These findings suggest that progress from
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precontemplation to contemplation involves an increase in the perceived pros (perceived
benefits) of physical activity; whereas, progressing from contemplation to action involves a
decrease in the perceived cons (barriers). This implies the increase in the pros followed by a
decrease in the cons should lead to a crossover in decisional balance across the stages of
change34. Consequently, it was hypothesized that the cross-over point (or “balance point”) for
pros and cons for physical activity behavior would be observed in the preparation stage, because
this finding has been observed in recent studies27, 28. Interestingly, results of this study revealed
the crossover occurred in the contemplation stage. It has been suggested that the stage in which
the crossover occurs is a function of how much and when the pros increase and how much and
when the cons decrease34. This implies that the strategies for moving patients from
precontemplation to contemplation, or toward thinking about physical activity must focus on
increasing perceived benefits; whereas, to move someone from contemplation to action, would
require a decrease in perceived barriers.
Another possible explanation could be the manner in which the preparation stage was defined
in the present study. The studies in which the crossover occurred in preparation, defined the
preparation stage with an intention to change behavior only. Based on recommendations from
previous research27, 28, 50, we defined the preparation stage as currently participating in planned
physical activity but less than the recommended guidelines AND an intention to engage in
planned physical activity at the target level within the next month. Therefore, the present data
reveal individuals in the preparation stage were engaging in some physical activity and
consistent with theory34, these individuals exhibited more pros and fewer cons than those in
previous stages. Consequently, consistent with the literature, the present data reveal the
crossover prior to the preparation stage.
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The clinical relevance of these findings suggests a systematic approach for changing the pros
and cons to facilitate progress from precontemplation to action. For example, initially the
intervention should first target increasing the perceived pros (benefits) of physical activity,
which should lead to progression from precontemplation to contemplation. Once progression to
the contemplation stage has occurred, the intervention should focus on decreasing the perceived
cons (barriers) to physical activity, while continuing to increase perceived pros. This should lead
to further progress from the contemplation to the action stage.
Lastly, as hypothesized, the experiential processes were used predominantly in the
precontemplation and contemplation stages, whereas behavioral processes were more
prominently used in the action and maintenance stages of change23. Specifically, scores for the
experiential processes of change increased in linear sequence from precontemplation to
preparation, before leveling off between preparation, action, and maintenance. The behavioral
processes increased linearly from precontemplation to action, and leveled off between action and
maintenance. This is consistent with theoretical predictions23, previous studies27, and narrative
reviews48 which indicate that behavioral processes peak during action and then level off during
maintenance. The lack of significance between action and maintenance suggests that efforts to
maintain physical activity habits do not require additional changes in behavioral and experiential
strategies 53a,b. Additionally, these data support previous research which reveals sedentary
individuals, those in the earlier stages of motivational readiness (precontemplation,
contemplation), tend to place greater emphasis on experiential processes, while regularly active
individuals, those in later stages of physical activity adoption tend to endorse more behavioral
processes26, 35.
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These results support previous studies which have demonstrated that an integration of the
stages and processes of change can provide a useful guide for interventions21, 32. The clinical
relevance of this work is that once an individual’s stage has been assessed, interventionists may
have a better idea of which processes to emphasize in order to facilitate progress to the next stage
of change24. Moreover, with the appropriate activities to meet the heart failure patient’s stage of
readiness for change, healthcare providers may facilitate a patient’s movement along the
continuum of change to alter lifestyle behaviors, such as physical activity, that can result in
improved outcomes13.
•

Predictors of the Stage of Change
The objective of specific aim two was to determine the most important predictors of physical

activity stages of change utilizing the constructs of the TTM among individuals with chronic
heart failure. This study is unique in that it is the first to have examined this in patients with
chronic heart failure. These data may provide clinicians with a greater understanding how to
‘move’ patients toward the action stages of behavior change. The results of this study are similar
to other studies that have used the full TTM to investigate the most important psychosocial
predictors of the exercise stages of change. For example, Cardinal et al. (2004) have used the full
TTM to investigate the most important predictors of the exercise stages of change among mainly
active adults with physical disabilities 27. In descending order of significance, the most important
predictors were behavioral processes of change, self-efficacy, cognitive (experiential) processes
of change, perceived pros, and perceived cons. In a similar study focusing on inactive adults with
disabilities 28, the behavioral processes of change also contributed mostly to the physical activity
stage of change distinction followed by the cognitive (experiential) processes of change, selfefficacy, and decisional balance. Further confirmation of this finding was found amongst
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university students where behavioral processes of change contributed to the stage-of-change
classification in the first function; whereas, the experiential processes of change and perceived
pros mostly contributed to the stage of change differences in the second function 50. Likewise, in
the present study, behavioral processes (r2= .78) were the most significant predictors, followed
by self efficacy (r2= .66), pros (r2= .44), cons (r2= -.38), and experiential processes (r2= .33).
These predictors contributed to the first discriminant function and were important in the
discrimination between precontemplation and the other four stages, as well as in distinguishing
individuals in contemplation and preparation from those in action and maintenance stages.
Furthermore, similar to previous results 50, the second function revealed that the experiential
process of change (r2= .80) and the pros of decisional balance (r2=.48) distinguished those in the
precontemplation stage from contemplation and preparation, as well as those in the preparation
stage from action and maintenance.
In contrast, in a study among older cardiac rehabilitation patients, slightly different results
were reported 13. In that study the authors concluded that self-efficacy was the most important
predictor, followed by perceived benefits of exercise (pros), perceived barriers to exercise (cons),
and interpersonal support for exercise 13. A possible reason for the differences in said study is
that predictors of stage of change in exercise adherence were examined in patients who were
recently discharged following a cardiac event. It could be argued these patients were more
concerned with issues of self-efficacy due to their recent events. Interestingly, other patients in
that study had, in fact, enrolled in cardiac rehabilitation. It could be argued that self-efficacy
scores would be higher for that subset of patients’ as well.
In summary, the behavioral processes of change appear to be the most important predictors
of physical activity stages of change among patients with chronic heart failure. Such results have
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been reported for individuals with27, 28 and without disabilities50, and university students3. These
results suggest that the behavioral processes as predictors may be similar across diverse
populations and conditions. In this study, self efficacy also contributed significantly for stage
prediction, followed by pros, cons, and experiential processes, reinforcing the use of all TTM
constructs for physical activity behavior change. It has been suggested that the experiential
(cognitive) processes of change were more important to inactive individuals than active
individuals, whereas, self-efficacy contributed more to active participants than inactive
participants. Clearly, more work needs to go into further understanding these constructs.
However, the clinical relevance of this work is that once an individual’s stage has been assessed,
interventionists may have a better idea of which processes to emphasize in order to facilitate
progress to the next stage of change. Moreover, with the appropriate activities to meet the heart
failure patient’s stage of readiness for change, healthcare providers may facilitate a patient’s
movement along the continuum of change to alter lifestyle behaviors, such as physical activity,
that can result in improved outcomes.
•

Classification Accuracy
Using the behavioral and experiential processes of change, self-efficacy, and the perceived

pros and cons to classify participants into their respective stage of change for physical activity,
the most reliably predicted stages were preparation (82.9%), precontemplation (81.8%),
contemplation (75.8%), followed by maintenance (62.1%), and action (47.8%). Overall, the
probability of correct stage classification was 71.6%. Relative to previous studies employing the
full TTM among different population segments, and using similar multivariate statistical
techniques, the overall prediction accuracy was similar to that reported by Cardinal and
colleagues27 in adults with physical disabilities (69.6%) but was slightly higher than other studies
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involving college students52, older adults53, and older adults with a cardiac diagnosis13, which
range from 50% to 64%. The enhanced classification accuracy observed in the present study
could be due to the fairly even distribution of individuals among the stages of change in this
study as compared to previous studies, the various methods of recruiting, or simply the relevance
of TTM for this population segment.
•

Hypothesis IV
A unique contribution of these data are the findings that the 6-minute walking distance is

capable of distinguishing individuals in the action and maintenance stages from the early stages
of readiness (precontemplation, contemplation). Moreover, using the 6-minute walking distance
to estimate VO2peak reveals that a greater majority of those individuals above 14 ml/kg/min are
in the action and maintenance categories. Perhaps more importantly these data suggest that the
majority of patients with heart failure in the early stages of readiness are below the 14 ml/kg/min
threshold, a powerful prognostic indicator of an increased likelihood of death or hospitalization
within 3 months to a year. Finally, these data suggest that individuals in the action and
maintenance stages perform a greater amount of physical activity, especially at higher intensities,
compared to the those in the early stages of readiness (precontemplation, contemplation).
The 6-minute walk test has been used as an outcome measure in clinical trials since 1988 54.
The test is a self-paced walk test, simple to administer, and because of the familiarity of the
activity is a measure of overall mobility and physical function. Importantly, the test carries
important prognostic information. The total group average for the maximum walking distance
(349±118meters) in this study appears to be quite typical for patients with heart failure, with a
NYHA Class II and III. For example, Opasich et al (2001) reported a maximum walking distance
of 396±92meters in 315 chronic heart failure patients (age: 53±9 years, NYHA class: II (182), III
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(133)) 55. More importantly, based on the literature indicating that a maximum walking distance
less than 300 meters is associated with an increased likelihood of early mortality47,56-58; the
results of the present study suggest many of the patients are at elevated risk for complications. In
fact, 36% of all the participants in this study scored below the 300 meter threshold. Interestingly,
patients who scored below 300m on the 6-minute walk test were not different from the patients
scoring above 300m, in terms of age, BMI, LVEF, resting blood pressure and heart rate. In
addition, no differences were noted for race, employment status and income, etiology, and length
of heart failure, comorbidities, or number of medications. One interesting observation in the
present study is that a greater percentage of women scored below the 300 meter threshold.
Given the evidence that the distance of < 300 m also identifies women at high risk of death 58,
this requires further examination and focus from a clinical perspective. A further important
observation is that the average age for the women in this study was significantly lower than the
men, yet their average maximum walking distance (MWD) was much lower as well.
Unfortunately, these findings can not be explained by the available information concerning the
clinical status of the patients in this study, but this should certainly receive greater attention in
future studies.
Generally, the validity of the 6-minute walk test has been investigated through the
comparison against a “gold-standard” functional capacity test 59. Usually the “gold-standard” test
for this comparison has been a maximal exercise test with or without gas analyses on a treadmill
or cycle ergometer. To date 28 such studies are available, and are extensively reviewed
elsewhere 59. For the most the comparison studies reveal moderate to strong correlations
between the 6-minute walk test and VO2peak obtained through exercise ergometry (treadmill or
cycle) 56. The consistent findings that the 6-minute walk test is a good estimate of functional
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capacity have led to several multivariate equations that allow estimation of the VO2peak. In the
present study, the equation developed by Cahalin et al. (1996) was used to estimate the VO2peak
of this cohort 47. The rationale for this selection was that the present study population was similar
to those in the aforementioned study 47, and the fact that the simple equation: VO2peak = 0.03
(MWD) + 3.98, was able to account for nearly 45% of the variance in that study. In this study the
average VO2peak was 14.42±3.52 ml/kg/min. The average estimated VO2peak in this study are
similar to many studies that have examined NYHA Class II and III heart failure patients. This
average is particularly relevant given the evidence in the literature that individuals below 14
ml/kg/min have a much poorer prognosis in terms of survival compared to those above this
threshold 60-62. In fact, even today the threshold is an important factor, considered clinically,
when evaluating heart transplant candidates 63. In other words those individuals that drop below
the threshold of 14 ml/kg/min are immediately moved up on the transplant lists, as their
immediate risk for mortality increases exponentially. In the present study 50% of patients are
below the threshold score. Again the data indicate a gender difference in that approximately 62%
of the women and 47% of the men are below 14 ml/kg/min.
In recent publications by a group of French investigators, a detailed self-administered
questionnaire, specifically for the heart failure patient, was used to examine daily energy
expenditure 45,64. The questionnaire deals with 7 dimensions of everyday life to provide a picture
of habitual activities. The questionnaire was compared against actual VO2peak measures and it
was found it to be valid and reliable. In the present study a translation of the French
questionnaire was used. The translation was made with help of the original investigators of the
questionnaire and with some modifications was implemented in the study. Most of the
modifications dealt with exchanging activities that were more appropriate choices for the present

90

study population. Recognizing that this approach may require further modifications and
improvements, the data did allow further comparison to the functional scores. The findings
revealed significant associations between the 6-minute walk test and the self-reported amount of
minutes spent at rest (r = -0.27, p = 0.02), performing activities between 3 and 5 METs (r = 0.52,
p = 0.0009), activities over 5 METs (r = 0.56, p = 0.0001). Moreover, a significant association
was apparent between the total minutes of physical activity performed throughout the day, and
the 6-minute walk test (r = 0.32, p = 0.005). This is the first study to report these associations
using a submaximal performance test. In comparison to previous work 45 the reported
associations are somewhat lower. The discrepancy may in part be a consequence of the
questionnaire modifications, or the fact that the 6-minute walk test was used. Irrespective of
those possibilities, the findings are intriguing and suggest the questionnaire is able to
differentiate between patients who score high or low on the 6-minute walk test. Interestingly, the
patients in the present study had lower estimated VO2peak values, then their French counterparts.
In addition, the patients in this study performed fewer activities above 5 METs and had slightly
lower overall energy expenditures over the course of the day. It is difficult to reconcile these
differences as the American patients were similar in terms of age, gender, LVEF, NYHA class,
and etiology of disease. However, there are apparent differences in terms of weight and BMI,
with the American cohort heavier (American Cohort: 95.28±26.43; French Cohort: 74.80±15.00)
and with a greater average BMI (American Cohort: 31.68±8.53; French Cohort: 25.08±4.00).
Unfortunately, failure to show an association between weight and BMI and the 6-minute walk
test and estimated energy expenditures, in the present study, does not allow for a real
appreciation of these apparent differences compared to previous studies 45,64.

91

In summary, the present data compare favorably to a number of studies which have used the
6-minute walk test to examine functional capacity in patients with heart failure. In addition to the
risks associated with the heart failure diagnosis, a large number of patients appear to be at even
greater risk for hospitalization and mortality, secondary to their low scores on the 6-minute walk
test, and subsequent estimated VO2peak. In addition, these data reveal significant associations
between measures of functional ability and a valid physical activity questionnaire for patients
with heart failure. Finally, patients in this study appear to spend fewer minutes performing
activities above 5 METs and overall physical activity throughout the day compared to a similar
study 45,64.
In regards to Hypothesis IV, it was predicted that the maximum walking distance would be
capable of distinguishing the action and maintenance stages from the precontemplation and
contemplation stages of readiness. As indicated in Table II, the univariate General Linear Model
analyses with the 6 minute walk distance as the dependent measure and stages of change as the
fixed factor, a significant main effect was revealed. Figure 1 shows that indeed the action and
maintenance stages were different from the precontemplation and contemplation stages of
readiness. Closer observation of these data reveal that the majority of patients in the action and
maintenance stages were in fact above the 300meter, and 14 ml/kg/min threshold, compared to
the majority of patients in the early stages (i.e., precontemplation, contemplation) who were
below these clinically important cut-offs. More specifically, 51% and 71% of patients in the
precontemplation stages were below the 300meter, and 14 ml/kg/min threshold compared to only
7.5% and early stages were in NYHA class III (precontemplation, contemplation, preparation)
47% vs. action/maintenance: 25% (p < 0.05), were women (early stage: 40% vs.
Action/Maintenance: 21%, p < 0.05), and had LVEFs below 30% (Pre-contemplation,
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contemplation, preparation: 56% vs. Action/Maintenance: 45%). Finally, those in the pre-action
stages reported fewer minutes of daily activity (Pre-action: 977±288min vs. Action/Maintenance:
1087±365min, p < 0.10), and activities above 5 METs (Pre-action: 11±23min vs.
Action/Maintenance: 29±23min, p < 0.05), then the patients in the Action and Maintenance
stages.
These data suggest that those in the early stages are clinically more fragile, are less involved
in daily physical activities and are women. The importance of this information obviously lies in
the fact that specific strategies need to be developed to move patients in these pre-action stages
toward the Action stage. This study is the first to identify individuals who may need more
specific behavioral strategies as part of their disease management. Clearly future studies should
continue to identify these patients and develop these strategies in clinical practice.
•

Clinical Relevance
Careful examination and appreciation of the TTM constructs generally results in greater

success in adoption of a targeted behavior, such as planned physical activity. In a meta-analysis
of eighty studies using the TTM in the physical activity domain, no study was included that
examined the TTM’s constructs among individuals with heart failure26. Interestingly the majority
of the guidelines for management of the heart failure syndrome emphasize the need for using
targeted behavioral strategies5, 6, 11. Therefore, considering the lack of data regarding the full
TTM in patients with heart failure, and given the success of the TTM for understanding physical
activity behaviors in other populations, the TTM has been identified as a potentially useful
model for understanding the exercise behavior of individuals with chronic heart failure10, 14.
However, before the TTM is widely used for intervention studies, its utility and relevance must
first be examined within this population segment.
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This study is unique in that the full TTM was evaluated in a group of patients with chronic
heart failure. It is anticipated that this information will greatly facilitate the further development
of even more effective heart failure programs. For example, research has demonstrated that an
integration of the stages and processes of change can provide a useful guide for interventions21,
32

. More specifically, knowledge of an individual’s self efficacy, decisional balance, and stage of

readiness to begin regular physical activity could be used to assist clinicians in developing
targeted, effective physical activity interventions and to guide strategies that go beyond
traditional educational approaches for individuals with chronic heart failure. Furthermore,
knowledge regarding factors that prevent a patient from participation may ultimately contribute
to a better understanding of the reasons for noncompliance and to the development of improved
strategies for physical activity promotion in patients with heart failure.
Finally, this study suggests that the stage of change algorithm aids in the identification of
patients with heart failure at increased risk for complications and early mortality. Consequently,
‘moving’ patients toward the action stages may ultimately contribute to the well-being of the
patient and perhaps have an impact on health-care costs associated with this disease.
•

Limitations
In considering the findings of this study, it is important to keep the following limitations in

mind. First, as mentioned previously, this was a cross-sectional design and therefore
developmental trends in stage of change cannot be observed. Future studies should include
longitudinal designs in order to examine the stability of various physical activity predictors
across time. Secondly, although the defined level of physical activity appears appropriate for
patients in this study, the exercise prescription must be something that is feasible for the
population and the best prescription for physical activity in patients with heart failure has yet to
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be determined. Additional research may be warranted to determine the most appropriate activity
levels for more diverse groups of patients.
4.5 Conclusion
In conclusion, this is the first study to examine stage of change for physical activity in
patients with heart failure on the basis of the full TTM. The data reveal that despite the fact that
participants in the study would be excellent candidates for heart failure intervention programs
including exercise training, only 35% of patients are actively engaged in planned physical
activity as recommended by the AHA. Thus, 65% of patients were in the pre-action stages of
readiness to engage in a treatment strategy known to be critical in the management of their
disease.
The stage of change algorithm revealed 22 patients in precontemplation, 33 in contemplation,
41 in preparation, 23 in action, and 29 in maintenance. In regards to the TTM constructs (selfefficacy, pros and cons of decisional balance, and experiential processes) the data revealed that
self-efficacy scores were lowest in the precontemplation stage and increased in linear fashion to
maintenance. Decisional balance changed from greater perceived cons and lower perceived pros
in the precontemplation and contemplation stages to lower perceived cons and higher perceived
pros in the action and maintenance stage. Experiential processes were used predominantly in the
precontemplation and contemplation stages, whereas behavioral processes were more
prominently used in the action and maintenance stages. These findings are similar to available
literature among patients with a cardiac diagnosis (not heart failure), and those with and without
disabilities. Therefore, these data support the external validation of TTM to a unique and
understudied population segment.
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In addition, this study aimed to determine the most important predictors of physical activity
stages of change utilizing the constructs of the TTM. Findings revealed that the most important
stage of change predictors were the behavioral processes (r2= .78) and perceived self-efficacy
(r2= .66), followed by pros (r2= .44), cons (r2= -.38), and experiential processes (r2= .33).
The clinical relevance of this work is that once an individual’s stage has been assessed,
interventionists may have a better idea of which processes to emphasize in order to facilitate
progress to the next stage of change. Moreover, with the appropriate activities to meet the heart
failure patient’s stage of readiness for change, healthcare providers may facilitate a patient’s
movement along the continuum of change to alter lifestyle behaviors, such as physical activity,
that can result in improved outcomes.
Finally, data from this study indicate that patients in pre-action stages of readiness to exercise
have significant lower exercise tolerance/capacity then those in the action and maintenance
stages. In fact, over 50% of patients in pre-action may be at even greater risk for complications
and early mortality secondary to scoring <300 meters on the six-minute walk test and having an
estVO2peak of <14 ml/kg/min. Moreover, patients in the pre-action stages have significant lower
daily energy expenditures. These data suggest greater clinical emphasis should be placed on
strategies to move patients toward the action and maintenance stages of readiness.
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CHAPTER 5. SUMMARY
5.1 Summary
The overall goal of the research conducted was to gain a greater understanding regarding the
management of patients with heart failure. A particular focus of the research projects was to
evaluate exercise tolerance and to examine exercise behavior. The rationale for this focus is
evidence that the clinical phase of heart failure includes a marked decline in functional state, as
defined by exercise tolerance and capacity with a subsequent decrease in quality of life.
Moreover, there is growing evidence that exercise training reverses many of the peripheral
abnormalities present in the heart failure patient1. These improvements translate in an increased
exercise tolerance, reduction in activity-related symptoms, and improved quality of life. Perhaps
most importantly, exercise training improves survival, reduces health care costs and rehospitalization in patients with chronic heart failure2. Unfortunately, despite this evidence
patient participation and adherence in these types of programs remain suboptimal.
Chapter 2 indicated that despite the overwhelming evidence of the benefits of exercise for
patients with heart failure, patients are not receiving adequate information regarding physical
activity. Furthermore, Chapter 2 also showed that measures of exercise tolerance and quality of
life were significantly lower for the patients with heart failure compared to age-matched controls.
Finally, some preliminary data indicated that a very basic home exercise program with frequent
patient contact resulted in modest improvements in exercise tolerance and perceived quality of
life.
Chapter 4, in part, evolved from failure to adequately recruit from the available heart failure
pool for projects 1 and 2. In fact, it appeared that many patients just did not want to make
behavior changes. Thus, Chapter 4 assessed the motivation and readiness of patients with heart
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failure to make necessary behavioral changes to aid in the management of their condition. The
findings revealed that only 35% of patients were actively engaged in planned physical activity as
recommended by the American Heart Association. Thus, 65% of patients were in the pre-action
stages of readiness to engage in a treatment strategy known to be critical in the management of
their disease. More specifically, the stage of change algorithm revealed 22 patients in
precontemplation, 33 in contemplation, 41 in preparation, 23 in action, and 29 in maintenance.
Further analyses revealed that self-efficacy scores were lowest in the precontemplation stage and
increased in linear fashion to maintenance. Decisional balance changed from greater perceived
cons and lower perceived pros in the precontemplation and contemplation stages to lower
perceived cons and higher perceived pros in the action and maintenance stage. Experiential
processes were used predominantly in the precontemplation and contemplation stages, whereas
behavioral processes were more prominently used in the action and maintenance stages. These
findings are similar to available literature among patients with a cardiac diagnosis (not heart
failure), and those with and without disabilities3-5. Therefore, these data support the external
validation of the Transtheoretical model to a unique and understudied population segment.
In addition, this study aimed to determine the most important predictors of physical activity
stages of change utilizing the constructs of the Transtheoretical model. Findings revealed that the
most important stage of change predictors were the behavioral processes and perceived selfefficacy.
Finally, data from this study indicated that patients in pre-action stages of readiness to
exercise have significant lower exercise tolerance/capacity then those in the action and
maintenance stages. In fact, over 50% of patients in pre-action may be at even greater risk for
complications and early mortality secondary to scoring <300 meters on the six-minute walk test
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and having an estVO2peak of <14 ml/kg/min6,7. Moreover, patients in the pre-action stages have
significant lower daily energy expenditures. These data suggest greater clinical emphasis should
be placed on strategies to move patients toward the preparation and action stages of readiness.
The clinical relevance of this work is that once an individual’s stage has been assessed,
interventionists may have a better idea of which processes to emphasize in order to facilitate
progress to the next stage of change. Moreover, with the appropriate activities to meet the heart
failure patient’s stage of readiness for change, healthcare providers may facilitate a patient’s
movement along the continuum of change to alter lifestyle behaviors, such as physical activity,
that can result in improved outcomes. In a meta-analysis of eighty studies using the
Transtheoretical model in the physical activity domain, no study was included that examined the
Transtheoretical model constructs among individuals with heart failure4. Interestingly the
majority of the guidelines for management of the heart failure syndrome emphasize the need for
using targeted behavioral strategies8-10. Considering this is the first study to have examined the
full Transtheoretical model in patients with heart failure, this study is unique and its findings
could greatly facilitate the further development of even more effective heart failure programs.
For example, research has demonstrated that an integration of the stages and processes of
change can provide a useful guide for interventions11, 12. More specifically, knowledge of an
individual’s self efficacy, decisional balance, and stage of readiness to begin regular physical
activity could be used to assist clinicians in developing targeted, effective physical activity
interventions and to guide strategies that go beyond traditional educational approaches for
individuals with chronic heart failure. Furthermore, knowledge regarding factors that prevent a
patient from participation may ultimately contribute to a better understanding of the reasons for
noncompliance and to the development of improved strategies for physical activity promotion in
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patients with heart failure. Finally, this study suggests that the stage of change algorithm aids in
the identification of patients with heart failure at increased risk for complications and early
mortality. Consequently, ‘moving’ patients toward the action stages may ultimately contribute to
the well-being of the patient and perhaps have an impact on health-care costs associated with this
disease.
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APPENDIX A. INFORMED CONSENT
CONSENT TO PARTICIPATE IN RESEARCH
The University of Mississippi Medical Center
Study Title:
Examination of the Constructs of the Transtheoretical Model in Patients with Heart failure: A Focus on
Physical Activity Readiness
Principal Investigator: Charles K. Moore, M.D.
Co-investigators: Michael A. Welsch, Ph.D., Tracie Parish, M.Ed., ATC/L
_____________________________________________________
Introduction: Heart failure is a significant health problem in the United States. Patients with this
condition are often hospitalized, and complain of chronic fatigue and can not perform many of the normal
daily activities. You are being invited to be in this study, because you have been diagnosed with heart
failure. Please ask us about anything in this document or that we tell you that you do not understand.
Purpose: The purpose of the study is to learn about reasons why some patients with heart failure do not
participate in certain behaviors known to help in controlling the heart condition.
Procedures: If you agree to participate in this study, you will be asked a series of Behavioral and
Knowledge questions which will give us information about your current behaviors such as your daily
physical activity. The questions will be given to you during one visit. In addition, you will be asked to
perform a 6 minute walking test, at a pace that is comfortable to you. We expect that it will take
approximately one hour to answer the questions and perform the walking test.
Risks: The risks associated with this study are very small and mostly involve risks during the 6-minute
walk test. The risks associated with the walking test are muscle soreness, stiffness or tightness, or in some
rare cases more severe problems such as chest pain, shortness of breath or cardiovascular complications.
Benefits: You may or may not receive a direct benefit from being in this research study. In identifying
your readiness to participate in heart healthy behaviors, we may be able to provide you with more
appropriate information that will help you understand how to stay healthy given your condition. We also
hope to learn information that may help others in the future.
Alternatives: This is not a treatment study and the only alternative is to not participate in the study.
Costs: There will be no additional costs to your participation in this study. In the case of injury or illness
resulting from your participation in this study, medical treatment is available to you at the University of
Mississippi Medical Center. You will be charged the usual and customary charges for any such treatment
you receive.
Compensation: You will not be paid for participating in this study.
Voluntary Participation and Withdrawal: Your participation is voluntary. If you decide not to
participate in this study you will not suffer a penalty or loss of benefits to which you are otherwise
entitled. If you decide to participate in this study you may discontinue your participation at any
time, without penalty or loss of benefits and it will have no effect on the quality of your medical
care, academic standing, job status, etc. (whatever phrase is appropriate).
108

Confidentiality: Every effort will be made to keep the information we learn about you private.
Study personnel, the Food and Drug Administration (FDA), the Office for Human Research
Protections (OHRP) and the University of Mississippi Medical Center’s Institutional Review
Board (IRB) and Office of Compliance may review the study records. If study results are
published your name will not be used.
Protected Health Information: Protected health information is any personal health information
through which you can be identified. The data collected in this study include your medical
history and information from the questionnaires and walking test. A decision to participate in this
research means that you agree to the use of your health information for the study described in this
form. This information will not be released beyond the purposes of conducting this study. The
information collected for this study will be kept until the study is complete. While this study is
ongoing you may not have access to the research information, but you may request it after the
research is completed.
Number of Participants: We expect about 200 participants to enroll in this study.
Questions: If you have questions about this study you may discuss your rights as a research
participant with the Chairman of the University of Mississippi Medical Center’s Institutional
Review Board, 2500 North State Street, Jackson, Mississippi 39216; telephone, 601 984-2815;
facsimile, 601 984-2961. The Institutional Review Board is a group of people not involved with
this study who have reviewed the study to protect your rights.
Statement of Participation: Your signature indicates that you have decided to participate after
having read the information provided above.
You will be given a copy of this consent document for your records.
SIGNATURES
By signing this form I am not waiving any legal rights I may have.
___________________________________________________________
Participant’s Printed Name
Date/Time
___________________________________________________________
Signature of Participant
Date/Time
___________________________________________________________
Printed Name of Person Obtaining Informed Consent
Date/Time

___________________________________________________________
Signature of Person Obtaining Informed Consent
Date/Time
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I acknowledge that the participant identified above has been entered into this study, with properly
obtained informed consent.
________________________________
Signature of Principal Investigator
________________________________
Date*
*Absent extenuating circumstances, the investigator’s signature should be obtained within 48
hours of the participant’s signature.
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INTRODUCTION
Heart failure (HF) is defined as the pathophysiological state in which an abnormality of cardiac
function is responsible for failure of the heart to pump blood at a rate commensurate with the
requirements of the metabolizing tissues, or to do so only from an elevated filling pressure
(Braunwald, 1988). Heart failure is not a homogenous disease. Rather, it is the final common
pathway of several other disorders that impair the heart’s pumping ability (Pernenkil, Vinson, et
al., 1997). Coronary artery disease is the cause of HF in about two thirds of patients with left
ventricular systolic dysfunction (Gheorghiade, Bonow, 1998). Other causes of HF are associated
with a nonischemic cardiomyopathy, which may result from long-standing hypertension, a toxinrelated illness (e.g., alcohol), a systemic illness affecting the heart (e.g., thyroid disease),
valvular disease, myocarditis, or idiopathic causes. Finally, heart failure could be the result of
underlying pericardial disease (Hunt, Baker, Chin, et al., 2001).
The insult to the cardiovascular system is frequently met with a variety of compensatory
adaptations with short- to long-time constants aimed to maintain cardiac output and arterial
pressure to adequately perfuse the brain and the heart. These compensatory adaptations include
(1) an increase in ventricular end-diastolic volume and pressure (ventricular dilatation); (2)
sympathetic nervous system activation; (3) neurohumoral vasoconstriction; (4) renal sodium and
water retention; (5) myocardial hypertrophy; (6) impaired vasodilatory capacity; and (7) intrinsic
changes in skeletal muscle. Although, these compensatory adaptations may be remarkably
effective under resting conditions, the capacity to sustain cardiac performance in the face of
hemodynamic overload relative to myocardial contractility is finite and exacts a price (Zelis,
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Sinoway, Leuenberger, et al., 1991). In fact, it is those compensatory mechanisms that
ultimately contribute significantly to the clinical severity of the disease.
The purpose of this review is twofold: (1) to describe the compensatory adaptations to
heart failure, with the focus on the morphological, biochemical, cellular, and neurohumoral
changes characteristic of heart failure and how these relate to the exercise tolerance, a marker of
the clinical severity of the disease, (2) to examine currently available strategies to manage the
heart failure patient, with specific focus on the need for multidisciplinary programs.
HEART FAILURE STATISTICS
An estimated 4.9 million Americans have heart failure, a chronic condition associated
with frequent hospitalizations, widespread functional impairment, and a high mortality rate. Each
year, approximately 550,000 new cases are diagnosed and nearly 300,000 patients die of heart
failure as a primary or contributory

cause

(AHA Heart & Stroke Facts, 2003).
Elderly individuals are particularly at

risk

for developing heart failure. In fact, HF

is the

most common hospital discharge
diagnosis for patients over 65 years. The
syndrome is the underlying reason for
15 million office visits and 6.5 million

12 to
Figure 1. Hospital Discharges for Congestive Heart Failure

hospital days each year (O’Connell &
Bristow, 1993). Furthermore, during the last 10 years, the annual number of hospitalizations has
increased from approximately 550,000 to nearly 900,000 for HF as a primary diagnosis and from
1.7 to 2.6 million for HF as a secondary diagnosis (Haldeman, Croft, et al., 1999). In addition to
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the substantial morbidity and mortality associated with this condition, there is a significant
financial impact on our society. In fact, heart failure is now the single most costly cardiovascular
illness in the United States, with total treatment costs estimated at $24.3 billion (AHA Heart &
Stroke Facts, 2003). The cost to society is expected to increase due to an aging population and
prolonged survival rates of individuals with cardiovascular disease, therefore imposing a large
burden on individuals and the healthcare system (Bourassa, Gurne, & Bangdiwala, et al., 1993).
THE HEART IN HEART FAILURE
Following partial destruction of the myocardium, and/or a pressure or volume overload, the
heart uses a series of short- to long-term adaptive strategies to maintain cardiac output
compatible with survival. Within seconds to minutes of a reduction in stroke volume, an
increase in venous return and inotropic state can cause ventricular dilation and increased
myocardial contractility (Ross, 1976).
Ventricular dilatation and myocardial contractility
Ventricular dilatation is the result of adaptive lengthening of the non-infarcted
sarcomeres (Pfeffer, M.A., & Braunwald, E. 1987) or may develop secondary to expansion of an
infarcted zone (Hutchins et al., 1978). This adaptive strategy aims to restore cardiac output
through the Frank-Starling mechanism despite a loss in contractile function (Starling, 1895). If
the preload reserve is inadequate to maintain cardiac output, activation of the sympathetic
nervous system results in an increase in myocardial contractility. Sympathetic activation causes
stimulation of beta-receptors and intracellular second messenger systems.
Unfortunately, stretching of the sarcomeres to a more optimal length is an adaptive
strategy that is easily pushed to the maximum, increases wall stress (and therefore myocardial
oxygen demand), and does not work well chronically (Zelis, Sinoway, Leuenberger, et al., 1991).
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In fact, left ventricular dilation (in particular end-systolic volume) represents one of the most
powerful prognostic indicators for cardiac failure and death (White, Norris, Brown, et al., 1987).
Furthermore, down-regulation or decreased responsiveness of beta-receptors and gradual
development of dysfunction of the stimulatory guanylate nucleotide binding protein, which
couples the beta-receptor to the adenylate cyclase system, and contractile apparatus ultimately,
renders catecholamine stimulation of the myocardium ineffective over the long-term
(Longabaugh et al., 1988).
Cardiac remodeling
To cope with a chronic elevation of myocardial wall stress, the heart remodels and
hypertrophies. Gradually, new sarcomeres (contractile units) are laid down to share the work
load and reduce the wall stress. Patients with cardiomyopathies have shown that an increase in
left ventricular end-diastolic volume and an almost doubling of left ventricular mass counter a
reduction in ejection fraction (Holubarsch et al. 1991). Clearly, such an adaptation has a much
longer time constant and is slow in onset and slow to regress. However, myocardial hypertrophy
exacts a price. More sarcomeres means more muscle that needs to be oxygenated which results
in an increase in myocardial oxygen demand. The increase in myocardial oxygen demand may
subsequently result in myocardial ischemia due to an inability to raise coronary flow beyond the
ceiling imposed by coronary artery atherosclerotic obstruction. Consequently the aim of
treatment of overt heart failure is to control the vicious cycle of cardiac failure through
restriction of physical activity, restriction of sodium intake, diuretics, vasodilators, digitalis
glycosides, and/or other inotropes.
Unfortunately if the underlying cause of heart failure is not corrected, patients enter the
next phase of the disease known as chronic heart failure defined by a gradual decline in physical
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function with occasional exacerbations of their condition. Chronic heart failure is a complex
clinical syndrome, or constellation of signs and symptoms, that may include fatigue and
shortness of breath on exertion (progressing to symptoms at rest), peripheral edema, orthopnea,
paroxysmal nocturnal dyspnea, nocturia, mental status changes, anorexia, and abdominal pain.
The symptoms appear to be the consequence of a variety of compensatory adaptations with
short- to long-time constants aimed to maintain cardiac output and arterial pressure to adequately
perfuse the brain and the heart. These compensatory adaptations were described above and will
be discussed in further detail in the next sections regarding the consequence of the heart failure
syndrome on physical function, as defined by exercise tolerance. It is important to recognize that
the compensatory adaptations are remarkably effective early on in the disease process and under
resting conditions. However, the capacity to sustain cardiac performance in the face of the
compensatory adaptations exacts a price (Zelis et al., 1991), as they ultimately contribute
significantly to the clinical severity of the syndrome. In fact, the cardinal symptoms of HF
include (1) dyspnea (2) significant intolerance to physical activity, and (3) chronic fatigue.
Consequently, the long-term management of the chronic heart failure patient must focus on the
control of the heart failure syndrome and the need to manage the compensatory changes
associated with the disease. It is clear from the present literature that clinicians and therefore
patients struggle tremendously with the long-term management of the syndrome, despite
evidence of available efficacious strategies.
THE PERIPHERY IN CHRONIC HEART FAILURE
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Intuitively, one would hypothesize that the clinical severity of heart failure is directly related to
the degree of cardiac dysfunction. Yet, most clinical measures of cardiac function (e.g.
cardiothoracic ratio; left ventricular ejection fraction) correlate poorly with the clinical severity
of heart failure, as defined by exercise capacity or tolerance (see Figures 2a and b) (Coats, 2001;
Parish, Alomari, Wood, et al., 2002). This discordance has led to the identification of multiple
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Figure 2a and b. Relationship between exercise capacity and tolerance and Left Ventricular Ejection Fraction

compensatory mechanisms with short- to long-time constants, which may contribute to the
marked exercise intolerance in heart failure. These compensatory mechanisms include: (1)
"hyper"-activation of neurohumoral factors, e.g. increased catecholamines and fluid-regulatory
hormones and a decrease in endothelium-mediated dilators, (2) alterations in skeletal muscle
blood flow, metabolism and function, and (3) structural vascular and skeletal muscle changes
(Drexler, 1991).
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Although, the purpose of the compensatory adaptations in heart failure is thought to be an
attempt to maintain a cardiac output and arterial pressure that adequately perfuse the brain and
the heart, it is the magnitude of these compensatory adaptations that eventually sows the seed for
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a series of maladaptive processes which lead to a decompensated state or even end-stage heart
failure (Zelis, Sinoway, Leuenberger, et al., 1991). Yet, to date, it is not clear to what degree the
compensatory adaptations in heart failure are inherent to the disease or to other contributing
factors such as physical deconditioning and/or malnutrition. The peripheral alterations in heart
failure are thought to be, in part, protective as they prevent blood pressure from decreasing when
the failing heart cannot adequately increase cardiac output (Zelis, Sinoway, Leuenberger, et al.,
1991). Others suggest that the peripheral alterations in heart failure in part mimic the
deconditioning process seen with prolonged physical inactivity (Adamopoulos & Coats, 1991;
Stratton, Dunn, Adamopoulos, et al., 1994). Thus, it is presently not clear to what degree the
exercise intolerance in heart failure is inherent to the disease itself, level of inactivity, or one or
more unidentified contributing factors.
Circulatory Compensatory Adaptations
In patients with low cardiac output, arterial pressure is supported by a rise in systemic
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vascular resistance. Therefore, in addition to the cardiac compensatory mechanisms discussed
above, heart failure is characterized by a complex series of circulatory adaptations which aim to
maintain arterial blood pressure. These circulatory adaptations include (1) neural
vasoconstriction, (2) humoral vasoconstriction, and (3) local impairment of vasodilatory
capacity. The compensatory mechanisms often act in concert to maintain arterial pressure, but
each has its own time-constant and ultimately contributes to the development of the "Heart
Failure Syndrome".
Alterations in cardiovascular reflexes
In the acute phase of low-output heart failure, arterial and cardiopulmonary baroreflexes
are activated to help maintain blood pressure. However, sensitivity of both receptors diminishes
contributing to blunted reflexes (Dibner-Dunlap & Thames, 1992; Eckberg, Drabinsky, &
Braunwald, 1971; Ellenbogen, Mohanty, Szentpetery, et al., 1989). It is thought that the marked
desensitization of the reflexes contributes to abnormal neurohumoral stimulation. Although the
precise mechanisms involved are not entirely understood, it is proposed that in patients with
heart failure the abnormalities in the cardiovascular reflexes could lead to a reduced restraining
influence on the sympathetic nervous system, thereby removing the restraining or "braking"
influence on the heart and circulation. In time, this would favor the development of a
neurohumoral excitatory state with tachycardia and sympathetically mediated vasoconstriction.
Alterations in the autonomic nervous system
A rise in systemic vascular resistance is accomplished initially, by activation of the
sympathetic nervous system. The effect of systemic activation on the heart was described above.
Activation of the sympathetic nervous system is very effective over the short term to maintain
blood pressure (Zelis & Flaim, 1982). Plasma norepinephrine concentrations, an index of the
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activity of this system, are generally two or three times higher in patients with heart failure in
comparison to healthy controls (Cohn, Levine, Olivari, et al., 1984). The magnitude of elevation
of plasma norepinephrine is related to the degree of left ventricular dysfunction and carries an
ominous prognosis (Cohn, Levine, Olivari, et al., 1984). The purpose of the increase in
sympathetic activation is to maintain cardiac output and arterial pressure through stimulation of
myocardial contractility and α1-adrenoreceptors in the vascular wall. Stimulation of the α1adrenoreceptors causes an increase in vasomotor tone and systemic vascular resistance.
However, any supportive effect of the increased sympathetic nervous system activity on arterial
blood pressure is, in time, superseded by a number of organ-specific consequences. The
potential adverse effects of sympathetic activation on cardiac muscle (see figure 4a and b), the
kidneys, and the vasculature is numerous and contributes to the clinical manifestations of heart
failure (Hackenthal, Paul, Genten, et al, 1990).
Humoral activation
Humoral activation is one of the hallmarks of the heart failure syndrome (Drexler, 1991).
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The purpose of humoral activation is to maintain arterial pressure secondary to an increase in
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blood volume. The increased volume also assists the failing heart by increasing the preload
which subsequently stretches the sarcomeres in the myocardium to a more optimal length during
the early phases of heart failure until myocardial hypertrophy develops. However, as a result of
chronic humoral activation two vicious cycles develop: (1) vasoconstriction and (2) sodium and
water retention. Arterial vasoconstriction causes an increase in systemic vascular resistance and
inevitably an increase in afterload and systolic wall stress. The sodium and water retention
causes an increase in circulating volume, which may be beneficial at first, but ultimately results
in an increased ventricular filling pressure and diastolic wall stress. Together, these vicious
cycles may eventually lead to progressive myocardial and vascular dysfunction, peripheral tissue
abnormalities, fluid accumulation, and finally the clinical picture of heart failure (Remme, 1994).
Activation of the renin-angiotensin-aldosterone axis is attributed to low renal perfusion
and sympathetic stimulation. The formation of angiotensin II, which is catalyzed by angiotensin
converting enzyme, located in the endothelium of the vascular tree, contributes to a rise in
peripheral vascular resistance, enhances renal sodium reabsorption, facilitates catecholamine
release from sympathetic nerve endings, and stimulates mineralcorticoid production in the
adrenal gland (Hackenthal, Paul, Genten, et al., 1990). Angiotensin II has also been implicated as
a growth factor or growth modulator in the cardiovascular system. The renin-angiotensinaldosterone axis is markedly activated in patients with decompensated heart failure.
With the discovery that the renin-angiotensin-aldosterone system is markedly activated in
heart failure, it is not surprising that a significant number of investigators have focused on the
role of angiotensin-converting-enzyme (ACE) inhibitors as a strategy to treat patients with heart
failure. Results from subsequent clinical trials have shown convincingly that cardiovascular
morbidity and mortality can be reduced in patients with left ventricular dysfunction (ejection
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fraction < 40%) secondary to ischemic heart disease following long-term use of ACE-inhibitors
(SOLVD Investigators, 1991; SOLVD Investigators, 1992; Pfeffer, Braunwald, Moye, et al.,
1992). Interestingly, the precise mechanism(s) of action of ACE-inhibitors are still not fully
understood. It is thought that the mechanism of action is in part cardioprotective and
vasculoprotective. A reduction in systemic vascular resistance secondary to inhibition of
angiotensin II generation may reduce afterload and myocardial work. Mechanisms for the
vasculoprotective properties include a reduction in angiotensin II production, decreased
bradykinin degradation, antagonism of macrophage function and migration as well as inhibition
of sympathetic nervous system and thrombotic activity (Pepine, 1996). All of these could result
in plaque stabilization, and may contribute to reversal of vascular dysfunction.
Arginine vasopressin is also elevated in heart failure (Schrier & Abraham, 1999). The
mechanism for the release of arginine vasopressin in heart failure is not well understood but is
believed to be due to non-osmotic causes. Perhaps a decreased sensitivity of atrial stretch
receptors, which normally serve to inhibit arginine vasopressin release with atrial distention,
contributes to the elevation of circulating arginine vasopressin. Non-osmotic stimulation of
arginine vasopressin has been linked to low stroke volume and cardiac output. Improvement in
cardiac performance by afterload reduction in patients with heart failure decreases arginine
vasopressin levels and enhances water excretion. A potential unfavorable consequence of
elevated arginine vasopressin is hyponatremia. Hyponatremia is a common manifestation of
severe heart failure and occurs when water is retained in excess of sodium. It has been shown to
be a powerful independent predictor of cardiovascular mortality (Lee & Packer, 1986).
Circulating atrial natriuretic peptide levels are reportedly increased in patients with heart
failure. The elevation in plasma atrial natriuretic peptide in heart failure patients is thought to be
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due to increased cardiac volume and/or pressure overload. Several studies have demonstrated
that atrial natriuretic peptide correlates with the functional class of patients with heart failure,
plasma renin activity, plasma norepinephrine concentrations, and mortality. As a result atrial
natriuretic peptide has emerged as an important diagnostic and prognostic marker in heart failure
(Gottlieb, Kukin, Ahern, et al., 1989).
More recent evidence suggests that there is a diminished response to and a gradual
impairment in the capacity to release atrial natriuretic peptide in heart failure (Volpe, Tritto, De
Luca, 1991). The mechanism for the hyporesponsiveness to atrial natriuretic peptide is thought to
be multifactorial and include (1) a reduction in renal perfusion, (2) increased renal sympathetic
nerve activity, (3) increased circulating catecholamines, (4) atrial natriuretic peptide receptor
downregulation, (5) enhanced atrial natriuretic peptide enzymatic degradation, and/or (6)
increased activity of the renin-angiotensin-aldosterone system. The impaired capacity to release
atrial natriuretic peptide may be the result of chronic volume and pressure overload and inability
of the atria to meet the demand of the system. Thus, a relative deficiency may develop in
patients with chronic heart failure with biologic consequences. It may therefore be hypothesized
that the diminished response to and impaired release of atrial natriuretic peptide contributes to
the pathophysiology of sodium and water retention and systemic vasoconstriction in patients
with heart failure (Brandt, Wright, Redfield, et al., 1993).
Alterations in Vasoreactivity
The above mentioned neurohumoral factors exert potent systemic and regional
vasoconstriction in patients with heart failure. However, it is surprising that there is a poor
correlation between plasma neurohumoral factors and systemic vascular resistance. This
suggests that there are still other factors that affect vascular tone. In fact clear evidence indicates
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that patients with heart failure have impaired vasodilatory capacity (Drexler, Hayoz, Munzel, et
al., 1992; Wilson & Ferraro, 1985). Moreover, ACE-inhibitors do not restore the vasodilatory
response following acute administration, indicating that blockade of the renin-angiotensinaldosterone system does not result in an immediate improvement in blood flow to working
muscle. Thus, it appears that there are other mechanisms involved in the impaired vasodilatory
capacity of patients with heart failure. There currently are three potential mechanisms, which
may explain the vasodilatory impairment seen in heart failure: (1) endothelial dysfunction, (2)
vascular stiffness, (3) vascular deconditioning, and (4) changes in venous function.
There is now compelling evidence that endothelium-mediated relaxation is attenuated in
both the coronary and peripheral circulation of patients with heart failure (Drexler, Hayoz,
Munzel, et al., 1992). The potential mechanism(s) of endothelial dysfunction are currently
unknown, although several hypotheses have been proposed. These hypotheses include (1)
alterations in endothelial cell surface receptors, (2) decrease in endothelial derived relaxing
factor synthesis, (3) rapid degradation of endothelial derived relaxing factor, and (4) increased
production of endothelium-derived contracting factors.
Alterations in endothelial cell surface receptors may be secondary to the atherosclerotic
process or may be a consequence of chronic low flow resulting in lack of stimulation of the
endothelial apparatus to produce dilating factors, such as nitric oxide and prostaglandins. It is
unclear if the production of endothelium-derived relaxing factor is perhaps secondary to
nutritional deficiencies in L-arginine, and/or the cofactors needed in the production process.
Rapid degradation of endothelial derived relaxing factor has been linked to increased oxygenderived free radical activity. The oxygen-derived free radical superoxide is a known inactivator
of endothelial derived relaxing factors. Oxygen-derived free radical production is increased in
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patients with heart failure (Belch, Bridges, Scott, et al., 1991). Thus, free radical-mediated
inactivation of endothelium-derived relaxing factor in the vasculature of patients with heart
failure could contribute to the impaired vasodilatory response.
Vascular stiffness may in part be the result of an increase in the vascular sodium content
subsequent to the hyperactivity of the renin-angiotensin-aldosterone system (Sinoway, Minotti,
Musch, et al., 1987). The increase in vascular sodium and water content leaves the vessels stiff,
less responsive to local metabolic stimuli, and may result in a change in the capillary basement
membrane morphometry. In fact, approximately one third of the reduced vasodilatory response
during exercise in patients with heart failure can be attributed to increased sodium and water
content in the vascular wall (Sinoway, Minotti, Musch, et al., 1987).
Impaired vascular function may also be the result of chronic vascular deconditioning

the forearm reportedly reduces
vasodilatory capacity. Conversely,
exercise training improves peak
vasodilatory capacity (Hornig,
Maier, & Drexler, 1996). Thus,
vascular deconditioning may be
secondary to a chronic decrease in
blood flow (see Figure 5).
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Interestingly, recent
investigations also report diminished venous function in patients with heart failure (Welsch,
Alomari, Parish, et al., 2002; Ikenouchi, Iizuka, Sato, et al., 1991). Moreover, measures of
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distance achieved on the 6-minute walking test, a measure of exercise tolerance (see Figure 6a
and b) (Welsch, Alomari, Parish, et al., 2002). These findings suggest factors that contribute to
exercise impairment in heart failure patients may extend to the venous system. Although the
precise factors are not entirely understood, the important contributions of the venous system in
terms of metabolic waste removal and end-diastolic volume, would suggest that any change in
this system could have a profound impact on the exercise response. Finally, evidence that venous
function influences arterial inflow through the venoarterial reflex (Tschakovsky & Hughson,
2000) suggests the importance of addressing venous health in heart failure.
Skeletal Muscle Compensatory Adaptations
Considerable attention has been given to intrinsic alterations in skeletal muscle which
may contribute to the clinical severity of patients with heart failure (Drexler, Riede, Munzel, et
al., 1992; Drexler, Riede, Hiroi, et al., 1988; Sullivan, Green, & Cobb, 1990; Sullivan, Green, &
Cobb, 1991). The consensus of these studies indicates significant skeletal muscle abnormalities
including (1) structural changes, such as muscle atrophy; (2) a marked decline in mitochondrial
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enzyme concentration and activity (Succinate dehydrogenase, Citrate synthase and cytochrome
oxidase); and (3) a reduction in mitochondrial volume and density.
Skeletal muscle atrophy
Muscle atrophy is common in patients with heart failure (Drexler, Riede, Munzel, et al.,
1992; Sullivan, Green, & Cobb, 1990). The mechanism for muscle atrophy in heart failure is not
entirely clear but has been linked to malnutrition, deconditioning, an increased catabolic state
due to sympathetic nervous system hyperactivation, an increase in serum cortisol, corticotropin,
and/or tumor necrosis factor. Thus, it appears that skeletal muscle atrophy could be an important
and potentially reversible contributor to exercise intolerance in patients with heart failure.
Histologic and biochemical alterations in skeletal muscle
It appears that skeletal muscle atrophy in heart failure is somewhat selective and more
pronounced in the Type I (high-oxidative) muscle fibers, compared to other fiber types. In
addition, to these morphologic changes, a decrease in the number of capillaries per fibers for
type I and type IIa fibers are also reported (Drexler, Riede, Munzel, et al., 1992; Drexler, Riede,
Hiroi, et al., 1988; Sullivan, Green, & Cobb, 1990).
The apparent loss in oxidative capacity in heart failure is further evident from studies
which have performed biochemical analysis of skeletal muscle (Drexler, Riede, Munzel, et al.,
1992; Drexler, Riede, Hiroi, et al., 1988; Sullivan, Green, & Cobb, 1990). A consistent
observation in these patients is a marked reduction in mitochondrial enzyme concentration for
succinate dehydrogenase citrate synthetase, and 3-hydroxacyl-coenzyme A-dehydrogenase and
enzymatic activities. In addition, muscle glycogen levels are also reduced. Ultrastructural
morphometry of muscle biopsies of the vastus lateralis indicated significant abnormalities of
skeletal muscle as compared to normals (Drexler, Riede, Munzel, et al., 1992; Drexler, Riede,
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Hiroi, et al., 1988). The volume density of mitochondria and surface density of mitochondrial
cristae, markers of structural correlates of oxidative capacity, were significantly reduced by 20%
in patients with severe heart failure. Capillary length density was reduced and fiber type
distribution of skeletal muscle was shifted to type II fibers. Cytochemical analysis of
cytochrome oxidase activity also revealed significant decreases in heart failure. Both the volume
density of mitochondria and surface density of mitochondrial cristae were significantly related to
VO2peak and VO2 at anaerobic threshold, but inversely related to the duration of heart failure
(Drexler, Riede, Munzel, et al., 1992; Drexler, Riede, Hiroi, et al., 1988). From these studies, it
appears that the literature supports the notion that a major component of heart failure is a
reduction in oxidative capacity due to intrinsic alterations in skeletal muscle.
Although, the mechanisms for the alterations in skeletal muscle metabolism in heart
failure patients are unknown, several factors (neurohumoral, chronic reductions in muscle
perfusion, and deconditioning) may be involved (Adamopoulos & Coats, 1991; Stratton, Dunn,
Adamopoulos, et al., 1994; Drexler, Riede, Munzel, et al., 1992). Chronic deconditioning may be
a key factor in the alterations in skeletal muscle metabolism, since recent studies have shown that
physical training can improve exercise capacity in patients with heart failure by delaying the
onset of anaerobic metabolism. However, chronic muscle underperfusion (at rest or during
exercise) and/or increased sympathetic stimulation could also cause many of the abovementioned abnormalities in skeletal muscle metabolism. Finally, “mal”-nutrition in these patients
may also contribute to the observed changes.
GOALS OF TREATMENT
Because of the multi-factorial, and often patient-specific, nature of the illness, treatment
of heart failure is extremely challenging and patients require close monitoring (Caldwell MA &
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Dracup K, 2001). The primary goals of heart failure management are to reduce the frequency of
heart failure exacerbations, extend survival, and improve quality of life. Additional goals include
maximizing independence, improving exercise capacity, enhancing emotional well-being, and
reducing resource use and cost of care (Rich, 1999). To achieve these goals, the ACC/AHA
Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult (2001)
have recently decided to take a new approach to the classification of HF that emphasizes both the
evolution and progression of the disease (Hunt, Baker, Chin, et al., 2001). In doing so, 4 stages
of HF are identified as shown in Figure 7 and Table I. Stage A identifies the patient who is at
high risk for developing HF but has no structural disorder of the heart; Stage B refers to a patient
with a structural disorder of the heart but who has never developed symptoms of HF; Stage C
denotes the patient with past or current symptoms of HF associated with underlying structural
heart disease; and Stage D designates the patient with end-stage disease who requires specialized
treatment strategies such as mechanical circulatory support, continuous inotropic infusions,
cardiac transplantation, or hospice care. The treatment goals within each stage differ and focus
on the control of risk and early detection of ventricular dysfunction in Stage A patients;
prevention of cardiovascular events and early detection of HF symptoms in Stage B patients;
pharmacologic approaches and behavior interventions in Stage C; and Stage D patients
aggressive management of fluid status, utilization of neurohumoral inhibitors, intravenous drug
therapy and mechanical or surgical intervention. The goals and steps for treatment are further
depicted in the figure below as developed by the ACC/AHA guidelines (Hunt, Baker, Chin, et
al., 2001).
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Figure 7. Stages in the Evolution of Heart Failure and Recommended Therapy by Stage

Pharmacological Treatment
The most common strategy used to manage patients with chronic heart failure is through
the use of pharmacological agents. Clearly, the purposes of pharmacologic therapy are to reduce
mortality, to alleviate the symptoms of HF, and to improve the patient’s functional capacity
(Hunt, Baker, Chin, et al., 2001). Recent consensus guidelines (2001) recommend that most
patients with symptomatic left ventricular dysfunction should be routinely managed with a
combination of 4 types of drugs: an ACE inhibitor, a beta-adrenergic blocker, a diuretic, and
(usually) digitalis (Packer, Cohn, et al., 1999; Hunt, Baker, et al., 2001). The value of these drugs
has been established in numerous large-scale clinical trials, and the evidence supporting a central
role for their use is compelling and persuasive. The purpose of this section of the review is to
provide evidence for the use of the aforementioned drugs. In so doing it must be recognized that
the review is somewhat biased toward individuals with left ventricular dysfunction, secondary to
coronary artery disease. Heart failure patients with other underlying etiologies may require
similar or vastly different pharmacological approaches from the consensus guidelines.
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Management of the heart failure patient with Diuretic Agents
Clinical trials have clearly demonstrated the benefits of using diuretic agents for fast
relief of sodium retention and symptoms of fluid overload (Patterson, Adams, Appelfeld, et al.,
1994; Sherman, Liuand, Baumgarden, et al., 1986). Moreover, diuretics contribute to improved
cardiac function and exercise tolerance (Wilson, Reichem, Dunkman, et al., 1981). Recent
guidelines suggest that diuretics should be prescribed to all patients who have evidence of, and to
most patients with a prior history of, fluid retention (Hunt, Baker, Chin, et al., 2001). Diuretics
should be administered promptly to patients with HF who present with symptoms of congestion
and patients should continue using these agents after improvement of symptoms (Konstam,
Dracup, Baker, et al., 1994; Packer & Cohn, 1999; Wilson, Reichem, Dunkman, et al., 1981).
Diuretics eliminate excess fluid volume and relieve symptoms related to circulatory
congestion (e.g., orthopnea and paroxysmal nocturnal dyspnea) by inhibiting the reabsorption of
sodium or chloride at specific sites in the renal tubules. Thiazides, metolazone, and potassiumsparing agents (e.g., spironolactone) act in the distal portion of the renal tubule; whereas, loop
diuretics (i.e., Bumetanide, furosemide, and torsemide) act at the loop of Henle (Brater, 1998;
Cody, Kubo, Pickworth, 1994). These two classes of diuretics differ in their pharmacologic
actions. The loop diuretics increase sodium excretion up to 20% to 25% of the filtered load of
sodium, enhance free water clearance, and maintain their efficacy unless renal function is
severely impaired (Damle & Talano, 1991; Hunt, Baker, Chin, et al., 2001). In contrast, thiazide
diuretics increase the fractional excretion of sodium to only 5% to 10% of the filtered load, tend
to decrease free water clearance, and lose their effectiveness in patients with moderately
impaired renal function (creatine clearance up less than 30 mL per min) (Damle & Talano, 1991;
Hunt, Baker, Chin, et al., 2001). Consequently, in some patients with mild heart failure, a
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thiazide diuretic (e.g., hydrochlorothiazide) may be adequate, but most patients require a more
potent loop diuretic because they are often needed to treat the volume overload associated with
HF disease pathophysiology (Hunt, Baker, Chin, et al., 2001).
The response to a diuretic is dependent on the concentration of the drug and the time
course of its entry into the urine (Brater, 1998; Cody, Kubo, Pickworth, 1994). Patients with mild
HF respond favorably to low doses because they absorb diuretics rapidly from the bowel and
deliver these drugs rapidly to the renal tubules. However, as the HF condition worsens, the
absorption of the drug may be delayed by bowel edema or intestinal hypoperfusion, and the
delivery of the drug may be impaired by a decline in renal perfusion and function (Vasko,
Cartwright, Knochel, et al., 1985; Brater, Chennavasin, Seiwell, et al., 1980; Vargo, Kramer,
Black, et al., 1995). Consequently, the clinical progression of HF is characterized by the need for
increasing doses of diuretics.
Because diuretics intensify the activation of the renin-angiotensin-aldosterone system by
decreasing renal perfusion, patients should be maintained on the lowest dose possible and may
even be used p.r.n. if symptoms are mild (Connolly, 2000). Although diuretics are successful in
controlling acute symptoms and fluid retention, diuretics alone are unable to maintain the clinical
stability of patients with HF for long periods of time (Richardson, Bayliss, Scriven, et al., 1987).
Therefore, diuretics should not be used as monotherapy in the treatment of HF. The risk of
clinical decompensation can be reduced, however, when diuretics are combined with an ACE
inhibitor, a beta-blocker, and digoxin (Captopril-Digoxin Multicenter Research Group, 1988;
Hunt, Baker, Chin, et al., 2001).
Appropriate use of diuretics is a key element in the success of other drugs used for the
treatment of HF. The use of inappropriately low doses of diuretics will cause fluid retention,
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which can diminish the response to ACE inhibitors and increase the risk of treatment with betablockers (Cody, Franklin, Laragh, 1982). Conversely, the use of inappropriately high doses of
diuretics will lead to volume contraction, which can increase the risk of hypotension with ACE
inbihitors and vasodilators (Cody, Franklin, Laragh, 1982;Massie, Kramer, Haughom, 1981) and
increase the risk of renal insufficiency with ACE inhibitors and angiotensin II receptor
antagonists (Packer, Lee, Medina, 1987).
The effectiveness of diuretic therapy is enhanced when the patient follows a reducedsodium diet. Sodium intake is strictly correlated with the administration of diuretics. If the
diuretic dose is increased to compensate for a more liberal sodium intake, the renin-angiotensin
system will be strongly activated and will promote thirst, as well as deplete potassium and
magnesium (Haller C, Salbach P, et al., 1995). Moreover, in the absence of sodium restriction,
diuretics become less effective (Cody RJ, Kubo SH, et al., 1994). Furthermore, patients may
become unresponsive to high doses of diuretic drugs if they consume large amounts of dietary
sodium, are taking agents that can block the effects of diuretics (e.g., nonsteroidal antiinflammatory drugs (Herchuelz, Derenne, Deger, et al., 1989; Gottlieb, Robinson, Krichten, et
al., 1992; Brater, Harris, Redfern, et al., 2001), or have a significant impairment of renal function
or perfusion (Risler, Schwab, Kramer, et al., 1994).
The principal adverse effects of diuretics include electrolyte depletion as well as
hypotension and azotemia. Diuretics can cause the depletion of important cations (i.e.,
potassium and magnesium), which can predispose patients to cardiac arrhythmias, particularly in
combination with digitalis therapy (Steiness & Olesen, 1976). The loss of electrolytes is related
to enhanced delivery of sodium to distal sites in the renal tubules and the exchange of sodium for
other cations, a process that is potentiated by activation of the renin-angiotensin-aldosterone
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system (Cody, Kubo, Pickworth, 1994). Potassium deficits can be corrected by the short-term
use of potassium supplements, or if severe, by the addition of magnesium supplements
(Solomon, 1987). Concomitant administration of ACE inhibitors alone or in combination with
potassium-retaining agents (such as spironolactone) can prevent electrolyte depletion in most
patients with HF who are taking a loop diuretic. Therefore, when these drugs are prescribed,
long-term oral potassium supplementation is frequently not needed and may be deleterious
(Hunt, Baker, Chin, et al., 2001).
Patients should be educated about the intended benefit of the medication, dosage, and
optimal time of day for ingestion (i.e., in the morning) (Baker, Dracup, Dunbar, 1994; Godden,
1994). Patients should also be informed about the rapidity of the diuretic effect and the need to
have access to a bathroom (Godden, 1994). Possible adverse effects should be mentioned in
advance, particularly those such as postural hypotension, which might precipitate falls in the
elderly (Dracup, 1996). The patient should be monitored for signs of overdiuresis or
hypokalemia, especially because symptoms such as lethargy and drowsiness are often
overlooked (Dracup, 1996).
Overdiuresis should be particularly avoided in patients who are beginning therapy with
ACE inhibitors because of the potential for hypotension or renal insufficiency. Once ACEinhibitor treatment has been established, the diuretic dose may be increased as needed to control
any persisting symptoms of volume overload (Konstam, Dracup, Baker, et al., 1994; Baker,
Konstam, Bottorff, 1994).
In summary, the efficacy of diuretics is well established, especially in combination with
other heart failure drugs. Diuretics are particularly useful in the day-to-day management of the
heart failure patient. As patients exhibit a sudden increase in bodyweight (e.g. secondary to
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dietary intake of foods high in sodium) and concomitant exacerbation of heart failure symptoms,
an increase in the dose of diuretic will often result in rapid relief. As the symptoms subside the
dosage may once again be decreased.
Management of the heart failure patients with ACE-inhibitors
The use of angiotensin-converting enzyme (ACE) inhibitors in the treatment of heart
failure is now considered a gold standard of care (Packer, Cohn, et al., 1999; Hunt, Baker, et al.,
2001). Published guidelines from the Agency for Healthcare Policy and Research (Konstam,
Dracup, Baker, et al., 1994), the American College of Cardiology and the American Heart
Association Task Force (Hunt, Baker, Chin, et al., 2001), and the European Society of
Cardiology Task Force (1997) all recommend ACE inhibitors for first-line therapy for patients
with heart failure. ACE-inhibitors decrease systemic vascular resistance and have been shown to
improve survival, reduce hospitalizations, and enhance quality of life in a wide range of patients
with left ventricular systolic dysfunction (Pfeiffer, Braunwald, Moye, et al., 1992; AIRE Study
investigators, 1993; SOLVD Investigators, 1992; SOLVD Investigators, 1991). As established
by the Studies of Left Ventricular Dysfunction (SOLVD) Prevention Trial, ACE-inhibitor
therapy is indicated in all patients with asymptomatic left ventricular dysfunction (SOLVD
Investigators, 1992). Additionally, controlled trials suggest that patients with advanced heart
failure respond favorably to treatment with both ACE-inhibitors and beta blockers in a manner
similar to those with mild to moderate disease (The CONSENSUS Trial study group, 1987;
Packer, Coats, Fowler, et al., 2001).
ACE-inhibitors act by inhibiting the enzymatic conversion of angiotensin I to angiotensin
II, a potent vasoconstrictor. Angiotensin II is elevated in patients with heart failure secondary to
poor left ventricular performance and hypoperfusion of the kidneys. The response to this
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situation is activation of the renin-angiotensin-aldosterone system in an effort to maintain
adequate perfusion of the organs. Unfortunately, in chronic heart failure the renin-angiotensinaldosterone system contributes to significant cardiovascular mal-adaptations that contribute to
the heart failure syndrome. The result of the inhibition of the converting enzyme is a decrease in
afterload . Moreover, ACE-inhibitors also inhibit the stimulation of the adrenal cortex to release
aldosterone. Consequently, sodium excretion is promoted and fluid retention controlled.
Additionally, ACE inhibitors also inhibit the breakdown of bradykinin, a potent vasoactive
peptide that stimulates the endothelium to produce nitric oxide, another potent vasodilator. The
combined effects of ACE-inhibitors, therefore, is a significant increase in cardiac index and
decrease in left ventricular filling pressures and systemic vascular resistance (Jessup, 1988). The
beneficial effects of ACE inhibitors in heart failure and after a myocardial infarction include a
marked improvement in survival and heart failure symptoms, and a reduction in the rate of
hospitalization. In addition, ACE-inhibitors are also cardioprotective and limit the negative
effects of ventricular remodeling (Greisinger, Espadas, & Ashton, 1998; Pinkowish, 1997). The
peak effect of the drug occurs somewhere between 1 hour and 90 minutes after oral
administration (Jessup, 1988). The benefits of ACE inhibition are usually seen during the first 90
days of therapy and extend to all patients, regardless of age, sex, etiology of CHF or NYHA class
(Pinkowish, 1997). Therefore, recent consensus guidelines recommend ACE-inhibitor therapy
for many patients with stage A heart failure and all patients with stage B, C, or D heart failure
(Hunt, Baker, et al., 2001).
Despite overwhelming evidence of the proven benefits of ACE-inhibitors, the unfortunate
reality is that only 30-40% of patients with CHF are receiving treatment with ACE inhibitors
(Fletcher & Thomas, 2001). Moreover, up to 50% of patients admitted to the hospital with
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chronic heart failure are discharged without prescriptions for ACE-inhibitors (Philbin, Rocco,
Lindenmuth, et al., 1999). These statistics highlight the need for motivating physicians to learn
more about current developments and guidelines in heart failure management.
It is not entirely clear what barriers underlie the underutilization of these drugs. However,
1) the physician’s uncertainty of the optimal dosage and 2) fear of potential side effects (i.e.,
nonproductive cough and hypotension), have been suggested. Yet side effects are fairly
predictable and reversible and can usually be successfully managed (Jessup, 2003).
Consequently, physicians should be familiar with current guidelines and inform the patients of
what to expect, such as providing information regarding the function, therapeutic dosing of
ACE-inhibitors, and side effects may improve the rate of utilization and treatment with this class
of drug.
Furthermore, patients should be informed about the purpose and importance of ACEinhibitors to survival, quality of life, and long-term prognosis (Dracup, 1996). Patients should be
monitored for adverse effects such as hypotension and renal insufficiency, which may be related
to volume depletion, and hyperkalemia (serum potassium > 5.5 mmol/liter) (Heart Failure
Guideline Panel, 1994; Dracup, Baker, Dunbar, et al., 1994). To avoid induction of
hyperkalemia, patients should be warned not to use potassium-containing salt substitutes without
first obtaining medical advice (Konstam, Dracup, Baker, et al., 1994). Patients should be
informed of possible side effects and understand that dehydration, excessive perspiration,
vomiting, or diarrhea may lead to volume depletion and a fall in blood pressure (Dracup, 1996).
In summary, the evidence for the use of ACE-inhibitors is overwhelming and should
represent one of the cornerstones in the management of the heart failure patient. Barriers against
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the use of ACE-inhibitors should be aggressively dealt with through education and continued
emphasis on available literature.
Management of the heart failure patient with Beta-blockers
The use of Beta-blockers in the management of patients with heart failure has remained
controversial for many years. However, recent large-scale clinical trials (Abraham, 2000) have
clearly shown their efficacy, especially in the long-term management of patients with HF. Recent
consensus guidelines recommend the addition of beta-adrenergic blockade to therapy with
diuretics and ACE-inhibitors for most patients with mild to moderate heart failure and left
ventricular systolic dysfunction (1999). Furthermore, although controlled clinical trials are
lacking, the use of beta-blockers in addition to ACE-inhibitor therapy for asymptomatic left
ventricular dysfunction (Stage B heart failure) may provide further protection from progression
to more severe HF. Consequently the use of these agents has recently been promoted (Hunt,
Baker, Chin, et al., 2001; Adams, Baughman, et al., 1999; Vantrimpont, Rouleau, Wun, et al.,
1997).
In the most recent Consensus Guidelines it is even suggested that in patients who respond
favorably to diuretic therapy, additional treatment with an ACE inhibitor and a beta-blocker is
warranted and should be maintained in patients who can tolerate them, because they have been
shown to favorably influence the long-term prognosis of HF (Hunt, Baker, Chin, et al., 2001).
Additionally, several studies have shown that beta-blockers may reduce hospitalizations and
mortality and improve quality of life in patients with systolic heart failure (Doughty, Rodgers,
Sharpe, et al., 1997; Packer, Bristow, Cohn, et al., 1996). Furthermore, beta-adrenergic blockade
has been shown to improve left ventricular ejection fraction to an extent greater than any other
form of pharmacological therapy for systolic heart failure (Abraham & Scarpinato, 2002). Recent
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data show that when a beta-blocker is added to an ACE inhibitor and diuretic, disease
progression is slowed and morbidity and mortality are significantly reduced (Packer, Bristow, et
al., 1996; Cardiac Insufficiency Bisoprolol Study II, 1999; MERIT-HF, 1999).
The evidence of improved ejection fraction with regression of left ventricular
hypertrophy is substantial, making an important addition to the standard treatment of ACE
inhibitors, diuretics, and digoxin (Connolly, 2000). A comprehensive analysis of 18 doubleblind, placebo-controlled trials of beta-blocker use in patients with chronic heart failure revealed
an improved overall ejection fraction of 29%, and reduced risk of mortality by 32%. These
findings are attributed to the antagonizing effects of these drugs on sympathetic nervous system
activity. Again in an effort to maintain adequate pressure in the face of poor left ventricular
performance, HF patients have elevated catecholamine levels. Sympathetic activation can
increase ventricular volumes and pressure by causing peripheral vasoconstriction (Smith,
Macmillan, & McGrath, 1997) and by impairing sodium excretion by the kidneys (Elhawary &
Pang, 1994). Norepinephrine can also stimulate cardiac hypertrophy needed to provide a greater
contractile force to eject the volume of blood. Moreover, catecholamines can also increase heart
rate and potentiate the activity and actions of other neurohormonal systems needed to help the
failing heart.
Unfortunately, the chronic elevation of these hormones and the hyperactivity of the
autonomic nervous system ultimately contribute to the worsening heart failure syndrome. For
example, ventricular hypertrophy necessitates a greater coronary blood supply. Thus, patients
with advancing coronary artery disease may consequently have greater myocardial oxygen
demands and increased myocardial ischemic episodes (Knowlton, Michel, Itani, et al., 1993).
Activation of the sympathetic nervous system can also promote arrhythmias by increasing the

141

automaticity of cardiac cells, and due to the development of hypokalemia (Reid, Whyte, &
Struthers, 1986; Billman, Castillo, Hensley, et al., 1997). Finally, by stimulating growth and
oxidative stress in terminally differentiated cells, norepinephrine can trigger programmed cell
death or apoptosis (Communal, Singh, Pimentel, et al., 1998). These deleterious effects are
mediated through actions on alpha-1, beta-1, and beta-2 adrenergic receptors (Reid, Whyte, &
Struthers, 1986; Smith, Macmillan, & McGrath, 1997; Elhawary & Pang, 1994; Knowlton,
Michel, Itani, et al., 1993; Billman, Castillo, Hensley, et al., 1997; Communal, Singh, Pimentel,
et al., 1998).
The effects of Beta-blockers are to occupy beta-adrenergic receptor sites and to prevent
norepinephrine and epinephrine from binding to these receptors and producing their stimulating
effects. In addition, Beta blockers also slow the conduction time through the atrioventricular
node, decreasing the chance of tachyarrhythmias, and they also help prevent the complications
associated with acute ischemia (Fletcher & Thomas, 2001). Most all types of Beta-blockers that
have been shown to be effective in the treatment of HF including those that selectively block
beta-1 receptors (e.g., bisoprolol and metoprolol) and those that block alpha-1, beta-1, and beta-2
adrenergic receptors (e.g., carvedilol) (Hunt, Baker, Chin, et al., 2001).
In a recent sub-analysis of the SOLVD data, HF hospitalizations and mortality were
found to be decreased in patients receiving a combination of ACE inhibitor and β-blocker,
independent of etiology of left ventricular dysfunction (Exner, Dries, Waclawiw, et al., 1999).
Analysis of the Survival and Ventricular Enlargement (SAVE) study demonstrated similar
cardioprotective effects of β-blockers in a cohort of post MI patients with decreased ejection
fraction. The use of β-blockers was associated with a decreased incidence of symptomatic HF as
well as decreased cardiovascular mortality (Vantimpont P, Rouleau JL, Wun C, et al., 1997).
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More recent trials further confirm the beneficial effects of beta-blockers involving patients with
heart failure from various etiologies and stages of severity (Jessup, 2003; Hunt, Baker, Chin, et
al., 2001). These effects include a reduction in mortality and morbidity, a decrease in rate of
hospitalizations and the incidence of sudden death, improvements in ejection fraction and
measures of quality of life, and favorable control of cardiac remodeling, (Foody, Farrell,
Krumholz, 2002; Farrell, Foody, Krumholz, 2002).
Interestingly, the short-term effects of beta-blockers may result in a temporary
exacerbation of symptoms (Packer, 1998). The precise mechanism for this is not understood but
may in part be secondary to the slight vasoconstricting effects of many of these agents. More
recent studies, which have used both alpha and beta blocking agents, such as carvedilol, appear
to be even more effective in the management of the patient, and do not seem to have the initial
negative effects of the traditional beta-adrenergic blockers (Bristow, Gilbert, Abraham, et al.,
1996). Regardless, the long-term effects of beta-blocking agents are uniformly beneficial and
improve the clinical status of patients (Packer, 1998). Placebo-controlled trials involving longterm treatment have shown improved systolic function after three months of treatment and
reverse remodeling after four months of treatment (Saxon, De Marco, Schafer, et al., 2002;
Bristow, 2000; Groenning, Nilsson, Sondergaard, et al., 2000). An important consideration is
that the beneficial effects of beta-blockers were also seen in patients already taking ACEinhibitors (Abraham & Scarpinato, 2002). This suggests that combined blockade of these two
neurohormonal systems can produce additive effects.
Given the potential complications associated with the initiation of beta-blocker therapy
close monitoring of the patient is warranted. Patients may have increased dyspnea and edema,
and may also experience symptomatic bradycardia with or without associated hypotension. It
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must also be recognized that these symptoms may return during titration phases. However, the
long-term benefits of using beta-blockers in the treatment of HF are far greater than the potential
period of increased symptomatology during intitiation of therapy; therefore, clinicians are urged
to add beta-blockers to treatment regimens without delay.
Beta-blockers should be used in all patients with stable heart failure without substantial
fluid retention and without recent exacerbations of heart failure requiring ionotropic therapy
(Hunt, Baker, Chin, et al., 2001). Beta-blockers should not be used, or should be used with
caution, in patients with reactive airway disease, patients with diabetes associated with frequent
episodes of hypoglycemia, and those patients with bradyarrhythmias or heart block who do not
have a pacemaker (Jessup, 2003).
Once the target dose has been achieved, patients can generally be maintained on longterm therapy with a beta-blocker with little difficulty. Patients should be advised that clinical
responses to the drug are generally delayed and may require 2 to 3 months to become apparent
(Massie, Kramer, & Haughom, 1981). Even if symptoms do not improve, long-term treatment
should be maintained to reduce the risk of major clinical events. Abrupt withdrawal of treatment
with a beta-blocker can lead to clinical deterioration and should be avoided (Waagstein, Caidahl ,
Wallentin, et al, 1989).
In summary, the long-term effects of beta-blockers are of significant benefit to the patient
with chronic heart failure. Consequently, the use of these agents should be a part of the
management of the patients. Particular care and monitoring should be provided during the initial
period following drug administration and during periods when the dose of the drug is increased.
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Management of the heart failure patient with Digitalis Glycosides
Digitalis glycosides are of particular importance in providing symptomatic relief in
patients with systolic dysfunction and in those with rapid atrial arrhythmias (Fletcher & Thomas,
2001). Digoxin is the only digitalis glycoside evaluated in clinical trials by the USFDA for use in
patients with HF (Gheorghiade et al., 1998). Digoxin is a positive ionotrope that acts directly on
the myocardium by inhibiting sarcolemmal sodium-potassium adenosine triphosphatase (ATPase) activity (Fletcher & Thomas, 2001; Akera, Baskin, Tobin, et al., 1973). Inhibition of this
enzyme in cardiac cells results in an increase in the contractile state of the heart. Inhibition of
ATP-ase within the kidney decreases renal tubular reabsorption of sodium and suppresses the
renin-angiotensin-aldosterone system (Torretti, Hendler, Weinstein, et al., 1972; Fletcher &
Thomas, 2001). Digitalis reduces the renal tubular reabsorption of sodium (Torretti, Hendler,
Weinstein, et al., 1972); the resulting increase in the delivery of sodium to the distal tubules
leads to the suppression of renin secretion from the kidneys (Covit, Schaer, Sealey, et al., 1983).
These observations have led to the hypothesis that digitalis acts in HF primarily by attenuating
the activation of neurohormonal systems and not as a positive inotropic drug (Gheorghiade &
Ferguson, 1991). The inhibitory effects on the sympathetic nervous system in combination with
reduced neurohormonal activity make digoxin an important pharmacologic weapon for
controlling HF (Fletcher & Thomas, 2001).
The clinical benefits have traditionally been attributed primarily to its inotropic action
(i.e., the ability to increase myocardial contractility). In view of current thinking that the
progression of HF and the risk of mortality may be related to the extent of sympathetic activity,
however, investigation has focused on the neurohormonal properties of digoxin. In a clinical
study of 26 patients with HF, Krum et al., (1995) found that digoxin inhibits sympathetic activity
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while increasing parasympathetic activity and that these effects persist over 4 to 8 weeks of
therapy (Krum, Bigger, Goldsmith, et al., 1995).
Several placebo-controlled trials have shown that treatment with digoxin for 1 to 3
months can improve symptoms, quality of life, and exercise tolerance in patients with mild to
moderate HF (Captopril-Digoxin Research Group, 1988; Dobbs, Kenyon, Dobbs, 1977; Lee,
Johnson, Bingham, et al., 1982; Guyatt, Sullivan, Fallen, et al., 1988; DiBianco, Shabetai,
Kostuk, et al., 1989; Uretsky, Young, Shahidi, et al., 1993; Packer, Gheorghiade, Young, et al.,
1993). These benefits have been observed regardless of the underlying rhythm (normal sinus
rhythm or atrial fibrillation), cause of HF (ischemic or nonischemic cardiomyopathy), or
concomitant therapy (with or without ACE-inhibitors). In a long-term trial that enrolled patients
who primarily had class II or III symptoms, treatment with digoxin for 2 to 5 years had little
effect on mortality but modestly reduced the combined risk of death and hopitalization (DIG
Investigators, 1997). In the recently completed DIG study (Digitalis Investigation Group), 6800
patients with heart failure and an ejection fraction of less than 45% were randomized to digoxin
or placebo and followed for an average of 37 months (DIG Investigators, 1997). Although
digoxin had no effect on overall mortality, heart failure deaths and hospitalizations were
significantly reduced (DIG Investigators, 1997). The effects of digoxin were similar across age
groups. Consequently, digoxin remains an important agent for heart failure management because
of its beneficial effects on hospitalizations and quality of life.
Physicians should consider using digoxin to improve the symptoms and clinical status of
patients with HF, in conjunction with diuretics, and ACE-inhibitor, and a beta-blocker (Hunt,
Baker, Chin, et al., 2001). If a patient is taking digoxin but not an ACE-inhibitor or a betablocker, treatment with digoxin should not be withdrawn, but appropriate therapy with the
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neurohormonal antagonists should be instituted (Hunt, Baker, Chin, et al., 2001). Digoxin is
prescribed routinely in patients with HF who have chronic atrial fibrillation, but beta-blockers
may be more effective in controlling the ventricular response, especially during exercise
(Matsuda, Matsuda, Yamagushi, et al., 1991; David, Segni, Klein, et al., 1979; Farshi, Kistner,
Sarma, et al., 1999). Digoxin is not recommended for use in patients with pure diastolic
dysfunction unless it is used as adjunct therapy in the modulation of the neurohormonal system
or for control of atrial arrhythmias Hunt, Baker, Chin, et. al., 2001).
Dosing of digoxin is affected by the patient’s age, weight, and renal function. Low doses
(0.125 mg daily or every other day) should be used if the patient is over 70 years old, has
impaired renal function, or has a low lean body mass (Jelliffe & Brooker, 1974). Although
physicians have been taught that digitalis produces frequent side effects, the drug is well
tolerated by most patients with HF (Steiner, Robbins, Hammermeister, et al., 1994). The
principle adverse reactions occur primarily when digoxin is administered in large doses, but large
doses are rarely needed to produce clinical benefits Arnold, Byrd, Meister, et al., 1980;
Gheorghiade, Hall, Jacobsen, et al., 1995, Slatton, Irani, Hall, et al., 1997). The major side
effects include cardiac arrhythmias (e.g., ectopic and re-entrant cardiac rhythms and heart block),
gastrointestinal symptoms (e.g., anorexia, nausea, and vomiting), and neurological complaints
(e.g., visual disturbances, disorientation, and confusion). Digitalis toxicity is commonly
associated with serum digoxin levels more than 2 ng per mL but may occur with lower digoxin
levels, especially if hypokalemia, hypomagnesemia, or hypothyroidism co-exist (Ingelfinger &
Goldman, 1976). Digoxin toxicity is potentiated by hypoxemia, electrolyte imbalances
(hypokalemia and hypomagnesemia), renal insufficiency, dehydration, and hypothyroidism. The
side effects associated with digoxin toxicity include cardiac block, gastrointestinal disturbances
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(anorexia, nausea, and vomiting) and visual disturbances (Fletcher & Thomas, 2001). The
possibility of drug interactions is a concern, as the concomitant use of quinidine, verapamil,
spironolactone, flecainide, propafenone, or amiodarone can increase serum digoxin levels and
may increase the likelihood of digitalis toxicity (Dracup, 1996). The dose of digoxin should be
reduced if treatment with these drugs is initiated. In addition, a low lean body mass and impaired
renal function can also elevate serum digoxin levels, which may explain the increase risk of
digitalis toxicity in elderly patients (Hunt, Baker, Chin, et al., 2001).
Patient education should include information about dosage, particularly if drug amounts
are changed, and counseling regarding possible signs and adverse effects of digitalis toxicity.
Additionally, the patient should inform the prescribing health care provider of any other
medications prescribed by other health care providers or taken over the counter (Dracup, 1996).
In summary, the use of digitalis glycosides in the management of chronic left ventricular
heart failure appears to be warranted despite the lack of understanding as to the mechanisms
behind the agents. Digitalis glycosides do not appear to be effective for all heart failure patients.
The narrow therapeutic window of these drugs warrants careful control and frequent monitoring.
Patients should be educated about these drugs and in regards to their potential side effects.
Management of the heart failure patient with combination drugs
Recent consensus guidelines recommend that patients classified as Stage C Heart
Failure: Symptomatic Left Ventricular Dysfunction should be routinely managed with a
combination of the 4 types of drugs discussed above (a diuretic, an ACE inhibitor, a betaadrenergic blocker, and (usually) digitalis) (Packer, Cohn, et al., 1999; Hunt, Baker, Chin, et al.,
2001). The value of these drugs has been established in numerous large-scale clinical trials, and
has been discussed in each section. The evidence supporting a central role for their use is
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compelling and persuasive. Patients with evidence of fluid retention should be given a diuretic to
reduce blood volume and edema, and diuretic therapy should be continued to prevent the
recurrence of fluid retention. Even if the patient has responded favorably to the diuretic,
treatment with an ACE inhibitor and a beta-blocker should be initiated and maintained in patients
who can tolerate them, because they have been shown to favorably influence the long-term
prognosis of HF (Hunt, Baker, et al., 2001). Recent data show that when a beta-blocker is added
to an ACE inhibitor and diuretic, disease progression is slowed and morbidity and mortality are
significantly reduced (Packer, Bristow, et al., 1996; Cardiac Insufficiency Bisoprolol Study II,
1999; MERIT-HF, 1999). ACE inhibitors decrease systemic vascular resistance and have been
shown to improve survival, reduce hospitalizations, and enhance quality of life in patients with
left ventricular systolic dysfunction (Pfeiffer, Braunwald, Moye, et al, 1992; AIRE Study
Investigators, 1993; SOLVD Investigators, 1992; SOLVD Investigators, 1991). Beta-blockers
interrupt the “toxic effects” of the over-active sympathetic nervous system. Additionally, several
studies have shown that beta-blockers may reduce hospitalizations and mortality and improve
quality of life in patients with systolic heart failure (Doughty, Rodgers, Sharpe, et al., 1997;
Packer, Bristow, Cohn, et al., 1996). Therapy with digoxin may be initiated at any time to
increase the force of left ventricular contraction, reduce symptoms, and enhance exercise
tolerance (Ware, Snow, Luchi, et al., 1984; Packer, Cohn, et al., 1999, Hunt, Baker, et al., 2001).
Management of the heart failure patient with other drugs
The pharmacological management of the patient with chronic heart failure is constantly
changing due to the advancing research and available data concerning new agents. The decision
to add or replace conventional therapies with such agents rests with the physician in charge of
the patient and should be based on the strength of evidence.
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Currently there are several agents under investigation, which may ultimately add to or
change the current recommendations. Examples of some of these new investigational drugs
include: vasopeptidase inhibitors, cytokine antagonists, angiotensin II antagonists, and
endothelin antagonists. In some trials there appears to be some evidence for the use of these new
agents, however, the strength of evidence is still limited in terms of long-term outcomes.
Finally, there is a distinct trend toward self-management by patients with heart failure.
Many patients are looking toward supplements and hormonal therapies to improve their heart
failure condition. The value of the majority of such agents remains unproven, and the long-term
safety has not been established. Examples of such supplements include: coenzyme Q10,
carnitine, taurine, and antioxidants. Growth hormone and thyroid hormone are also therapies
under consideration. Again, the decision to implement these unconventional practices must be
considered on an individual basis with careful attention to the strength of evidence provided for
the type of patient under care.
Pharmacological agents heart failure patient must avoid
Three classes of drugs should be avoided in most patients with Stage C heart failure
because they can exacerbate the HF syndrome. These drugs include: 1) antiarrhythmic agents, 2)
Calcium channel blockers, and 3) Nonsteroidal anti-inflammatory drugs (Hunt, Baker, Chin, et
al., 2001). Antiarrhythmic agents can exert important cardiodepressant and proarrhythmic effects
(Packer, 1991). Of available agents, only amiodarone has been shown not to adversely affect
survival (Hunt, Baker, Chin, et al., 2001). Calcium channel blockers can lead to worsening heart
failure and have been associated with an increased risk of cardiovascular events (Packer, Kessler,
Lee, 1987). Of available agents, only amlodipine has been shown not to adversely affect survival
(Hunt, Baker, Chin, et al., 2001). Nonsteroidal anti-inflammatory drugs can cause sodium
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retention and peripheral vasoconstriction and can attenuate the efficacy, and enhance the toxicity,
of diuretics and ACE inhibitors (Heerdink, Leufkens, Herings, et al., 1998; Herchuelz, Derenne,
Deger, et al., 1989; Gottlieb, Robinson, Krichten, et al., 1992; Bank, Kubo, Rector, Heifetz, et
al., 1991).
Problems with implementation of optimal pharmacological care
Importantly, despite the clear efficacy of the above-described pharmacological
approaches for treatment of heart failure, there is consistent evidence that many physicians fail to
properly treat their patients. In the latest study concerning this issue, Dr. Gregg Fonarow of the
University of California, Los Angeles, looked at how often patients hospitalized with heart
failure were discharged with four standard kinds of care. He found they are often missing,
although stated this varied widely from hospital to hospital. "There are certain hospitals in the
United States where 100 percent of the patients get this," he said. "There are others where
patients had a better chance of winning the lottery than getting the indicated care." Clearly these
discrepancies point at significant barriers that exist on the providers’ side in the proper delivery
of care.
Non-Pharmacological Management
It is interesting to consider that despite the available pharmacological strategies, the
prevalence of heart failure continues to rise, as is the number of deaths from the disease.
Furthermore, it is important to recognize that in spite of the overwhelming evidence that the
aforementioned drugs are effective in the management of chronic heart failure the reduction in
mortality and improvements in clinical manifestations of the disease are relatively modest.
Finally, it must be recognized that heart failure patients in the general population, who are
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receiving appropriate drug therapy, do not appear to fare as well as those patients participating in
clinical trials.
These factors clearly point at the complexity of the heart failure syndrome and the need
for constant vigilance on part of the physician and patient. The purpose of the following section
is to describe some available non-pharmacological strategies that with optimal pharmacotherapy
appear to be of extreme importance in managing the heart failure syndrome. The fact, that many
of these factors appear to have a large behavioral component, one must clearly recognize that the
management of this disease has become quite multidisciplinary.
A major goal in the non-pharmacologic management of the heart failure syndrome is
aimed principally at modifying lifestyle and obtaining better compliance with the therapeutic
regimen (Colonna, Sorino, D’Agostino, et al., 2003). Modifications of lifestyle can be helpful in
controlling the symptoms of heart failure and maintaining clinical stability. For example, it has
been suggested that basic habits of moderate sodium restriction, weight monitoring, exercise, and
adherence to medication schedules may aid in avoiding fluid retention or alerting the patient to
its presence (Jessup, 2003 NEJM).

In a review of the literature from 1966 to 1993 (Dracup,

Baker, Dunbar, et al., 1994), counseling and health education increased life expectancy and
quality of life, and reduced hospitalization of patients with heart disease. In 1994, the Agency for
Healthcare Policy and Research (AHCPR) published guidelines for the management of patients
with HF. Suggested topics for education and counseling of patients with heart failure are listed in
Table II (AHCPR, 1994).
Sodium Restriction
Sodium retention is in part a consequence of neurohumoral activation, which is a
fundamental hallmark of CHF. The value of this compensatory strategy is to retain fluid
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necessary to raise blood volume in the face of a reduction of contractile function. The downside
of this strategy is that patients are at significant risk for exacerbations of their condition when
sodium intake is increased. Thus careful day-to-day management of sodium intake is a crucial
component of heart failure care.
Excess dietary intake of sodium can induce sodium and water retention, especially in
persons who are more sensitive to sodium intake, such as obese patients (Hall, 1997; Luft &
Weinberger, 1997). Sodium and water retention plays an important role in the pathogenesis of
hypertension and congestive heart failure (CHF) (Reisin, 1990; Andreoli, 1999). Chronically
high dietary intake of sodium may contribute to the development of CHF by increasing blood
pressure (pressure overload) or extracellular fluid (volume overload).
Several cross-sectional epidemiologic studies (Liebson, Grandits, Prineas, et al., 1993;
Messerli FH, Schmieder, Weir, 1997; Schmieder, Messerli, Garavaglia, et al., 1988; Kupari,
Koskinen, Virolainen, 1994) have suggested a significant and independent association between
dietary sodium intake and left ventricular hypertrophy. In the Treatment of Mild Hypertension
Study (Liebson, Grandits, Prineas, et al., 1993), dietary sodium intake was estimated from 2
consecutive overnight urine collections and left ventricular structure was assessed by M-mode
echocardiography in 511 men and 33 women with mild hypertension. After adjusting for age,
sex, race, body mass index (BMI), previous medication, alcohol consumption, cigarette smoking,
physical activity, and systolic blood pressure, a difference of 25 mmol per 8 hours in urinary
sodium excretion was associated with a 41% (95% confidence interval, 22%-63%) increase in
the odds of left ventricular hypertrophy. Messerli and colleagues (Messerli FH, Schmieder, Weir,
1997) revealed 9 cross-sectional studies in which the association between dietary sodium intake
and left ventricular mass was assessed. The correlation coefficients for the relationship varied
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from 0.22 to 0.61, with p<.05 in each of the studies. Animal studies (Frohlich, Chien, Sesoko, et
al., 1993; Sugimoto, Fujimura, Takasaki, et al., 1998) also indicate that high sodium intake is an
independent risk factor for the development of cardiac hypertrophy. However, there are sparse
data on the relationship between dietary sodium intake and the risk of HF from prospective
cohort studies.
A recent study by Jiang, et al. (2002) took advantage of the large sample size and
prolonged follow-up experience of participants in the first National Health and Nutrition
Examination Survey (NHANES I) Epidemiologic Follow-up Study (NHEFS) to examine the
relationship between dietary sodium intake and incidence of CHF in a nationally representative
sample of the US general population. Study participants consisted of 5233 nonoverweight and
5129 overweight men and women without a history of CHF at their baseline examination.
Overweight was defined as a body mass index (calculated as weight in kg divided by the square
of height in meters) of 25.0 or greater for men and women. Dietary sodium and other nutrient
intake estimates were obtained by a 24-hour dietary recall method at the baseline examination,
conducted from 1971 to 1975. The incidence of CHF was assessed using medical records and
death certificates obtained in 1982 to 1984, 1986, 1987, and 1992. During an average of 19 years
of follow-up, 413 cases of CHF in nonoverweight and 679 cases of CHF in overweight
participants were documented. The cumulative incidence of CHF was not significantly
associated with baseline sodium intake in the nonoverweight participants. For example, the
cumulative incidence of CHF at 90 years, adjusted for total caloric intake, was 35.6%, 42.9%,
37.4%, and 47.4% among patients within the first, second, third, and fourth quartiles of dietary
sodium intake, respectively (p=.48 for trend). In contrast, dietary sodium intake was significantly
associated with risk of CHF among overweight individuals. The cumulative incidence of CHF at
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age 90 years, adjusted for total caloric intake, was 44.0%, 43.6%, 53.6%, and 63.1% among
patients within the first, second, third, and fourth quartiles of dietary sodium intake, respectively
(p=.02 for trend). Furthermore, after adjustment for known CHF risk factors, the relative risk of
CHF among overweight participants was 1.43 (95% CI, 1.07-1.91) for those whose sodium
intake was greater than 113.6 mmol/d compared with those whose intake was less than 50.2
mmol/d. The relative risk of CHF for a 100 mmol/d higher intake of sodium or per 1743 kcal
(average energy intake in the study population) were 1.26 (95% CI, 1.03-1.53) and 1.21 (95%
CI, 1.04-1.40), respectively. Data suggest that a high dietary intake of sodium is an independent
risk factor for congestive heart failure in overweight persons. Furthermore, the findings suggest
that sodium reduction may play an important role in the prevention of CHF in the US general
population.
A reduction in dietary sodium intake can have substantial hemodynamic and clinical
benefits in patients with advanced heart failure (Cody, Kubo, and Pickworth, 1994).
Interestingly, the magnitude of sodium restriction is not clear. In a review article, many
physicians, primarily cardiologists, showed a wide array of opinions on sodium restriction. Only
25% suggested a sodium diet of <2g, whereas, 33% of the physicians suggested no added salt in
cooking for patients with NYHA class II CHF (Hlatky, Fleg, et al., 1986). Although the efficacy
of restricting sodium to specific levels has not been studied, in general the degree of sodium
restriction depends on the severity of heart failure. It has been suggested that sodium should be
limited to a maximum of 2-3 g per day for mild to moderate heart failure, and less than 2 g per
day for severe heart failure (Weinberger & Kenny, 2000; Konstam, Dracup, Baker, et al., 1994).
A 2 g sodium diet is frequently recommended (HF Guideline Panel, 1994; Dracup K, Baker DW,
et al., 1994). However, no studies have been conducted to evaluate specific recommendations
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related to sodium restriction (Konstam, et al., 1994). In general, a 2 g sodium diet is unpalatable
for many patients, whereas a 3 g sodium diet may be a more realistic goal for patients with mild
to moderate heart failure (Grady KL, Dracup K., et al., 2000). It can be achieved by avoiding
salty foods (e.g, canned or frozen foods) and by not adding salt to foods after cooking. When
this goal is met the clinical results indicate improved hemodynamics and decreased CHF
exacerbations. If sodium restriction strategies remain ineffective, patients may require larger
doses of diuretic agents for adequate control. (Tucker, Van Den Berg, & Knox, 1980). More
importantly, moderate sodium restriction permits the use of lower doses of diuretics (Consensus
Recommendations, 1999), which is clearly advantageous to the patients considering the
problems associated with long-term diuretic use (such as electrolyte imbalance and worsening
lipid profiles). The effectiveness of diuretic therapy is enhanced when the patient follows a
reduced-sodium diet. Sodium intake is strictly correlated with the administration of diuretics. If
the diuretic dose is increased to compensate for a more liberal sodium intake, the reninangiotensin-aldosterone system will be strongly activated and will promote thirst, as well as
deplete potassium and magnesium (Haller C, Salbach P, et al., 1995). Moreover, in the absence
of sodium restriction, diuretics become less effective (Cody RJ, Kubo SH, et al., 1994).
Dietary sodium indiscretion is a common reason for exacerbations of heart failure, and
inadequate patient education can contribute to failure to follow the prescribed diet. Both patients
and their families or caregivers need thorough, constant and specific instructions about how to
achieve the prescribed sodium restriction. Most people are knowledgeable about obvious sources
of sodium but are unaware of the sodium content of less obvious sources. Patients should be
advised not to add salt to food during preparation and to avoid foods containing large amounts of
sodium, such as highly processed foods, canned foods, luncheon meats, and “fast” foods

156

(AHCPR, 1994). Patients should be taught to look for words other than “salt” on food labels, for
example sodium or potassium hydrochloride (Fletcher & Thomas, 2001). The use of salt
substitutes and spices, such as lemon, pepper, and garlic, may be helpful (Haller C, Salbach P, et
al., 1995). Dietary instruction must take into account ethnic preferences and may require
individualized counseling by a dietician (Grady, Dracup, et al., 2000). Referral to a dietician or
advanced practice nurse with expertise in diet counseling may promote better patient and family
understanding of the diet and of the options for making a sodium-restricted diet palatable
(Konstam, Dracup, et al., 1994).
In summary, it appears that indiscretion of sodium intake contributes to heart failure
exacerbations. The main problem patients face is that given the heightened neurohumoral milieu
many patients are on a tightrope in terms of their fluid balance. Any fluctuation in sodium intake
may therefore contribute to a condition of fluid overload, which causes additional stress on a
weak cardiovascular system and lead to acute congestive heart failure. Consequently, patients
must receive thorough, constant and specific instructions about how to control sodium intake.
The evidence that moderate to aggressive sodium restriction is beneficial to the heart failure
patient is strong, preventing hospitalization, lowering medical costs and reducing mortality.
Alcohol
Alcoholic beverages can be detrimental in patients with HF because alcohol is a
myocardial depressant and may, even in small doses, further depress myocardial contractility
(Regan, 1990). However, no studies of the effect of moderate ingestion of alcohol on functional
status or death have been conducted. In general, alcohol intake should be strongly discouraged
and patients with HF should limit consumption to one drink per day (HF Guideline panel, 1994;
Grady, Dracup, Kennedy, et al., 2000). Alcohol avoidance is clearly imperative in patients with

157

alcohol-induced cardiomyopathy and, if necessary, these patients should be encouraged to attend
Alcoholics Anonymous to maintain long-term sobriety (Soler-Soler & Permanyer-Miralda, 1994;
Fletcher & Thomas, 2001).
Daily Weights
Periodic self-examination of certain parameters can be useful for the management of the
disease. A daily weight check represents an index to identify any possible problems of water
retention. In a retrospective review of 585 patients hospitalized for CHF, 59% of the
exacerbations were traceable to excessive sodium retention, with a subsequent overloading of the
circulation (Bennett, Huster, and Baker, et al., 1998).
All patients should be instructed to weigh themselves each morning (after urinating and
before eating) and record the data in a log, which should be taken to every visit with the clinician
(Konstam, Baker, Dracup, et al., 1994). An unjustified increase in weight of 3-5 pounds in 1-3
days should induce the patient to consult his or her physician for any eventual therapeutic
adjustments that, if carried out in time, may help avoid hospitalization (Konstam, Baker, Dracup,
1994; Fletcher & Thomas, 2001; Colonna, Sorino, D’Agostino, et al., 2003). It has been
suggested that highly cooperative patients can be given a diuretic regimen that they can selfadjust based on daily weights (Dracup, Baker, Dunbar, et al., 1994; Colonna, Sorino,
D’Agostino, et al., 2003). It is imperative that the patient understands that weight gain may mean
the body is retaining fluid and a phone call to the doctor or specific center may help prevent an
exacerbation (Colonna, Sorino, D’Agostino, et al., 2003).

Fluid Restriction
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Drinking large amounts of fluids should be avoided, although fluid restriction is not
recommended unless hyponatremia develops (HF Guideline Panel, 1994). Whereas sodium
restriction has been a standard suggestion, the reduction of water intake in patients with HF has
not always been recommended. The controversy arises from the suggestion to restrict water
intake only in hyponatremic patients (Konstam, Dracup, Baker, 1994). No controlled prospective
trials have examined this issue. However, patients with advanced HF may need to have their
daily fluid restricted to 2 L per day (Fletcher & Thomas, 2001). This is a clinical judgment based
on signs of congestion, fluid overload, and weight gain. Limiting fluid intake to 2 L per day
usually helps to maintain weight and can reduce the use of large doses of diuretics. It is
important to remind patients that certain foods, such as fruits or soups, contain a large amount of
water (Colonna, Sorino, D’Agostino, et al., 2003).
Smoking Cessation
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Smoking of tobacco is to be forbidden in patients with HF (Konstam, Dracup, Baker, et
al., 1994). Besides the well-known coronary risk factors that lead to atherosclerotic disease,
smoking has certain hemodynamic effects that aggravate the condition of the patient with HF. It
leads to an increase in heart rate and
systematic arterial pressure. Additionally,
there is a slight increase in the pulmonary
arterial pressure, the filling of the left
ventricle, and peripheral vascular and
pulmonary resistance, along with a
reduction in the cardiac output, especially
in patients with ischemic cardiomyopathy.
Smoking may induce a slight reduction in
the volume of left ventricular ejection.
This is associated with the increased need
for oxygen because of the increased
cardiac workload caused, in turn, by the
increase in heart rate and peripheral
resistance, as well as by the reduction in

the

amount of oxygen because of the presence

of

carboxyhemoglobin. In patients with HF,

this

series of cardiocirculatory effects
associated with bronchopathic breathing
problems, typical for smokers, does

Figure 8a -c. Cardiac Responses to Acute Exercise in Heart
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nothing to precipitate or aggravate CHF.
Physical Activity
As discussed in the section on pharmacological approaches to the treatment of heart
failure there is clear evidence that numerous pharmacological agents are available which help
improve central hemodynamics by reducing cardiac afterload or enhancing myocardial
contractility. Additional pharmacological agents are used to reduce excessive fluid retention.
Following initiation of such therapy mortality is reduced, and many patients experience
resolution of their symptoms at rest (Hunt, Baker, Chin, et al., 2001). However, most patients
continue to experience activity-related symptoms, including shortness of breath, muscle fatigue,
and weakness. As a result patients with heart failure often complain of chronic fatigue and are
unable to perform many of their normal activities of daily living. Thus, despite traditional
pharmacologic treatment, the clinical phase of heart failure includes a marked decline in
functional state, as defined by exercise tolerance and capacity with a subsequent decrease in
quality of life.
Cardiac Responses to Acute Exercise in Heart Failure
Previous studies which have examined the cardiac response to an acute bout of exercise
in patients with heart failure demonstrated characteristic responses to dynamic exercise (see
Figure 8a-c) (Sullivan, Knight, Higginbotham, et al., 1989). However, as functional class
declines there is a progressive decrease in the cardiac output, stroke volume, blood pressure and
heart rate reserve capacity (Hanson, 1994). A reduction in cardiac output during exercise and
perhaps more importantly a loss in cardiac reserve is an important factor limiting exercise
tolerance in patients with heart failure.
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Circulatory Responses to Acute Exercise in Heart Failure
Studies which have examined circulatory responses to an acute bout of exercise in
patients with heart failure generally
report a reduction in nutritive flow to
muscle (see Figure 9) (Sullivan,
Knight, Higginbotham, et al., 1989).
Consequently, exercise performance
is markedly reduced in the majority
of patients. It is, however, important
to recognize that the reduction in

Figure 9. Leg Blood Flow during Acute Exercise in Heart Failure

blood flow to working muscle is not entirely due to a reduction in cardiac output or local
vascular impairment. In fact, a major consideration is a change in the distribution of blood flow
during exercise (Wilson & Ferraro, 1985).
Whereas the blood flow distribution
in a healthy individual may lead to as much
as 75 to 80% of the cardiac output reaching
the working muscle, this is not the case in
the heart failure patient. Not only do
patients with heart failure have difficulties
opening up tissue beds, but due to the
overall stiffness of the vasculature these
patients also have an inability to constrict in
non-working tissue (Wilson & Ferraro,
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Figure 10a and b. Lactate Responses to Acute Exercise in Heart

1985). Consequently, blood flow abnormalities are complex and not solely due to impaired
vasodilatory function. Moreover, if the vascular problems indeed extend to the venous system,
the inability to properly remove metabolic end-products from the tissue beds and the inability to
increase pre-load with exercise may contribute to the reduced blood flow to tissue. Considering
the cardiovascular system is a closed circuit, we speculate cardiac insufficiency, decreased
arterial reactivity, reduced muscle blood flow, venous alterations and elevated cardiac pressures
contribute to a reduction in the driving pressure across metabolic tissue. Consequently, decreased
driving pressure could affect metabolic waste removal, alter cardiac filling kinetics and decrease
exercise tolerance (Welsch, Alomari, Parish, et al., 2002).
Skeletal Muscle Responses to Acute Exercise in Heart Failure
Skeletal muscle abnormalities contribute to the clinical severity of the heart failure
syndrome. It is, therefore, no surprise that patients with heart failure have higher lactate levels at
submaximal workloads compared to controls (see figure 10a and b) (Sullivan, Knight,
Higginbotham, et al., 1989).
Recent reports also suggest the rate of change in oxygen kinetics is significantly altered
in patients with heart failure (see Figure 11) (Cohen-Solal, Laperche, Morvan, et al., 1995).
Heart failure patients have much
slower recovery on-kinetics and
off-kinetics as a result of a bout
of exercise. In particular the
slower recovery from physical
activity may carry some
significant prognostic
Figure 11. Oxygen Kinetics to and following Acute Exercise in
Heart Failure
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information, and may in part explain why patients with heart failure often complain of symptoms
of chronic fatigue.
Finally, skeletal muscle atrophy contributes to a significant reduction in both muscle
strength and endurance in patients with heart failure. Consequently many daily tasks are indeed
more than a chore and often result in excessive fatigue and shortness of breath. Unfortunately,
the chronic fatigue and shortness of breath contributes to the vicious cycle of deconditioning as
the patient becomes more and more reluctant to engage in these sorts of activities.
Evidence for the Importance of Exercise Training
Until the late 1980s physical activity for heart failure patients was discouraged and many
patients were told to refrain from physical exertion (Smith, Braunwald & Kelly, 1992). This
conservative approach was due to a concern for a greater risk for cardiovascular complications
during exercise. Arguably, this conservative approach has contributed to the considerable
morbidity in heart failure patients. Reports since the 1980s clearly indicate that heart failure
patients can safely participate and benefit from exercise training programs. As a result exercise
training has emerged as a beneficial adjunct to the management of patients with heart failure (see
Table III and IV).
The first report indicating that heart failure patients could safely participate and benefit
from a cardiac rehabilitation program dates back to 1979 (Lee, Ice, Blessy, 1979). In this study,
post myocardial infarction patients, with an average ejection fraction of 18% were trained at 70%
to 85% of their maximal heart rate for 20 to 45 min, 4 days per week. The training program
averaged about 19 months and resulted in a significant increase in exercise tolerance (Lee, Ice,
Blessy, 1979). Since that study, a number of studies have been conducted, and despite
considerable variation in the duration, intensity and length of training, a consistent finding is that
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heart failure patients can increase exercise capacity and tolerance following a period of exercise
training without increasing the risk for cardiovascular complications (see Table III) (Jette, Heller,
Landry, et al., 1991; Belardinelli, Scocco, Mazzanti, et al., 1992; Coats, Adamopoulos, Radaelli,
et al., 1992; Belardinelli, Georgiou, Cianci, 1995; Hambrecht, Niebauer, Fiehn, et al., 1995;
Keteyian, Levine, Brawner, et al., 1996; Radaelli, Coats, Leuzzi, et al., 1996; Welsch, 1996;
Dubach, Myers, Dziekan, et al., 1997; Willenheimer, Erhardt, Cline, et al., 1998; Callaerts-Vegh,
Wenk, Goebbels, et al., 1998; Reinhart, Dziekan, Goebbels, et al., 1998; Belardinelli, Georgiou,
Cianci, et al., 1999; Taylor, 1999; Sturm, Quittan, Wiesinger, et al., 1999; Keteyian, Brawner,
Schairer, et al., 1999; Wielenga, Huisveld, Bol, et al., 1999; Kiilavuori, Naveri, Salmi, et al.,
2000; McKelvie, Teo, Roberts, et al., 2002; Erbs, Linke, Gielen, et al., 2003; Giannuzzi,
Temporelli, Corra, et al., 2003). The average increase in exercise capacity defined as VO2peak is
approximately 25%, with the majority of the improvement occurring by the third week, although
improvements continue slowly up to 6 months. In addition to the consistent improvements in
maximal exercise performance, indices of submaximal exercise such as measured by the 6minute walk also improve (Parish, Alomari, Wood, et al., 2002).
The mechanism(s) involved in the improvements observed with exercise training suggest
that the changes in exercise capacity and tolerance are more related to reversing the peripheral
compensatory abnormalities, rather than improvements in cardiac function (see Table IV).
Cardiac output shows either no change (Sullivan, Higginbotham, & Cobb, 1988), or a small
increase following a period of chronic exercise training (Coats, Adamopoulos, Radaelli, et al.,
1992). However, it is important to note that exercise training does not appear to worsen the
process of left ventricular remodeling. In fact, randomized trials do not report any adverse effects
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of exercise training on regional wall motion, left ventricular systolic function and dimensions
(Erbs, Linke, Gielen, et al., 2003; Giannuzzi, Temporelli, Corra, et al., 2003).
Exercise training improves respiratory muscle function and markers of work of breathing
(Coats, Adamopoulos, Radaelli, et al., 1992; Mancini, Henson, La Manca, et al., 1995). In
particular, a selective respiratory muscle training program contributed to both physiological and
clinical improvements in patients with chronic heart failure. The improvements were evident in
terms of greater ventilatory muscle endurance, and increases in strength of both the inspiratory
and expiratory muscles (Mancini, Henson, La Manca, et al., 1995). Moreover, training resulted
in an increase in the maximum walking distance on the 6-minute walk test. Perhaps, most
importantly, the majority of the patients engaged in this type of training reported a subjective
decrease in dyspnea during activities of daily living (Mancini, Henson, La Manca, et al., 1995).
A consistent response of exercise training in patients with heart failure is improved
autonomic balance (Coats, Adamopoulos, Radaelli, et al., 1992; Radaelli, Coats, Leuzzi, et al.,
1996; Kiilavuori, Toivonen, Naveri, et al., 1995; Roveda, Middlekauff, Rondon, et al., 2003).
This is reflected through an apparent shift away from the hyperadrenergic state typically
observed in these patients. Markers of the autonomic system including resting heart rate, heart
rate variability, sympathetic nerve activity and plasma catecholamine concentrations are all
favorably altered following exercise training (Coats, Adamopoulos, Radaelli, et al., 1992;
Radaelli, Coats, Leuzzi, et al., 1996; Kiilavuori, Toivonen, Naveri, et al., 1995; Roveda,
Middlekauff, Rondon, et al., 2003). In addition, the concentration of the fluid regulatory
hormones angiotensin II, aldosterone, vasopressin and arginine vasopressin under resting
conditions are significantly reduced perhaps reflecting the improved autonomic balance (Braith,
Welsch, Feigenbaum, et al., 1999).
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Recent evidence also indicates the benefits of exercise training on reversing the stiffness
and lack reactivity of peripheral arteries (Hornig, Maier, & Drexler, 1996; Hambrecht, Fiehn,
Weigl, et al., 1998; Kobayashi, Tsuruya, Iwasawa, et al., 2003). Presumably, vessels that are less
stiff and better able to dilate or constrict contribute to improved distribution of the available
cardiac output to working skeletal muscles. Interestingly, the improved vasodilatory capacity
appears to be specific to the area trained as 4 weeks of handgrip exercise only showed restored
flow-dependent dilation in the trained arm. Moreover, the beneficial effect of training was also
lost after 6 weeks of cessation of training (Hornig, Maier, & Drexler, 1996). This suggests the
importance of a well-rounded training stimulus, but also emphasizes the benefits of local training
on vascular beds, something that may be particularly useful in patients with severe heart failure.
In fact, it is interesting to consider that a whole-body training program increases coronary flow
reserve as evidenced by increased vasoreactivity of epicardial vessels (Hambrecht, Wolf, Gielen,
et al., 2000). Combined these findings indicate the enormous potential of exercise training in
reversing the maladaptive vascular changes evident in these patients.
Exercise training significantly improves skeletal muscle function, blood flow and
metabolic capacity in patients with heart failure (Coats, Adamopoulos, Radaelli, et al., 1992;
Sullivan, Higginbotham, & Cobb, 1988; Stratton, Dunn, Adamopoulos, et al., 1994; Hambrecht,
Fiehn, Yu, et al., 1997; Pu, Johnson, Forman, et al., 2001). The magnitude of leg muscle blood
flow increases reportedly are similar in heart failure patients compared to healthy normal
controls, indicating the adaptive response is preserved (Sullivan, Higginbotham, & Cobb, 1988).
Following a local forearm training protocol, muscle bioenergetics, as assessed by 31P-NMR
spectroscopy, improved only in the trained forearm. Skeletal muscle responses to exercise after
the one month program indicated less phosphocreatine utilization, higher muscle pH at
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submaximal workloads, and improvement in phosphocreatine recovery kinetics. In part, these
changes are indicative of an improved mitochondrial ATP synthesis rate. Finally, patients with
heart failure who engage in regular physical exercise show enhanced oxidative enzyme activity
in the working skeletal muscle and a concomitant re-shift to type I fibers. The improvements are
at least in part secondary to a significant increase of the surface density of cytochrome c oxidasepositive mitochondria and the surface density of mitochondrial cristae (Hambrecht, Fiehn, Yu, et
al., 1997).
Moreover, recent evidence supports the safety and efficacy of resistive training in
patients with heart failure (Pu, Johnson, Forman, et al., 2001; Hare, Ryan, Selig, et al., 1999).
Recognizing the overwhelming evidence that resistive training can have a significant impact on
functional ability, implementation of a tailored resistive program may be an important
component in the management of these patients. Evidence that heart failure patients can adapt to
resistance training was recently shown. Training resulted in significant increases in strength and
endurance associated with a lower O2 consumption at submaximal workloads (Pu, Johnson,
Forman, et al., 2001). No complications with the training program were observed. Thus, it
would appear a program of combined aerobic and resistance training could be quite beneficial.
However, given the lack of large clinical trials the safety of resistance training in patients with
HF needs to be further established. Combined, these findings suggest that skeletal muscle
abnormalities in heart failure are, in part, due to a deconditioning process, and can be partially
reversed through exercise training.
Thus, there is growing evidence that exercise training may reverse many of the peripheral
abnormalities present in the heart failure patient. Exercise training may improve autonomic
function, skeletal muscle blood flow and localized oxidative capacity (see Table IV). Together,

168

these changes may translate in an increased exercise tolerance, reduction in activity-related
symptoms, and improved quality of life. These findings assume added importance in light of
previous reports that exercise capacity is one of the most powerful predictor of survival of heart
failure patients (Bittner, Weiner, Yusuf, et al., 1993). Perhaps most importantly, a recent metaanalysis of randomized controlled exercise training trials reports a significant improvement in
survival time in patients with
chronic heart failure (see Figure
12a) (Piepoli, Davos, Francis, et
al., 2004). Time to death or
admission to hospital was also
significantly extended (see
Figure 12b) (Piepoli, Davos,
Francis, et al., 2004).
Guidelines, Risk
Stratification, and Exercise
Prescription
The Committee on
Exercise, Rehabilitation, and
Prevention of the American Heart

Figure 12a and b. Effects of Exercise Training on Survival
time and Hospital Admissions in Heart Failure Patients

Association Council on Clinical Cardiology American Heart Association, recently, published a
scientific statement on the role of exercise in heart failure (Pina, Apstein, Balady, et al., 2003).
The Committee concludes that exercise training in patients with heart failure seems to be safe
and beneficial in improving exercise capacity, exercise duration, and parameters of submaximal
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exercise performance. In addition, quality of life improves in parallel to the improvements in
exercise capacity. Furthermore, benefits have been reported in muscle structure and
physiological responses to exercise, such as improvements in endothelial function,
catecholamine spillover, and oxygen extraction in the periphery, among others. The committee
encourages the stratification of individuals in risk categories prior to engaging in a physical
activity program. These risk categories should be based on the individuals’ clinical
characteristics and likelihood of untoward events. Patients classified as Stage A, should be
encouraged to participate in exercise training programs to prevent the further development of the
disease. Stage B and C patients are also encouraged to participate in activity programs, but these
patients may require more specific attention in terms of monitoring and exercise prescriptions.
Patients in Stage D have symptoms at rest or on minimal exertion (including profound fatigue),
and generally cannot perform most activities of daily living. Consequently, physical activity
should be limited until these patients have improved hemodynamic function secondary to
specialized treatments.
Importantly, it must be recognized that agreement on a universal exercise prescription for
heart failure patients does not exist. Consequently, an individualized approach is recommended,
using standards provided in the American Heart Association Standards (Fletcher, Balady,
Amsterdam, et al., 2001). Prior to starting the program a clear understanding of the patient's
medical history, present medical and physiological status, and personal need is necessary to
maximize safety and efficacy. Once the heart failure patient is deemed medically stable, and
fluid status is adequately controlled, the patient should be introduced to an exercise training
program. The exercise prescription should have specific guidelines concerning the frequency,
intensity, duration, mode, and progression of the exercise program. Initially, because of the
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marked exercise intolerance, it may be necessary to use an interval training approach, with 2-6
min low level activity interspersed with appropriate periods of rest. Frequency of training may
be as much as 2 to 3 times a day during the early stages of the program. Warm-up and cooldown periods should be longer to allow adequate time for the body to prepare and recover from
the activity. Depending on the patient's medical status, reported symptoms during training, and
tolerance of the exercise session, intensity, duration and frequency may be altered.
Determination of an appropriate exercise intensity for the heart failure patient on the
basis of maximal exercise capacity is often difficult. If a symptom-limited graded exercise test is
used the exercise prescription should be based on VO2reserve, rather than heart rate reserve,
secondary to frequent impaired chronotropic responses. The use of the VO2reserve method has
been recommended by the American College of Sports Medicine especially for low-fit clients
(ACSM Position Stand, 1998). The starting intensity for patients with heart failure is generally
quite low and should be as tolerated. As the patient responds favorably a more defined program
may be developed starting at 40-50% of VO2reserve, or slightly below any significant symptoms,
such as angina, exertional hypotension, dysrhythmias, and shortness of breath. More constant
supervision may be needed during the early stages of the exercise program for all heart failure
patients, with the use of more intensive monitoring of blood pressure responses and
electrocardiograms. In addition, the rating of perceived exertion scales should be used, guiding
patients to a rating of 11-14 (on the 15-grade category Borg scale), whereas symptoms of angina
and dyspnea should not exceed 2+ on a "0-4" scale ("Moderate, Bothersome" on the Angina
scale and "Mild, Some Difficulty" on the Dyspnea scale). The duration of exercise should be
gradually increased again depending on patient's tolerance. The choice of exercise for heart
failure patients has traditionally focused predominantly on cardiovascular activities, such as
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walking and cycling. Clearly these activities are necessary to remain independent and it is
therefore important to gradually progress the patients to higher intensities and longer durations if
additional work is tolerated. However, decisions on progression should not solely be based on
the observed responses during exercise, but the clinician should also determine to what extent the
exercise impacts the patient’s remainder of the day.
Current guidelines by the American Heart Association and other organizations do not
include guidelines for a resistance training component for heart failure patients. However, the
Committee recognizes that resistive exercises can offer the opportunity to strengthen individual
muscle groups. However, since the safety of resistance training in patients with heart failure
needs to be further established in larger trials, it would seem a conservative approach may be to
use light to moderate resistance training as part of a well-rounded program for select patients.
Thus, the principles of exercise prescription for heart failure patients are similar to those
for healthy people. The major differences relate to the application of these principles to the
patient. The goal of an exercise program for the heart failure patient is to reduce morbidity
associated with the disease and maintain functional capacity for independent living. Generally,
heart failure patients should start out slowly, and initially aim to increase duration of exercise.
How well the heart failure patient adapts to the training program should dictate the frequency
and magnitude of progression. Finally, patients should be made familiar with the use of a
physical activity pyramid to recognize that a gradual increase in overall activities interspersed
with proper rest periods throughout the day is pertinent in the management of their condition (see
Figure 13).
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Rest and Relaxation
Sleeping
and
Reading

Work or Leisure-related
Physical Activities
Structured
Physical Activity
Functional
Activities

Yard work,
Stairclimbing
Dancing & Lifting

Cardiovascular, Muscular,
and Flexibility using
specific frequency,
intensity, and duration
Making bed, moving from sitting to standing,
Cooking, Washing-up, Bathing, and other
Household activities, Light Walking, Grocery
Shopping

Figure
13. Physical Activity Pyramid for Chronic Heart Failure Patients.
In summary, patients with medically stable heart failure should be considered for
participation in an exercise training program. Guidelines for and components of an exercise
program for the heart failure patient are similar to other clinical populations and healthy
individuals. However, the exercise prescription should be designed to meet the unique goals and
demands of the patient.

Compliance
Up to 65% of hospital admissions are due to noncompliance with both pharmacologic
and nonpharmocologic treatment regimes (Dahl & Penque, 2000). There are many reasons that
patients may not comply with a therapeutic regimen. Lack of knowledge, poor motivation,
decreased understanding, lower perceived self-efficacy, forgetfulness, and decreased support
from family and other caregivers have been identified as factors that contribute to
noncompliance (Bennett, Huster, Baker, et al., 1998; Conn, Taylor, & Kelley, 1991; Happ,
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Naylor, Roe-Prior, 1997; Ni, Nauman, Burgess, et al., 1999; Jaarsma, Halfens, Huijer-Abu Saad,
1999; Dracup, Baker, Dunbar, et al., 1994). Additionally, a patient may not comply with a
prescribed regimen because he or she is unconvinced of the benefits of doing so or because he or
she perceives that the side effects or inconveniences of following the regimen outweigh any
benefits (Grady, Dracup, Kennedy, et al., 2000). Furthermore, it has been suggested that one
reason for high rates of noncompliance may simply be lack of understanding of the treatment
plan (Dracup, Baker, Dunbar, et al., 1994).
Noncompliance with diet and medications can rapidly and profoundly affect the clinical
status of patients, and increases in body weight and minor changes in symptoms commonly
precede the major clinical exacerbations that require emergency care or hospitalization
(ACC/AHA, 2001). In fact, some studies have demonstrated that it is the lack of recognition by
the patient of the symptoms of a worsening pathology that has led to a delayed use of appropriate
treatment (Friedman, 1997; Francis, 1998). It has been suggested that if patients know the
symptoms and signs of worsening heart failure, they may be able to seek care early and avoid
hospitalization (Dracup, Baker, Dunbar, et al., 1994; Konstam, Baker, Dracup, et al., 1994). For
example, patients should be told that dyspnea and fatigue are normal responses during moderate
exertion in patients with heart failure. This explanation will help alleviate anxiety over
performing daily activities that might provoke shortness of breath. However, physicians and
patients must understand that progressive dyspnea on exertion or sudden changes in orthopnea or
paroxysmal nocturnal dyspnea are not expected. Moreover, excessive fatigue during and
following exertion must also be considered. In general, a sudden deviation from the normal
responses may indicate worsening heart failure and such information should be communicated to
the health care provider immediately (Konstam, Baker, Dracup, et al., 1994).
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It is important to consider that healthcare providers also contribute to heart failure patient
noncompliance and hospital readmissions. Impediments to patient compliance include advising
changes that disregard the patient’s current lifestyle and failing to counsel or advise patients on
how to adapt their current lifestyle to accommodate recommended changes (Dunbar, Jacobson,
& Deaton, 1998). Healthcare providers may fail to follow appropriate treatment guidelines
(Fonarow, Stevenson, Walden, et al., 1997; Hunt, Baker, Chin, et al., 2001), or make
recommendations without detailing how to implement the recommendations (Grady, Dracup,
Kennedy, et al., 2000). For example, clinicians may fail to adequately educate and counsel the
patient or support person who may be responsible for purchasing food, cooking, and
administering medications (Konstam, Baker, Dracup, et al., 1994). Another important factor that
contributes to patient noncompliance and rehospitalization for worsening heart failure is
inadequate discharge planning and follow-up after discharge (Vinson, Rich, Shah, et al., 1990).
Therefore, it is important to consider that the barriers to successful management of patients are
also present on the healthcare provider’s side. Physicians and other providers should be attuned
to the problem of noncompliance and its causes, discuss the importance of compliance at followup visits, and assist patients in removing barriers to compliance (eg, cost, adverse effects, or
complexity of the therapeutic regimen) (Dracup, Baker, Dunbar, et al., 1994). For example, if
medication cost is a factor in noncompliance, suggestions for lower-cost medications or financial
assistance programs should be provided (Grady, Dracup, Kennedy, et al., 2000).
Rosenstock (1975) explains that to comply with treatment, patients must understand the
nature of their illness, why they are being treated, how long the treatment will last, and the
results of treatment (Rosenstock, 1975). Descriptive research of 41 patients with chronic HF
found that almost all patients could not correctly define HF, less than half could correctly

175

identify their medications, and almost three fourths of patients did not weigh themselves daily
(Bushnell, 1992). A complete, comprehensible explanation of the illness has been shown to
increase compliance with the treatment plan (Bushnell, 1992), improve functional capacity and
quality of life, and reduce hospital readmission rates (Rich MW, Beckham, & Wittenburg, 1995;
Fonarow, Stevenson, & Walden, 1997; Dahl & Penque, 2000). Therefore, the education of the
patient and his family or caregiver represents a fundamental aspect of therapy.
Education
Given the complexity of the heart failure syndrome and the available treatment strategies,
education and counseling of patients and their families are vitally important for maintenance and
clinical stability (Grady, Dracup, Kennedy, et al., 2000). In a review of the literature from 1966
to 1993 (Dracup, Baker, Dunbar, et al., 1994), counseling and health education increased life
expectancy and quality of life, and reduced hospitalization of patients with heart disease.
Moreover, multiple studies have shown that patients who are educated and knowledgeable about
their disease process and understand how their medications work and the importance of
compliance have fewer hospital readmissions and experience an increase in functional capacity
and quality of life (Rich, Beckham, & Wittenburg, 1995; Fonarow, Stevenson, & Walden, 1997;
Dahl & Penque, 2000). Quality of life and social functioning may be more important to patients
than physiological impairment and long-term survival (Rideout, Montemuro, 1986; Dracup,
Walden, Stevenson, et al., 1992), and practitioners should emphasize that patients with heart
failure can live active and enjoyable lives (Dracup, Baker, Dunbar, et al., 1994). A recent study
of 51 patients with heart failure revealed that a majority placed greater importance on improved
symptoms rather than longer survival as the preferred outcome (Stanek, Oates, McGhan, et al.,
2000). Therefore, the goals of education and counseling are to assist patients in compliance with
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the therapeutic regimen, to maintain clinical stability and function, and to improve quality of life
(Grady, Dracup, Kennedy, et al., 2000). These goals are best achieved when the patient and
family are knowledgeable about every aspect of the condition and treatment and are active
participants in the plan of care (Konstam, Baker, Dracup, 1994).
A complete, comprehensible explanation of the illness increases compliance with the
treatment plan (Bushnell, 1992). Patients and their support group must understand their disease;
a specific but simplistic discussion of the basic pathophysiology and etiology of heart failure,
using language that the patient can thoroughly grasp, is vital (Dracup, Baker, Dunbar, et al.,
1994). The educational needs of heart failure patients have traditionally included topics such as
anatomy and physiology, medications, sodium restrictions, dietary changes, activity levels, and
psychological responses (Dracup, Baker, Dunbar, et al., 1994; Hagenhoff, Feutz, Conn, et al.,
1994). Hagenhoff et al. (1994) studied the perceived learning needs of 30 hospitalized heart
failure patients and 26 nurses, who ranked these categories according to importance (Hagenhoff,
Feutz, Conn, et al., 1994). Patients and nurses agreed that medication information was the most
important to learn. Psychological concerns and activity received the lowest rankings, and the
researchers suggested that, because of shorter lengths of hospital stay and decreased opportunity
for patient education, these aspects could be taught in the outpatient setting (Hagenhoff, Feutz,
Conn, et al., 1994). The general trend across all patient education content areas was for patients
to rate the information as more important to learn than the nurses rated the information. These
findings suggest that patients value education regarding their condition during their
hospitalization for HF and this should continue to be an important focus of care for this
population (Hagenhoff, Feutz, Conn, et al., 1994). However, patient comprehension can be
limited in the hospital due to the shortened length of stay, the unfamiliar environment, anxiety,
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fatigue, and inability to concentrate owing to acute illness (Knox & Mischke, 1999). Therefore,
due to the complex nature of the illness, patient education should extend to the outpatient setting
(Connolly, 2000) and requires collaboration between the patient and health care providers from
the inpatient, outpatient, and home care settings (Knox & Mischke, 1999). The Agency for
Healthcare Policy and Research (AHCPR) guidelines for the management of heart failure
patients suggest that education become a standard part of management plans and that both
content and counseling be included (Konstam, Dracup, Baker, et al., 1994).
A clear and organized plan of patient education and counseling is critical to the
achievement of optimal outcomes. Counseling and education have been observed to improve
patient outcomes and decrease unnecessary hospitalizations in patients with HF (Dracup, Baker,
Dunbar, et al., 1994). Patients with HF benefit most when educated about sodium and fluid
restrictions and other dietary issues as well as the pathophysiology of HF, medications, signs and
symptoms of worsening heart failure, and activity or exercise (Dracup, Baker, Dunbar, et al.,
1994). In 1994, the Agency for Healthcare Policy and Research published guidelines for the
management of patients with HF, and suggested topics for education and counseling of patients
with heart failure are listed in Table II (Konstam, Dracup, Baker, et al., 1994). Because not all
components of the program are appropriate for all patients, treatment must be individualized and
adapted to accommodate the needs and circumstances of each patient.
Aggressive management in the outpatient setting is essential to improving survival and
reducing the risk for hospitalization (Connolly, 2000). Although it is important to discuss
medications and dietary recommendations with patients who are being discharged from the
hospital, a full discussion of these topics should be conducted in the outpatient setting and
repeated as often as necessary (Connolly, 2000). Patients do not absorb and retain all necessary
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information in a single educational session (Mullen, Mains, & Velez, 1992). Therefore, patient
education should occur over time and be an ongoing process (Dracup, Baker, Dunbar, et al.,
1994). Patient and family understanding needs to be continually assessed and counseling
activities adjusted accordingly (Konstam, Baker, Dracup, et al., 1994). Providers should be
sensitive to differences in patients’ language, culture, and educational level that may impair
understanding and compliance (Estey, Musseau, & Keehn, 1991). In addition, written
educational materials and video or audio-tapes can help clarify information and enhance
discussions but should serve as adjuncts to and not as replacements for one-on-one education
(Grady, Dracup, Kennedy, et al., 2000).
The telephone may be a simple, useful tool for enhancing compliance. Telephone
technology was used in the medical field in the diagnosis of respiratory problems as early as
1979 (Grument, 1979). Effective telephone care can yield correct and timely diagnosis and
treatment, promote compliance with the treatment regimen, and enhance patient and health care
provider satisfaction (Guy, 1995).
Compliance is also enhanced when the patient participates actively in developing the plan
of care and when families are informed and supportive partners in this plan (Hubbard,
Muhlenkamp, & Brown, 1984; Swain & Steckel, 1981). Therefore, patients and their families
should be encouraged to ask questions about any aspect of the management of heart failure or a
recommended intervention (Dracup, Baker, Dunbar, et al, 1994). Education regarding proposed
interventions should be designed to help patients and their families arrive at realistic expectations
about risks and benefits (Konstam, Baker, Dracup, et al., 1994). Nursing interventions, family
involvement, and support groups may all help patients cope with heart failure and make the
many lifestyle changes required by the disease (Dracup, Baker, Dunbar, et al., 1994).
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Of the general measures that should be pursued in patients with HF, possibly the most
effective, yet least utilized is close attention and follow-up (Hunt, Baker, Chin, et al., 2001).
Patient education and close supervision, which includes surveillance by the patient and his or her
family between physician visits, can reduce the likelihood of noncompliance and can often lead
to the detection of changes in body weight or clinical status early enough to allow the patient or a
healthcare provider an opportunity to institute treatments that can prevent clinical deterioration
and hospitalization (Konstam, Dracup, Baker, et al., 1994). ). In general patient selfmanagement includes monitoring the level and intensity of symptoms (for example, shortness of
breath or pain) and objective data (blood pressure and glucose levels) and adjusting the treatment
plan accordingly (Dunbar, Jacobson, Deaton, et al., 1998). For patients with heart failure, the
self-management plan includes monitoring changes in symptoms such as fatigue, shortness of
breath, daily body weights, and knowing when to report the changes to the health provider
(Konstam, Dracup, Baker, et al., 1994). Supervision between physician visits ideally may be
performed by a nurse or physician assistant with special training in the care of patients with HF.
Such an approach has been reported to have significant clinical benefits (Rich, Beckham,
Wittenberg, et al., 1995; Shah, Der, Ruggerio, et al., 1998; Fonarow, Stevenson, et al, 1997;
Philbin, 1999). A detailed analysis of hospital readmissions in heart failure patients who were
participating in a clinical trial that provided comprehensive discharge planning and homecare
intervention by an advanced practice nurse revealed that failure to adhere to the treatment plan
was the predominant factor related to readmission (Happ, Naylor, Roe-Prior, 1997). Even though
patients were provided with individualized intervention by advanced practice nurses who
focused on preventing exacerbations of heart failure through symptom recognition, medication,
dietary education, and modification of poor health behavior, there was a 33% readmission rate in
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the intervention group within the first 6 months after hospital discharge. Most readmissions
occurred after the intervention had ended (1 month), suggesting that more follow-up may be
needed by some patients (Happ, Naylor, Roe-Prior, 1997). Social support and individual
motivation to learn and manage health behavior were also viewed as influential in adherence to
the prescribed treatment (Happ, Naylor, Roe-Prior, 1997). These findings illustrate the overall
complexity in addressing the education process for heart failure patients.
Education will only work if the patient’s willingness to learn is appreciated. Therefore,
the provision to patients and their families/caregivers of behavioral strategies to increase
adherence is vital. There are many strategies to assist patients to comply with their heart failure
regimen, such as the use of a daily reminder routine, filling a pill box that contains 1 week’s
medications, the implementation of incremental monitoring by caregivers, the use of medication
information and reminder cards, and counseling (Stewart, Pearson, & Horowitz, 1998).
Behavioral theories, such as the Transtheoretical model of behavior change (Prochaska,
Norcross, & DiClemente, 1994), may be useful in designing effective approaches to patient
education programs. Although there have been no studies in which outcomes of these methods
with heart failure patients have been reported, these approaches could be used individually or in
a combined framework to guide strategies that go beyond traditional patient educational
approaches (Dunbar, Jacobson, Deaton, et al., 1998).
The Transtheoretical approach views the process of changing health behavior as
occurring in several specific stages, referred to as stages of change (Prochaska, Norcross, &
DiClemente, 1994). The transtheoretical model of behavior change (TTM) was first described in
1982 as a proposed mechanism of smoking cessation (Prochaska & DiClemente, 1982). This
model has been validated and applied to a variety of behaviors that include smoking cessation,
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exercise behavior, and dietary behavior (Prochaska, Velicer, Rossi, et al., 1994; Hellman, 1997;
Glanz, Patterson, Kristal, et al., 1994). Understanding behavior change as a process rather than a
single event, the TTM attempts to explain how, rather than why, behavior change occurs
(Prochaska, Norcross, & DiClemente, 1994). The TTM states that there are five distinct stages
(see Table ?) involved in behavior change, during which 10 different processes of change (Dunn,
Marcus, Kampert, et al., 1997) may be used (see figure 14). The TTM suggests that for
successful behavior change, interventions must be tailored to a person’s current stage of
readiness and make use of the appropriate processes of change (Prochaska, Norcross, &
DiClemente, 1994).
One role of the physician is to assist patients in understanding their health and to help
them make the changes necessary
for health improvement
(Zimmerman, Olsen, & Bosworth,
2000). A change in patient lifestyle
is necessary for management of
long-term illnesses, such as heart

The Transtheoretical Model and
Stages of Change
PreContemplation Preparation
contemplation
40%
20%
40%

Action

Maintenance

Consciousness Raising
Dramatic Relief
Environmental Re-evaluation
Self Re-evaluation
Self-Liberation
Reinforcement Management
Helping Relationships
Counter Conditioning
Stimulus Control
Prochaska et al. The Transtheoretical Model and Stages of Change.
In Health Behavior and Health Education

failure (Konstam, Dracup, Baker,
et al., 1994). By assessing stage of readiness regarding a particular behavior or a lifestyle pattern
and determining whether the patient has experience with attempting the change, the clinician can
determine which interventions might be most effective in managing the heart failure patient. The
specific motivational interventions vary by stage of change. For example, if patients state that
they have never tried a low sodium diet but are considering reducing sodium, they may be in the
contemplation phase, and interventions would include raising their consciousness about the
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importance through calculating the sodium in food typically consumed and investigating low
sodium alternative products at the grocery store. Emotional arousal is also important for
successful behavior change at this stage and could include imagery to visualize fluid building up
in an overloaded pump (heart). If the patient reports trying to reduce sodium intake in the past
but finding the diet intolerable, the patient’s stage of change is relapse. Interventions could
include setting up a personal reward system, seeking the help of family members, and helping
the patients focus on the positive aspects of what they are doing for their overall health.
MULTIDISCIPLINARY PROGRAMS
Heart failure rarely occurs as an isolated disease process, and management is frequently
confounded by a host of medical, behavioral, psychological, social, and economic factors. A
considerable amount of the economic cost associated with heart failure care is attributable to
repeated exacerbations that frequently require hospitalization, with rates ranging from 30% to
50% within 3 to 6 months of the initial discharge (Gooding & Jette, 1985; Rich & Freedland,
1988; Vinson, Rich, et al., 1990). Moreover, behavioral factors contributing to readmissions
include nonadherence to diet, medication, and activity regimens, social isolation, inadequate
symptom self-assessment and management, inadequacies in patient and care-giver education, and
poor discharge planning and follow-up, suggesting that such readmissions could be prevented, or
significantly delayed, with better health care and improved patient participation in his or her
treatment. (Konstam, Dracup, et al., 1994; Rich, Vinson, et al., 1993; Vinson, Rich, et al., 1990;
Dracup, Baker, et al., 1994; Happ, Naylor, et al., 1997; Ghali, Kadakia, et al., 1988; Kaspar,
Gerstenblith, et al., 2002; Rich, Beckham, et al., 1995).
It follows that management of these patients requires appropriate attention to all aspects
of care, both pharmacologic and nonpharmacologic, and that comprehensive disease
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management may best be accomplished through the use of a multidisciplinary team approach
(Grady, Dracup, et al., 2000). A recent AHA Scientific statement examined the team
management of heart failure patients (Grady, Dracup, et al., 2000) and indicated that components
of successful healthcare delivery models for heart failure include staff skilled in the
understanding of the pathophysiology of heart failure, patient assessment and evaluation of
symptoms, education and counseling (focusing on symptoms and medication compliance),
dietary consultation, and physical activity and exercise recommendations (Grady, Dracup, et al.,
2000). Therefore, the following section discusses the various multidisciplinary trials that have
been conducted over the past 21 years. The trials are presented chronologically, with the
observational studies first, followed by the randomized trials. The multidisciplinary trials are
further summarized in Tables VI - XI.
Observational Studies
Tables VI-VIII summarizes characteristics from 17 observational studies evaluating the
efficacy of various multidisciplinary heart failure disease management strategies. The first
observational study (Cintron et al. 1983) combined meticulous management in a HF clinic with
easy accessibility to a nurse practitioner. Fifteen HF patients were seen an average of every 3
weeks for 7 to 48 months for a mean follow-up period of 24 months. Assessments included a
history, physical examination, and appropriate laboratory studies. Strong emphasis was placed on
weight control, diet, home situation, and family support. Medications were reviewed and, when
necessary, cardiology consultation was obtained before adjusting therapy or recommending
hospitalization. The average age of the study participants was 65 years, and all but three had
NYHA Class IV symptoms. When compared with an equivalent period of time before enrollment
in the clinic, hospitalizations declined by 61%, and hospital days were reduced by 85%.

184

Although annual total costs for outpatient care increased by $11,000, inpatient costs decreased
by $131,000, yielding an average cost savings of $8,000 per patient. In addition, all patients
reported improved satisfaction with the process of care.
Interestingly, despite the positive findings from Cintron (1983) it was not until 12 years
later before the next observational study appeared. Kornowski et al. (1995) described a program
of 42 housebound elderly patients (mean age 78±8 years) with NYHA class III or IV heart
failure who were examined weekly at home by internists and a paramedical team. Home visits
consisted of providing the patient a report about the medical condition, a history and physical
exam, review of medications, laboratory studies as necessary, and discussion of a treatment plan
for the subsequent week. Physical therapy, oxygen, IV infusions and supplemental visits were
also available as needed. The year prior to entry into the program was compared with the first
year of home surveillance. Participation in the program was associated with a 62% reduction in
total hospital admissions (3.2 +1.5 to 1.2 +1.6 hospitalizations/year), a 72% decrease in
cardiovascular admissions (2.9+1.5 to 0.8 +1.1 hospitalizations per year), and 77% fewer
hospital days (26+14 to 6 +7 days per year, p=0.001). In addition, functional status as assessed
by ability to perform daily activities on the patient global status index (1 to 4 scale), improved
from 1.4 ± 0.9 to 2.3 ± 0.7 (p<.001). This study showed improved outcomes but at an uncertain
trade-off in resource use between increased home visits and decreased hospitalizations for the
intervention. Although the cost of the intervention was not assessed, study coordinators projected
that the intervention resulted in increased cost savings (Kornowski, Zeeli, Averbuch, et al.,
1995).
In 1996, Lasater and coworkers (1996) examined a 6 month nurse-managed, home-based
program for cardiomyopathy and heart failure patients. In addition to the nurse, access to a

185

physician, dietician, and social worker was available as needed. 80 patients discharged with a
primary diagnosis of heart failure were automatically enrolled in the program, which focused on
preventing heart failure exacerbations through patient education about pharmacotherapy, diet,
and activities of daily living. Medication compliance assessments were also performed, and
assistance with financial concerns was provided as needed. Follow-up clinic visits were
scheduled at the nurse’s discretion and averaged 3.7 visits per patient over the 6-month period.
Patients recorded daily weights and a weight gain of 4 pounds served as a threshold for
increasing diuretic therapy. Compared to the 6-month period immediately before entry into the
program, the overall hospitalization rate decreased by 14%, and the average length of stay
declined from 7.3 to 5.7 days, a 22% change. In addition to a 32% reduction in total hospital
days, hospital charges decreased by $500 per patient and a retrospective cost analysis concluded
that the intervention was cost saving.
Three observational trials were conducted in 1997. In the first of these studies, West el al.
(1997) used a strategy of physician-supervised but nurse-mediated, home based heart failure
management, not involving home visits (West, Miller Parker, et al., 1997). Like Kornowski et al.
(1995), West and colleagues (1997) studied a disease management strategy in a group of patients
recruited from a northern California HMO.
Patients were followed for an average of 138 ± 44 days. The mean age of the study population
was 66 years, with 71% men, and 40% were in NYHA functional class III or IV. Nurses directed
the implementation of consensus guidelines to maximize vasodilator doses, reduce dietary salt
intake, monitor patients for early evidence of worsening heart failure, and provide patient
support and education by frequent telephone contact. The intervention consisted of an initial

186

comprehensive visit followed by regularly scheduled telephone calls. The average number of
telephone contacts per patient during follow-up was 13.
Compared with the 6 months before enrollment, general medical and cardiology visits
declined by 23% and 31%, respectively (p<.03). Hospitalization rates for heart failure and for all
causes declined 87% and 74%, respectively (p=0.001), compared with the year before
enrollment. Additionally, self-reported dietary sodium intake measured by food-frequency
questionnaires showed a persistent and significant reduction of 38%, declining from 3.4 to 2.1 g
per day (p<0.0001). Furthermore, patients reported substantial improvements in multiple indices
of symptom status and quality of life, including NYHA functional class, Duke Activity Status
Index, and both the physical and mental component scores of the Medical Outcomes Study Short
Form 36 (SF-36) Health Survey (West, Miller Parker, et al., 1997). Although the investigators
did not report on cost of the intervention, it is likely that the marked reduction in resource
utilization was associated with significant cost savings.
Also in 1997, Fonarow et al. (1997) described a program of intense inpatient
management followed by careful post-discharge follow-up among 214 patients referred for
treatment of advanced CHF and evaluation for heart transplant (Fonarow, Stevenson, et al.,
1997). Participants in this study were younger than those in previous studies, with an average age
of 52 years, 81% were men, and the mean LVEF was 21%. Forty-four percent of the patients
were in NYHA class III, whereas 56% were in class IV. After discharge, patients received close
follow-up with frequent telephone contact and clinic visits. Telephone calls were made 2-3 days
after any major medication change and at routine intervals between 2 and 8 weeks, as warranted
by clinical stability and patient need for reassurance.
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The protocol consisted of invasive hemodynamic monitoring and intensification of the
medical regimen, including high-dose vasodilators, diuretics, and digoxin. Patient education and
lifestyle modification were emphasized by nurses with specialized training in heart failure and
reinforced by printed teaching materials. Furthermore, regular, unsupervised exercise was
recommended, although no specific detail was provided.
Compared to the 6-month period preceding referral, there was an 85% reduction in
hospital admissions (Fonarow, Stevenson, Walden, et al., 1997). Factoring in the initial 214
admissions for transplant evaluation yielded a net reduction in total hospitalizations of 44%.
Additionally, dosages of ACE-Inhibitors or isosorbide dinitrate, and diuretics markedly
increased; whereas calcium channel blockers and type I antiarrhythmic agents were virtually
eliminated. Furthermore, NYHA functional class improved significantly (p<0.001) with 49% of
the patients reclassified as functional class I or II. Finally, peak oxygen consumption increased
from a mean of 11.0 + 3.6 to 15.2 + 4.4 mL/kg/min, an increase of 38% at the 6-month followup, which placed these patients outside of the cardiac transplant range (Fonarow, Stevenson,
Walden, et al., 1997). The estimated net savings of the intervention, after subtracting the initial
hospital costs and nursing costs during follow-up, was $9,800 per patient. The potential to reduce
both symptoms and costs suggests that referral to a heart failure program may be appropriate not
only for potential heart transplantation, but also for medical management of patients with
functional class III and IV heart failure (Fonarow, Stevenson, Walden, et al., 1997).
A similar study was conducted by Hanumanthu et al. (1997), in which 134 patients were
referred to a heart failure and transplantation program for periods ranging from 30 days to 1 year
(Hanumanthu, Butler, Chomsky, et al., 1997). The average age of the participants was also
52+12 years and the mean LVEF was 29+11. In comparison to Fonarow’s study, the HF/
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transplant team provided comprehensive management, which included intensive medical therapy
and patient education. Compared with the 1-year period prior to the intervention, cardiovascular
hospitalizations declined from 210 to 104, a reduction of 53% (p<0.01), and heart failure
admissions decreased from 97 to 30, a 69% reduction. Additionally, at 6-month follow-up, mean
peak exercise oxygen consumption improved from 12.8+4.7 to 15.7+4.8 mL/kg/min (p<0.01) an
increase of 23%. An added component of this study in comparison to Hanamanthu’s work was
that Quality of life was also assessed, using the Minnesota Living with HF Questionnaire (scale:
0 –105, higher score=more impairment). Composite scores improved significantly from 57+27 to
35+26 (p<0.01), a difference of 34 points.
Tilney et al. (1998) referred 1,915 medicare HMO patients with CHF in a proprietary
disease management program (Tilney, Whiting, Horrar, et al., 1998). The average age was 74
and 50% of participants were male. In this 12-month program nurse-managers coordinated
patient education and clinical surveillance, in collaboration with home care specialists,
pharmacists, and the patient’s primary physician. Using patients as their own controls and other
historical reference groups, investigators found a 20% reduction in daily dietary salt intake.
Additionally, hospitalization rates decreased significantly from 164 to 60, a reduction of 60%,
resulting in a marked decrease in health care costs (55%).
The apparent success of the multidisciplinary programs also spurred individual
physicians to attempt such strategies in a setting with fewer resources. Smith et al. (1997)
followed up 21 patients in a cardiomyopathy clinic composed of a cardiologist and nurse
practitioner. New patients referred to the clinic with LVEF < 45% were enrolled in the program.
The average age was 61 years, 90% were white and 100% were male. The intervention included
comprehensive patient education, optimization of medication dosages, and regular clinic visits.
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Compared with the 6-month period preceding entry into the clinic, heart failure admissions and
emergency visits declined by 87% (14 to 2, p= 0.017) and 100% (8 to 0, p=0.002), respectively.
However, the frequency of clinic visits was determined by symptom severity and the need for
medication changes and increased 5-fold, averaging approximately 10.5 per patient during a 6month follow-up period. Additionally, LVEF increased from 24% to 36%, NYHA class
improved significantly from 2.6 + 0.5 to 2.2 + 0.5, as did the Minnesota Living with Heart
Failure Scores, with an average improvement of 23 points (p=0.001). Finally, exercise time
increased from 6.7 to 8.8 min (p=0.005), although maximum oxygen consumption remained
unchanged (15.4 ml O2/kg/min initially and 15.3 ml O2/kg/min at the end of 6 months (Smith
LE, Fabbri SA, Pai R, Ferry, et al., 1997).
Similar results were obtained in patients enrolled in an outpatient interactive home
monitoring program (Shah, Ruggerio, Heidenreich, et al., 1998). In this study, Shah and
colleagues examined the utility of a high technology approach that used patient self-assessment
with automated reminders (Shah, Ruggerio, Heidenreich, et al., 1998). Twenty-seven men with
NYHA class II to IV heart failure and average age of 62 (range 42-81) participated in the 8-week
program, which consisted of weekly mailings of heart failure educational materials and weekly
telephone counseling sessions by a heart failure nurse. In addition, a paging system was used to
transmit computer-generated reminders to the patient to take medications and to maintain daily
records of weight, heart rate, and blood pressure, and these data were monitored by a study
nurse. Physicians received monthly progress reports, as well as immediate notifications by fax
whenever significant changes in clinical status occurred. Patients were followed up for an
average of 8.5 months, and hospitalizations for equivalent periods before and after the
intervention were compared. Although hospitalization rates declined by 50%, this difference was
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not significant. However, cardiovascular admissions were reduced significantly, as were total
hospital days and hospital days for cardiovascular causes. Patient acceptance of the program was
high; 82% of patients rated the program useful or very useful. Enthusiasm was particularly high
among the NYHA class III to IV patients, of whom 15 of 17 (88%) rated the program very
useful, compared with 4 of 10 class II patients. These data suggest that close telephone
monitoring can prevent hospitalizations for heart failure among both recently discharged patients
and ambulatory outpatients and among both elderly and middle-aged persons (Shah, Der,
Ruggerio, et al., 1997).
Heidenrich and colleagues (1999) provide further evidence supporting the clinical use
and cost-effectiveness of heart failure disease management programs (Heidenreich, Ruggerio, &
Massie, 1999). Sixty-eight patients with NYHA class II or III heart failure and an average age of
73 years were enrolled from multiple small practices (largely primary care) in northern
California and followed-up for an average of 7.4 months. A nonrandomized parallel control
group was composed of 86 patients matched to the intervention group on the basis of medical
claims during the preceding year. As an adjunct to physician care, the intervention consisted of a
low-intensity, home-based, computer-assisted telemonitoring system supplemented by weekly
educational mailings and phone calls. The mailings described 52 HF topics (1 per week for 1
year), including diet, exercise, common therapies, and simple anatomy and physiology. A nurse
discussed the topics during 10-minute weekly phone calls and educational points were
reinforced. The nurse only offered education and made no changes in management. New
symptoms, medications, and physician visits were recorded. Physicians were notified by fax
when there was a change in the patient’s clinical condition, but such notification occurred
infrequently (approximately once in 3 months per patient) and was nonintrusive, thereby
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facilitating physician acceptance. Compared with the pre-intervention period, total medical
claims during the 1-year period after implementation of the intervention declined by $1100 per
patient in the treatment group but increased by an average of $9600 in the comparison group.
Hospital days were also reduced significantly in the intervention group, but there was little
change in quality of life as measured by the SF-36. As in other studies, the beneficial effects of
the intervention were greater in patients at higher risk for recurrent hospitalizations. The
intervention was well accepted by study participants, and compliance rates with the
telemonitoring program were high (Heidenreich, Ruggerio, & Massie, 1999).
This study differs in several aspects from previous studies that have noted reduced
resource use with multidimensional programs for patients with heart failure. Several of these
programs were limited to patients with severe heart failure (Fonarow, Stevenson, Walden, et al.,
1997) or were limited to discharge planning (Rich, Beckham, Wittenberg, et al., 1995).
Additionally, all medical care was provided by the patient’s physician, and the study nurses
served only as counselors and educators. This is in contrast to the programs reported by West et
al (1997), and Cintron (1983), which used nurse practitioners to aid in medication management
with the supervision of physicians. Because the program is of low cost and does not require
direct supervision by the primary physician, it may be easily adaptable to a wide range of health
care providers and clinical practice settings. Limitations include the nonrandomized design,
small sample size, relatively low recruitment rate (implying potential sampling bias), and
inability to assess the effects of individual program components. Despite these limitations, this
study is an important contribution to the growing body of literature supporting the use of novel,
multidisciplinary programs of patient monitoring, education, and physician notification in the
management of heart failure.
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Knox et al. (1999) described the efforts of a physician-led multidisciplinary team to
provide coordinated care across the continuum of health care for patients with heart failure. The
integrated 18-month program comprised components of inpatient consultation and education, an
outpatient CHF clinic, home care, and a telephonic system to monitor patient compliance with
recommended therapy. The program employed daily monitoring, ongoing education, and
consistent communication by all members of the health care team and was designed to decrease
length of stay, reduce costs, prevent readmissions, and improve compliance with the treatment
regimen. As a result of pathway implementation, direct costs declined 50% and length of stay
decreased to 4.0 days compared with 6.2 days before the program’s inception. Results also
revealed reductions in the 30-day readmission rate, from 17% to 2.3%, and hospitalization rates
of 0.6/pt/year compared with the national benchmark of 1.7/pt/year. After 18 months,
telemanagement patients’ compliance rates averaged 89.5%. Additional clinical outcomes
included patient satisfaction, improvements in percentage of daily weights recorded, frequency
of dietary consultation, documentation of LV function, prescribing appropriate medications, &
scheduling follow-up care (Knox & Mischke, 1999).
Results of this study (Knox & Mischke, 1999) support previous reports that
hospitalization rates in patients with heart failure can be substantially reduced by improved
patient education, patient self-monitoring of weight, and rapid response to early signs of clinical
decompensation (Rich, Beckham, Wittenberg, et al., 1995; Fonarow, Stevenson, Walden, et al.,
1997; Hanumanthu, Butler, Chomsky, et al., 1997) A unique aspect of this study was that
patients were viewed as “co-managers” of their illness and education and treatment were
individualized to the specific learning styles and needs of each patient (Knox & Mischke, 1999).
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In 1999, Wilson and coworkers examined whether home health care services for heart
failure were associated with decreased hospitalization frequency and costs (Wilson, Smith,
Dahle, et al., 1999). 35 patients, mean age 57 +11 and average LVEF of 20 +10% were referred
to 18 home health agencies for administration of IV diuretics (n=19), home inotropic therapy
(n=10), and general monitoring to ensure compliance with diet and medication and to detect
clinical deterioration (n=6). Specific instructions for patient care were provided to each home
care agency. Patients were enrolled for a mean of 94+94 days and nursing visits averaged 2.8
+1.7 days, and ranged from daily to weekly. The average weekly charges were $348/patient and
costs increased to $1,382/patient with inotropic therapy. Patients were hospitalized 47 times for
HF during the 3-month period prior to enrollment compared to 52 times after referral (p=NS).
Furthermore, after adjusting for deaths, patients were hospitalized at a rate of .45 per month
before enrollment compared to .66 per month after (p<0.05). Annualized hospitalization rates
averaged 5.4 hospitalizations per year in this study versus 3.2 hospitalizations per year in the
study by Kornowski et al (Kornowski, Seely, et al., 1995), and approximately 2.7
hospitalizations per year in a randomized study by Rich et al (Rich, Beckham, et al, 1995).
Despite the use of relatively costly services, no significant decrease in hospitalization
rates was seen in this population (Wilson, Smith, Dahle, et al., 1999). Several potential reasons
exist why this study, in contrast to previous studies, failed to demonstrate reduced hospitalization
rates after home-care referral. First, the overall quality of home health care delivered to these
patients was less consistent than in previous studies. For example, the present study used 18
home health agencies with different protocols and nursing staff with varying levels of expertise.
In contrast, Kornowski (Kornowski, Seely, et al., 1995), Rich et al. (Rich, Beckham, Wittenberg,
et al., 1995), Stewart et al. (Stewart, Pearson, Horowitz, 1998), and Knox and Mischke (1999)
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used a single agency of home health care nurses who delivered care using standard protocols.
However, the authors argue that the type of protocol used in the present study more likely
reflects actual clinical practices in the United States, as most clinicians are compelled to work
with a diverse group of home health agencies (Wilson, Smith, Dahle, et al., 1999).
Constantini et al. (2001) assembled a disease management team to achieve goals of
adhering to nationally published guidelines (Task Force of the Working Group on HF, 1997) for
care of patients with HF, and of identifying opportunities to improve quality & efficiency of
hospitalized HF patients (Constantini, Huck, Carlson, et al., 2001). Hospital length of stay, total
costs, and use of recommended guidelines were compared between 173 patients before team
implementation but with available guidelines, 283 care managed patients, and 126 concurrent
non-care managed patients. The nurse provided patient education, assessed discharge needs,
evaluated the patient’s ability to comply with a prescribed plan, and recorded daily responses to
medical treatment. Based on individual responses, the nurse or cardiologist modified the
treatment plan as necessary. Patients were referred as needed to ancillary services such as
physical therapy, social services, and dietary and substance abuse counseling. Results revealed
that care-managed patients achieved higher rates of ACE-inhibitor use than baseline or non care
managed patients (95%, 60%, & 75%, respectively; p<0.001), as well as increased adherence to
guidelines for daily weight monitoring and assessment of LV function. Hospital length of stay
was lower (median 3,4, & 5 days, respectively; p<0.001) as were costs of hospitalization
(median, $2934, $3209, & $4830, respectively; p<0.01). These results clearly indicate the
importance for physicians to strictly follow the available guidelines for the management of these
patients (Constantini, Huck, Carlson, et al., 2001).
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Hershberger et al. (2001) described a program of extensive telemanagement, preemptive
hospitalization for decompensated patients, continuity of care from inpatient to outpatient, and
implementation of effective therapy as defined by consensus statements (Konstam, Dracup,
Baker, et al., 1994; Williams, Bristow, Fowler, et al., 1995; Packer, Cohn, et al., 1999). One
hundred eight patients with HF were enrolled in the university-based outpatient HF management
program (Hershberger, Hanyu, Nauman, et al., 2001). Average age of the participants was 52
+12 years, 73% male, and 87% were white. Nurse coordinators contacted patients weekly or
biweekly for 4 to 6 weeks for close symptom surveillance & adherence to medical regimens.
Telephone follow-up was estimated at 20 to 30 minutes per patient per month for the first three
months, 5 to 10 minutes per patient per month thereafter. The total outpatient visits were 361,
with an average of 3.3 per patient during the 6 months of follow-up. Although patients were seen
collaboratively, each clinic patient encounter was discussed briefly with the group of 2-4
cardiologists, 4-5 nurses, and social worker to provide comprehensive ongoing knowledge of
each patient’s status. Educational topics included sodium restriction, pharmacological therapy,
warning symptoms of adverse medical interactions and HF progression, behavioral techniques
for improving adherence to dietary and medical therapy, and guidelines of when to notify a nurse
of a change in condition. Additionally, patients were given a brochure with information on
sodium restriction, physical activity, smoking cessation, self-monitoring of drug related
symptoms, and daily monitoring of symptoms and weight. Furthermore, nurses assessed
knowledge of HF and care, QOL, confidence to control symptoms, and health habits.
Compared with 6 months before referral, the intervention was accompanied by a 52%
reduction in risk of hospitalization for CV causes (56.1% vs. 27.2%,p<.001) and a 72% reduction
in ER visits for CV causes (53.6% vs. 14.5%, p<.01). Total hospital admissions decreased by
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59% from 94 to 39; whereas, total ER visits decreased from 83 to 19, a difference of 77%. QOL
scores improved over time with a change score of 11.2 (p<.001) at 3 months & 10.7 (p<.001) at
6 months. Finally, the proportion of patients with NYHA class III-IV decreased from 67% at
baseline to 49.1% at 6 months (p=0.01).
This study was the first to examine the pre-and postprogram differences in patient
knowledge of and adherence to self-care recommendations (Hershberger, Hanyu, Nauman, et al.,
2001). There was a significant improvement at 6 months after referral in the patients’ knowledge
regarding daily weight monitoring, importance of restricting dietary salt intake, and contacting
providers if experiencing a sudden weight change. The proportion of patients weighing
themselves daily increased by 24% (p=0.02). Nevertheless, no changes were observed in selfreported adherence to dietary salt restriction and medical dosage compliance. This finding
suggests that an increase in knowledge is not necessarily accompanied by concomitant changes
in self-care behaviors among patients with heart failure (Hershberger, Hanyu, Nauman, et al.,
2001).
Holst et al. (2001) assessed the ability of a 6-month HF care management program
including intensive education, and referral to a tailored exercise program to reduce readmissions
and improve quality of life and functional status in 42 outpatients with class III-IV HF. Average
age of the population was 54+12 and 75% were male. The program consisted of an initial 1-hour
consultation with a cardiologist and a 30 min introductory session with a study nurse to establish
communication for subsequent management coordination. All patients later attended a 2-hour
education session for partners and families, which was predominately a group session, but done
on an individual basis if required. Similar to the study by Knox and Mischke (1999), patients
were encouraged to take an active role and follow an action plan with instruction to seek medical
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care if symptoms worsened (Holst, Kaye, Richardson, et al., 2001). Purpose of education was to
improve patients’ understanding of HF, stressing warning signs & symptoms of deterioration.
Additionally, Patients received advice from a dietician regarding diet, fluid, & sodium
management, daily weights, and instructions on diuretic adjustment. Medication advice was also
outlined, with a goal to optimize use of ACE inhibitors and beta-blockers. Moreover, Patients
attended an exercise program 2-3x/week for 8 weeks, which was part of an existing cardiac
rehabilitation service. Exercise components included walking, biking, rowing, stepping, weight
resistance training, calisthenics, and work and activity conditioning. Patients completed 3
sessions at each attendance, and exercised at an intensity of 50-60% of HR max, a max breathing
frequency of 24/min, and a Borg rating of 9-12 for RPE. Furthermore, patients were encouraged
to maintain a home program of daily walking for 10-30 min, with aim for total exercise per day
of 30-60 min, 5-7 days per week. Patients attended the clinic an average of 3.4 times over the 6
month period, with an average of 4 phone contacts during the first month and 1 per month for the
remainder of follow-up.
Compared with the 6 month period prior to enrollment, hospital admissions difference of
87.2%. Additionally, visits to the general practitioner declined from 1.94+2.22 to 0.69+1.28
visits per patient (p=.006). Dosages of ACE-inhibitors and beta-blockers administered increased
by 42% (p<.0008) and 61% (p<.0001), respectively. Moreover, NYHA functional class
improved from 3.1+.35 to 1.8+.82 (p<0.0001) and exercise capacity, as assessed by the 6MW,
improved from 413+117m to 496+93.2m (p<0.0001). Furthermore, data revealed significant
improvements in LVEF, cardiac depression scale, and QOL. The program resulted in an
estimated cost savings of AUD $6198 per patient over a 6 month time frame (Holst, Kaye,
Richardson, et al., 2001).
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Also in 2001, Whellan and colleagues (2001) used a strategy of physician-supervised but
nurse-mediated heart failure management, incorporating specific concepts from previously
described disease management programs (Fonarow, Stevenson, Walden, et al., 1997;
Hanumanthu, Butler, Chomsky, et al., 1997; West, Miller, Parker, et al., 1997; and Shah, Der,
Ruggerio, et al., 1998). 117 patients with heart failure were followed in a tertiary setting for a
median of 4.9 months. The median age of participants was 62 years, 55% were white and 62%
male. 50% of the patients were in NYHA Class III or IV, with a median LVEF of 23%
(Whellan, Gaulden, Gattis, et al., 2001). Nurses directed the implementation of consensus
guidelines (Konstam, Dracup, Baker, et al., 1994; Williams, Bristow, Rowler, et al., 1995; Heart
Failure Society of America, 1999) to maximize vasodilator dosage, reduce dietary salt intake,
monitor patients for early evidence of worsening heart failure, and provide patient support and
education by frequent telephone contact (Whellan, Gaulden, Gattis, et al., 2001). The group
developed a patient education manual that reviewed topics such as medication purpose,
importance of adherence, potential adverse effects and appropriate actions to take should adverse
effects occur, diet, weight monitoring, physical activity, and resources available to HF patients.
The manual also included a diary for diet and daily weights. Inpatients were provided with a
consultation and a patient education manual and were contacted within 1 week after discharge.
Frequency of follow-up was based on clinical stability and severity of illness and could be
adjusted by the physician as needed. NYHA Class IV patients received weekly clinic visits for
the first month and weekly telephone calls for the first 3 months; whereas, clinic visits for
NYHA Class II-III patients were scheduled every 6 weeks with biweekly telephone calls.
Data collection was performed at 3-month intervals and compared to equivalent periods
preceding enrollment. Primary outcome measures were medication use and resource utilization.
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Results revealed that use of ACE inhibitors was high and did not change; however, there was a
50% increase in target dose (p<.01). Beta-blocker use and dose significantly increased from
52% to 76%, (p<.01) and from 6% to 25%, (p<.01), respectively. Additionally, hospitalization
rate decreased from 1.5 to 0 per patient-year (p<.01), while the number of clinic visits
significantly increased from 4.3 to 9.8 clinic visits per patient-year (p<.01). Finally, the total cost
of care decreased by a median of $8571 per patient-year, excluding the cost of providing the
program and any costs incurred by the patient such as transportation.
Todero et al. (2002) examined symptom occurrence, symptom characteristics, and quality
of life in 102 elderly patients recently hospitalized following an acute HF exacerbation. Nurses
visited each patient in their home at baseline, approximately 1 month after hospital discharge,
and again 2 months later to collect study data. At baseline all participants were shown a patient
educational video and were given an educational manual for reference. The program content was
derived from AHCPR clinical guidelines (Konstam, Dracup, Baker, et al., 1994) and included
routine reminders to monitor symptoms, with suggestions for symptom management (Todero,
LaFramboise, & Zimmerman, 2002). Patients received follow-up and further education
reminding them when to take medications, weigh daily, reduce dietary sodium, get routine
exercise, & manage worsening symptoms by 1 of 4 methods: Health Buddy, phone calls, home
visits, or combination of home visits and health buddy. Phone and home visit educational
counseling sessions were scheduled approximately weekly over 5-6 weeks until all topics were
discussed. The health buddy assessed patient status and provided information in smaller
segments daily. A preliminary analysis revealed no differences based on method of follow-up;
therefore, data were combined for the analyses. Results revealed significant improvements in
QOL as assessed by RP, BP, MH, & VT subscales of the SF-36 questionnaire, with trends
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toward improvement in PF & GH subscales. The occurrence of all symptoms was less at 2
months, with the exception of shortness of breath, which persisted. Although participants still
reported shortness of breath as the most common symptom, it was less frequent, less severe, and
caused less interference with activity and enjoyment. These data provide information on the most
common and distressing symptoms in a community-based HF population. This information may
be useful in guiding assessments and designing specific interventions to include in a home-based
disease management program. Furthermore, results suggest that a home-based disease
management program implemented in a variety of ways can improve symptom status and quality
of life in heart failure patients after discharge from the hospital (Todero, LaFramboise, &
Zimmerman, 2002).
In summary, the available evidence regarding the efficacy of the multidisciplinary
programs for patients with heart failure is extensive spanning approx 2 decades, across the globe,
and across various stages of the disease. These observational studies suggest that a
multidisciplinary approach to HF disease management may be associated with important clinical
benefits, including fewer readmissions and hospital days, improved quality of life and patient
satisfaction, increased exercise tolerance, and a reduction in cost of care. However, these data are
limited by the facts that the studies were nonrandomized (and therefore lacked a suitable control
group) and that the before-after comparison with respect to readmissions may have
overestimated the magnitude of benefit, as well as the potential cost savings. Furthermore,
because few of the studies were blinded, the data on quality of life, exercise tolerance, and
patient satisfaction may be confounded by the patient’s desire to please the health care provider,
by a learning effect, or other patient or observer biases. Therefore, although the observational
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data are encouraging, they are by no means definitive, and they require confirmation by carefully
conducted randomized trials.
Randomized Studies
At present, sixteen randomized trials regarding the management of heart failure have
been conducted. Despite the fact that few trials are similar in design, duration of study, or
consistency of the multidisciplinary team, a clear consensus emerges following the review of
results. The randomized trials are further summarized in Tables IX-XI.
The first randomized trial to examine the efficacy of a multidisciplinary program was
conducted by Rich et al. (1993), and was a prospective randomized pilot study designed to
evaluate a nurse-directed multidisciplinary management strategy in elderly patients hospitalized
with heart failure (Rich Vinson, Sperry, et al., 1993). The average age of participants was 79+6
years, 41% were men and 50% were nonwhite. Participants were randomized in a 2:1 ratio to
traditional care supplemented by a nurse-directed multidisciplinary team (n=63) or traditional
care as determined by the patient’s usual physician (n=35). The intervention included
comprehensive patient education by a geriatric cardiovascular nurse, a review of medications
with recommendations to reduce side effects and improve compliance, individualized dietary
instruction by a registered dietician, social services consultation to facilitate discharge planning
and aid in the transition to the home environment, and close follow-up after discharge by a home
health nurse and the study team. Participants were followed for 90 days and primary endpoints
were all-cause readmissions and the number of days hospitalized during follow-up. Readmission
rates in the intervention group and control group were 33.3% and 45.7%, respectively, reflecting
a difference of 27.1% in favor of the intervention. Additionally, the intervention group spent an
average of 4.3 days in the hospital compared with 5.7 days in the control group, an absolute

202

difference of 1.4 days per patient. Although encouraging, none of these differences were
statistically significant. The authors concluded that further investigation in a larger trial was
warranted, and that an appropriate cost analysis should be incorporated into such a trial (Rich,
Vinson, Sperry, et al., 1993).
In 1994, Kostis et al. (1994) conducted a small, randomized trial involving 20 patients
with heart failure. All but one participant was in NYHA Functional Class II, and all were
receiving ACE-inhibitors. Participants were randomly assigned to one of three groups:
nonpharmacologic treatment (n=7), digoxin (n=7), or placebo (n=6). Nonpharmacologic
treatment included exercise training, cognitive therapy, stress management, and dietary
instruction aimed at weight control and salt reduction. After 12 weeks, patients randomized to
nonpharmacologic therapy experienced significantly greater improvements in exercise tolerance,
anxiety and depression scores, and weight control when compared with the digoxin and placebo
groups. These benefits occurred despite the fact that ejection fraction increased with digoxin use
but was unchanged in the other two groups (Kostis, Rosen, Cosgrove, et al., 1994).
Based on findings from his previous study (Rich, Vinson, Sperry, et al., 1993), Rich and
coworkers (1995) performed a controlled trial of a nurse-directed, care management program to
determine readmission rates within 90 days of hospital discharge, quality of life, and costs of
care for high-risk elderly patients hospitalized with HF (Rich, Beckham, Wittenberg, et al.,
1995). A total of 282 HF patients in an urban tertiary center who were at high risk of hospital
readmission were randomly assigned to one of two groups: 1) conventional physician-directed
care (n=140), or 2) conventional care supplemented by a nurse-directed multidisciplinary team
(n=142). The study intervention was similar to their pilot study (Rich et al., 1993) and included
intensive patient education prior to discharge, which was reinforced during frequent and regular
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contacts by a home health representative and the study team. The intervention continued for 90
days following discharge, and during this period all-cause readmissions were reduced 44%, heart
failure readmissions were reduced 56%, readmissions for other reasons were reduced 29%, and
the proportion of patients requiring multiple readmissions was 61% lower in the intervention
group (Rich, Beckham, Wittenberg, 1995). Additionally, patients receiving the study
intervention reported improved quality of life, enhanced compliance with medications and diet,
and a greater knowledge of the heart failure syndrome (Rich, Beckham, Wittenberg, 1995). The
monetary savings associated with fewer hospitalizations offset the costs of the program, resulting
in an average reduction in medical costs of $460 per patient during the 3-month study.
Importantly, during an additional 9-month post intervention follow-up period, heart failure
readmissions remained 29% lower in the intervention group, suggesting a persistent beneficial
effect of the program and implying additional cost savings.
Weinberger et al. (1996) described a program of intensive primary care during and
immediately following hospital discharge among 1,396 severely ill veterans with CHF, diabetes,
chronic obstructive pulmonary disease or more than one of the three diagnoses (Weinberger,
Oddone, & Henderson, et al., 1996). Six hundred ninety five patients were randomized to the
intervention, which involved close follow-up by a nurse and a primary care physician, beginning
prior to discharge and continuing for six months, while the remaining 701 patients received usual
care. Primary outcome measures were readmissions and secondary outcomes included quality of
life and patient satisfaction with care. The average age of study participants was sixty-three
years, 99% were male, and 65% were white. Of the 504 patients with HF, 51% were in Class III
or IV. During the 6-month follow-up period, patients in the intervention group had significantly
higher rates of readmission per month than those in the control group, 0.19 vs 0.14, respectively.
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Additionally, total days of re-hospitalization were significantly higher in the intervention group
when compared with controls 10.2 vs. 8.8, respectively. Although patients in the intervention
group reported improved satisfaction with care, there were no differences between groups in
quality of life scores, which remained very low. The results were similar regardless of the
patient’s primary diagnosis.
These findings appear to challenge results from previous studies. There are several
possible explanations for the inconsistencies. First, the design is different from that used in other
studies. For example, the intervention merely provided increased access to healthcare, rather than
represented a "disease management program". Second, in most cases, the primary care physician
only had a single contact with the patient before hospital discharge, thereby prohibiting the
establishment of an effective physician-patient relationship. Moreover, there was inadequate
opportunity to perform a complete evaluation of the patient and optimize treatment during the
initial hospitalization. Lastly, the intervention was not disease specific and did not provide any
kind of algorithm or systematic approach to the treatment of heart failure exacerbations. These
results imply that providing increased access to healthcare without providing an improved
structure or algorithm for healthcare delivery is unlikely to enhance outcomes.
Three additional trials (Stewart, Pearson, & Horowitz, 1998; Cline, Israelsson,
Willenheimer, et al., 1998; Serxner, Miyaki, & Jeffords, 1998) were published in 1998 that
contradicted the findings of the previous study (Weinberger, Oddone, & Henderson, 1998), but
supported the findings of Rich (1995). In the first study, Stewart et al. (1998) randomly assigned
ninety-seven elderly patients admitted for heart failure to standard care after discharge (n=48) or
a home-based intervention (n=49) (Stewart, Pearson, Horowitz, 1998). The intervention was
unique in that it comprised a single home visit one week after discharge by either a nurse or a
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pharmacist. The purpose of the visit was to optimize medication management, identify early
clinical decompensation, and intensify medical follow up and caregiver vigilance as appropriate.
The average age of the participants was 75 years and 50% of the patients were women. All
patients had at least one prior hospitalization for heart failure, and all but 6 patients were in
NYHA Functional Class II (n=48) or III (n=43). The primary end point of the study was the
frequency of unplanned readmission plus out of hospital death within 6 months of discharge.
Results revealed that patients randomized to the home based intervention had 42.3% fewer
unplanned readmissions (36 vs 63; p=0.03) and 45.1% fewer out-of-hospital deaths.
Additionally, home-based intervention patients also had 43% fewer days of hospitalization (261
vs 452; p=0.05) and fewer multiple (>3) readmissions for HF during follow-up (0 vs 5 patients;
p=0.02). Furthermore, hospital costs averaged $3,200 per patient in the intervention group
compared with $5,400 in the control group, a nonsignificant reduction of 40.7%. The estimated
cost of the study intervention was $190 Australian dollars. Outpatient medical costs did not
differ between groups.
This study (Stewart, Pearson, Horowitz, 1998) should be compared with two previously
reported, randomized controlled investigations (Weinberger, Oddone, & Henderson, 1996; Rich,
Beckham, Wittenberg, et al., 1995). In one of these studies, broad interventions (increased access
to outpatient primary care) yielded unfavorable results in relation to extent and duration of
readmissions (Weinberger, Oddone, & Henderson, 1996). In the other study, however, use of a
similar but more intensive intervention specific to management of HF was associated with a
significant increase in the time to first readmission or out-of-hospital death at 3 months after
discharge (Rich, Beckham, Wittenberg, et al., 1995). As with this study (Stewart, Pearson,
Horowitz, 1998), the difference between groups was largely mediated by fewer multiple
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readmissions among patients exposed to the nurse-directed home-based intervention (Rich,
Beckham, Wittenberg, et al., 1995).
In another report, Cline and coworkers (1998) add further evidence in favor of a nurseled multidisciplinary intervention following hospitalization due to HF (Cline, Israelsson,
Willenheimer, et al., 1998). The unique aspect of this program was that families also received
education about the HF syndrome. One hundred ninety patients with HF were randomized by
computer-generated allocation to the intervention group (n=56) or usual care (n=76) to evaluate
the efficacy of a HF management program on hospitalization and health care costs one year after
admission for heart failure. The intervention group and their families received education about
heart failure and self-management, with follow-up at an easy access, nurse directed outpatient
clinic for one year after discharge. The control group was managed according to routine clinical
practice. The education program consisted of two thirty-minute information visits by a nurse
during hospitalization and a one-hour information visit for patients and families two weeks after
discharge. There was only one prescheduled clinic visit at 8 months after hospital discharge.
However, the nurse was available by telephone during clinic hours and was able to see patients at
short notice. Adherence to prescribed medication was emphasized and patients received
guidelines for self-management of diuretics. The control group was followed up at the outpatient
clinic by either cardiologists in private practice or by primary care physicians. One-year
mortality did not differ between groups. Time to first readmission over the same period however
was 33% longer in the intervention group (106 vs 141 days; p<0.05), with 49% fewer total days
of hospitalization (8.2 vs 4.2; p=0.07). Furthermore, there was a trend toward a mean annual
reduction in healthcare costs per patient of US $1300 in the intervention group compared with
costs in the controls (US$2294 vs 3594; p=0.07). It should be noted that this study recruited
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patients with a much lower rate of readmission than those in the previous two studies (Rich,
Beckham, Wittenberg, et al., 1995; Stewart, Pearson, Horowitz, 1998).
In a third report, Serxner et al. (1998) reported findings of a study involving 109 patients
randomized to an educational mailing intervention (n=55) or standard care (n=54) after
hospitalization for heart failure. The intervention was designed to encourage self-management
and consisted of a series of mailings at 3 to 4 week intervals that contained a personalized letter
and a variety of educational materials (booklets, brochures, fact sheets, resource guides, and a
video), as well as compliance aids (medication sheets and a weight chart). Interviews were
conducted before and after the three-month intervention to assess compliance and quality of life,
and readmissions were monitored for 6 months. The average age of the participants was 71
years, and 52% were women. Results indicated that 27% of the patients in the intervention group
were readmitted at least once during the 6-month follow-up period compared with 50% of the
patients in the control group (p=0.025). Moreover, multiple readmissions were more common in
the control group, and the study intervention resulted in 52% fewer total readmissions (43 vs. 21
readmissions; p<0.01). Additionally, individuals receiving the study intervention reported better
overall health status, greater confidence in self-management, and enhanced compliance with diet,
medications, and weight monitoring as compared to control group patients. Furthermore, the
investigators reported that although the cost of the education program was $50 per patient, the
intervention reduced overall costs, and there was a net return on investment of $8:$1 for the
hospital and $19:$1 for third party payers (Serxner, Miyaki, & Jeffords, 1998).
In 1998, Ekman and colleagues evaluated the feasibility of a nurse-monitored, outpatient
care program for elderly patients (mean age = 80 years) previously hospitalized with moderate to
severe HF (Ekman, Andersson, Ehnfors, et al., 1998). Upon hospital discharge, one hundred fifty
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eight patients with NYHA class III-IV HF were randomized to the structured-care intervention
(n=79) or standard care (n=79). The structured care program followed established guidelines for
medical treatment and principles for care of the patients were based on previously documented
experiences (Konstam, Dracup, Baker, et al., 1994; Dracup, Baker, Dunbar, et al., 1994; Rich,
Vinson, Sperry, et al., 1993). The main goal of the intervention was that patients would learn to
recognize and monitor symptoms of deterioration and be familiar with effects and side effects of
the medication they had been prescribed (Ekman, Andersson, Ehnfors, et al., 1998). Patients
were instructed to call the nurse if worsening symptoms occurred or if they had questions
pertaining to their illness. The nurse was available by beeper during business hours; however, an
attending doctor was responsible for medical decisions. Each patient was contacted a week after
hospital discharge and offered a visit to the clinic, together with a caregiver. In addition to clinic
visits, nurses regularly contacted patients by telephone to follow-up discussions concerning
medication, weight, diet, or questions raised by the patient’s apprehension of the illness. During
the six month follow-up period, the median number of telephone contacts was four calls per
patient. Twenty-two (28%) patients and eighteen (23%) relatives or caregivers made spontaneous
telephone contacts; whereas, seven patients (9%) made spontaneous clinic visits due to
decompensation, leading to acute admissions. Among the seventy-nine patients randomized to
the structured care group, 23 patients (29%) never visited the nurse and this was explained by
death (11 patients), fatigue or unwillingness (11 patients), and institutional care (1 patient).
Patients who never visited the nurse showed the following characteristics at entry: female sex,
advanced age, and need of assistance at home.
Results of the structured-care program did not demonstrate any beneficial effect on the
number of readmissions and hospital days. If anything, structured care tended to be associated
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with an increase in hospital days (mean difference in hospital days was 8 days; p=0.29).
Interestingly, these results are in agreement with a previously discussed study, which
demonstrated that structured management, with increased access to primary care after hospital
discharge, was associated with an increased rate of hospitalizations in severely ill patients
(Weinberger, Oddone, & Henderson, 1996). One explanation for these results may be that
structured care may lead to the detection of previously unrecognized medical problems, owing to
improved communication between caregivers and patients as compared to conventional care.
This, in combination with easier access to inpatient care, may increase readmission rates. The
authors concluded that the outpatient, nurse-monitored symptom management program was not
feasible for the majority of these elderly patients with moderate to severe HF, mainly because of
the small proportion of eligible patients and the high dropout rate (Ekman, Andersson, Ehnfors,
et al., 1998). Furthermore, management of these patients may have to be more individualized and
adjusted to the patient’s home situation.
Based on previous studies, it can be expected that patients who are able to care for
themselves effectively will encounter fewer problems leading to rehospitalizations or
unnecessary visits to the emergency department (Happ, Naylor, Roe-Prior, 1997; Rich, Gray,
Beckham, et al., 1996; Rich, Beckham, Wittenberg, et al., 1995; Vinson, Rich, Sperry, et al.,
1990; Gooding & Jette, 1985). However, some authors argue that because of increased access to
care and increased knowledge about the illness, it is also possible that education and support
leads to an increase in health care resource use (Weinberger, Oddone, & Henderson, 1996;
Ekman, Andersson, Ehnfors, et al., 1998). In various multi-faceted interventions, education is an
important aspect of the intervention, such as the availability of a heart failure clinic or a heart
failure team (Ekman, Andersson, Ehnfors, et al., 1998; Rich, Beckham, Wittenberg, 1995;
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Fonarow, Stevenson, Walden, et al., 1997), The specific contribution of education and support
alone to such programs is seldom isolated. Therefore, Jaarsma and colleagues (1999) conducted
a trial to determine the effect of patient education and support by a nurse on self-care and
resource utilization in patients with severe HF (Jaarsma, Halfens, Huijer, et. al., 1999).
A total of one hundred seventy nine patients hospitalized with NYHA class III-IV HF
were randomized to a nurse-led educational intervention (n=84) or to usual care (n=95) (Jaarsma,
Halfens, Huijer, et. al., 1999). The average age of participants was seventy-three years and fiftyeight percent were male. The supportive education intervention consisted of intensive, systematic
and planned education by a study nurse about the consequences of heart failure in daily life,
using a standard nursing care plan developed by the researchers for older patients with heart
failure (Jaarsma, Halfens, Huijer, et. al., 1999). Education took place over a ten-day period,
beginning in the hospital and continuing through a home visit within a week of discharge;
however, all patients were followed for nine months. An investigator telephoned the patients one
month after discharge and visited the patient at three months and nine months after discharge for
data collection. Data were collected on self-care abilities, self-care behaviors, readmissions,
visits to the emergency heart center, and use of other health care resources.
No statistically significant differences were found between the two groups in self-care
abilities. The supportive educational intervention was effective, however, in enhancing self-care
behavior after discharge. On average, patients were compliant with nine of nineteen items of
self-care behavior at baseline. As can be expected, the effects of the intervention were most
powerful on short-term behavior, which is reflected in significant differences in self-care
behavior between the two groups both at one month and at three months after discharge (14 vs
12; t=3.8, p=0.001, and 12.2 vs 10.6; t=2.9; p=0.05, respectively). Both control and intervention
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patients decreased self-care behavior over time; however, the intervention patients still reported
complying with more behaviors than control patients at nine months (11.2 vs. 10.3;
t=1.6;p=0.11). Although the difference between groups at nine months was not statistically
significant, the increase from baseline remained substantially significant in the intervention
group, but not in the control group. No significant effects on resource utilization were found. The
authors concluded that education and support from a nurse in a hospital setting and at home can
significantly increase self-care behavior in patients with severe HF (Jaarsma, Halfens, Huijer, et.
al., 1999). The decrease in self-care behaviors over time suggests that although patient selfmanagement should play an important role in care management strategy, the study design should
ensure concomitant outpatient supervision and enforcement of education to achieve success.
Additionally, it can be expected that certain aspects, for example those relating to adapting
activities, may not be affected by education and support. The data indicated that, due to their
poor physical behavior, most patients already rested during the day, spread activities throughout
the day, and decreased activities when needed, (Jaarsma, Halfens, Huijer, et. al., 1999).
Therefore, interventions that encourage regular exercise at the patient’s own pace may be
needed, because it has been shown that exercise can improve functional capacity and attitudes
(McKelvie, Teo, Roberts, et al., 2002).
Jerant and colleagues (2001) compared the effectiveness of three hospital discharge care
models for reducing CHF-related hospital readmission costs: 1) home telecare delivered via a 2way video-conference device with an integrated electronic stethoscope (n=13); 2) telephone
follow-up (n=12), and 3) usual outpatient care (n=12) (Jerant, Azari, & Nesbitt, 2001). Prior to
hospital discharge, thirty-seven patients were randomized to one of the three care models using
sealed envelopes containing randomly generated numbers and were followed for one year.
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Patients assigned to telephone care received scheduled phone calls from the study nurse in the
intervening period, whereas, those assigned to the video-based telecare group received scheduled
home telecare visits. For urgent questions or problems, the groups in telecare and telephone
groups had access to nurse via the medium appropriate to their group assignment. Patients in all
groups received a home nursing visit shortly after discharge and a second home nursing visit
approximately sixty days later, during which subjects completed the SF-36 questionnaire (Ware
& Sherbourne, 1992) and the Minnesota Living with HF questionnaire (Rector & Cohn, 1992).
Additionally, during all in-person, telecare, and telephone encounters, the study nurse assessed
signs and symptoms, activities of daily living, medication use, and dietary factors, provided
education, and developed patient-centered goals for the frequency and content of follow-up visits
(Jerant, Azari, & Nesbitt, 2001). Furthermore, a set of algorithms were drawn from national
consensus recommendations to help the study nurse better determine the adequacy of HF drug
regimens (Advisory Council to Improve Outcomes Nationwide in HF, 1999). Patients
randomized to usual care received only the care directed by their primary care physicians in the
period between in-person nursing visits (Jerant, Azari, & Nesbitt, 2001). The primary outcome
measure was HF-readmission charges during a 6-month period after randomization.
Ninety-two telecare encounters (76%) were limited by at least one technical problem.
Video problems were judged to be severe in only five encounters (4%) and heart and lung sound
resolution was inadequate in only two encounters (2%). Mean HF-readmission charges were
86% lower in the telecare group ($5,850+$21,094) and 84% lower in the telephone group
$7,320+$24,440) as compared to the usual care group ($44,479+$121,214). However, the
between-group difference was not statistically significant (P=0.262). Both the intervention
groups had significantly fewer HF-related emergency department visits (P=0.0342) and charges

213

(P=0.0487) than the usual care group. Trends favoring both interventions were noted for all other
utilization outcomes.
Based on these results, video-based home telecare does not appear to offer incremental benefits
beyond telephone follow-up in reducing frequent hospital readmissions and emergency
department visits for patients with HF (Jerant, Azari, & Nesbitt, 2001). More importantly, these
data imply that deployment of distance technologies, such as telephone follow-up, to provide
post-hospitalization monitoring could yield substantial reductions in hospital readmissions,
emergency visits, and costs of care in select patients with HF.
In 2002, Doughty and coworkers examined the effect of an integrated heart failure
management program on quality of life and hospital readmissions in patients with NYHA class
III-IV HF (Doughty, Wright, Pearl, et al., 2002). The aim of this study was close liaison between
patient, family, general practitioner (GP), and the hospital-based heart failure clinic. One
hundred and ninety seven patients admitted to Auckland Hospital with an exacerbation of HF
were enrolled in the study. Participants were randomized to the intervention group (n=100
patients, 64 GPs) or usual care (n=97 patients, 68 GPs) using the general practitioner as the unit
of randomization. The intervention consisted of an evaluation and an individual education
session with the nurse within two weeks of hospital discharge. Subsequently, two group
educational sessions (each lasting 1.5 to 2 hours) were offered within six weeks of hospital
discharge, and a third session after 6 months. These sessions were led by a cardiologist and a
study nurse, and content was based on current HF guidelines (Konstam, Dracup, et al., 1994).
Each patient was given a diary for recording medication information and daily weights, and a
follow-up plan was devised for each patient aiming for 6 weekly visits alternating between the
GP and heart failure clinic (Doughty, Wright, Pearl, et al., 2002). A letter was faxed to the GP on
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the same day patient visited the HF clinic to document any changes in the management plan.
Patients randomized to usual care continued under standard care of the GP with additional
follow-up measures as recommended by the inpatient medical team.
Patients in the intervention group attended the HF clinic an average of four times during
the twelve-month follow-up period. Sixty percent of the intervention group attended the first
group education session, and forty percent attended the six-month session. The main effect of the
intervention was attributable to the prevention of multiple readmissions. Although first
readmissions for all causes were similar in intervention and control groups (64 vs 59,
respectively), subsequent all-cause readmissions were fewer in the intervention group compared
with the control group (56 vs 95, respectively, 2p=0.015) with an associated reduction in bed
days. Additionally, the Minnesota Living with Heart Failure scores showed markedly impaired
quality of life at baseline, with mean physical functioning and emotional scores of 25.6+12 and
10+7, respectively. The physical dimension of quality of life showed a greater improvement in
the intervention group from baseline to twelve months compared with the control group (-11.1 vs
–5.8, respectively; 2p=0.015); however, there was no significant change in the emotional score in
either group (-3.3 vs –3.3, respectively; 2p=0.97).
These results are in contrast to those previously discussed by Weinberger et al. (1996),
who reported higher readmission rates in the intervention group as compared to controls (0.19 vs
0.14 per month, p=0.005), implying that a disease-specific protocol of primary with specialist
care, as in the current study (Doughty, Wright, Pearl, et al., 2001), may be important
requirements for the success of such management programs. Additionally, Cline et al. (1998)
reported only modest effects of a nurse-led hospital-based clinic for HF management, with an
increase in the time to first readmission but only a trend to fewer hospital admissions in the
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intervention. The study design by Cline et al. (1998) differed from this study (Doughty, Wright,
Pearl, et al., 2001), as it did not involve a structured approach to integration between the patient
and primary and secondary care. Therefore, these authors (Doughty, Wright, Pearl, et al., 2001)
suggest that not only is it necessary to have a disease specific protocol, but also a structured,
integrated approach between the patient and primary and secondary care.
Previous studies have suggested that multidisciplinary disease management programs can
substantially reduce the risk of readmission, with as much as a fifty-six percent reduction in HF
readmissions and a forty-four percent reduction for all-cause readmission (Rich, Beckham,
Wittenberg, et al., 1995). However, these interventions have generally included medical
management components, and consequently, it is difficult to identify the critical factors
responsible for success. Additionally, it has been suggested that behavioral factors such as
noncompliance with medications and diet, and delay in seeking preventive care may contribute
to readmissions and premature mortality (Dracup, Baker, Dunbar, et al., 1994; Happ, Naylor,
Roe-Prior, 1997). Therefore, Krumholz and coworkers (2002) evaluated the effect of a formal
education and support intervention on the rate of readmission or mortality, and hospital costs for
patients with HF (Krumholz, Amatruda, Smith, et al., 2002).
Eighty eight patients aged >50 admitted with HF to Yale-New Haven Hospital were
enrolled in the study, and randomized to the intervention (n=44) or usual care (n=44). The
intervention was designed to empower the patient and improve compliance, and occurred in two
phases: 1) the initial phase, and 2) the telemonitoring phase. The initial phase consisted of an
initial educational session with a nurse within two weeks of hospital discharge using a teaching
booklet. Home visits were performed for forty-five percent of the patients unable to travel to the
hospital. Baseline meetings did not include clinical assessments or modification of treatment.
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During the telemonitoring phase, a nurse contacted the patient by phone weekly for four weeks,
then biweekly for eight weeks, and then monthly for a total intervention period of one year. The
purpose of telephone contact was for education, not for modification of current regimens or to
provide recommendations for treatment.
The median age of the participants was 74 years; 57% were men and 74% were
Caucasian. Among the eighty-eight participants in the study, twenty-five patients (56.8%) in the
intervention group and thirty-six patients (81.8%) in the control group had at least one
readmission or died during the one-year follow-up. Overall, there were 49 all-cause readmissions
in the intervention group and 80 in the control group in the year following discharge (p=0.06),
indicating a 39% reduction in readmissions. After adjusting for clinical and demographic
characteristics, the intervention group had a significantly lower risk of readmission compared
with the control group. Although the average cost of the intervention was $530 per patient,
hospital readmission costs were higher in the control group by an average of $7,515 per patient
(p=0.02), yielding an overall cost reduction of $6,985 per patient in the intervention group.
Krumholz et al. (2002) extends previous work on disease management for patients with
HF (Rich, Vinson, Sperry, et al., 1993; Rich, Beckham, Wittenberg, et al., 1995; Stewart,
Pearson, Horowitz, 1998) by specifically evaluating the impact of education and support without
medication management as an outcome for these patients. This intervention differs from other
programs, as it focuses on enabling patients to take an active role in managing their illness based
on knowledge and education rather than relying on physicians or nurses actively intervening to
adjust medical care and regimens (Krumholz, Amatruda, Smith, et al., 2002). In comparison to
work by Jaarsma and colleagues (1999), this study demonstrated that a brief education and
support intervention by a nurse could increase self-care behaviors among patients who had been
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hospitalized with HF (Krumholz, Amatruda, Smith, et al., 2002). However, unlike this study, the
nurse in the Jaarsma study made a home visit to every patient and all of the intervention occurred
within 10 days of discharge (Jaarsma, Halfens, Huijer Abu-Saad, et al., 1999). Furthermore, in
contrast to this study, Jaarsma et al. (1999) found no significant change in resource utilization,
although there were trends that favored the intervention group, indicating that a longer follow-up
may be necessary. Although it was theorized that the outcomes were achieved through promotion
of patient compliance and empowerment, this trial did not explicitly test the mechanism of
intervention (Krumholz, Amatruda, Smith, et al., 2002). Future studies may explore the potential
mechanisms for maximal benefits of education and support.
The findings of a study by Kasper and coworkers (2002) extend the work of Rich et al.
(1995) to a longer intervention period (six months vs. three months) and to a younger population
(median age of sixty four years vs. seventy nine years). Additionally, Kasper et al. (2002)
emphasized the involvement of the patient’s primary physician, as well as active initiation and
titration of medications by nurses. The purpose of the study was to determine whether an
outpatient program designed to implement optimal medical therapy, increase patient
understanding and compliance and reduce financial barriers to care, coupled with frequent
telephone monitoring and clinic follow-up, could decrease mortality and hospital readmissions,
as well as improve compliance and quality of life, at no extra cost in patients with HF (Kasper,
Gerstenblith, Hefter, et al., 2002). Two hundred patients hospitalized with HF at increased risk
for readmission were randomized to a six-month multidisciplinary program (n = 102) or usual
care (n = 98). The median age of the study patients was sixty-four years, forty percent were
women, and ninety four percent were in NYHA functional class II or III. A cardiologist and a HF
nurse evaluated each patient and made recommendations to the patient’s primary physician
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before randomization. It is important to note that primary-care physicians were not excluded
from HF disease management, but rather were integrated into the team care of their patients. The
intervention consisted of an algorithm designed by cardiologists according to available HF
guidelines and clinical experience (Konstam, Baker, Dracup, et al., 1994; Williams, Bristow,
Fowler, et al., 1995). Nurses adjusted medications according to the algorithm which also
included a 2-g sodium restricted diet, as well as a recommendation to exercise by walking for 20
min at least four days per week (Kasper, Gerstenblith, Hefter, et al., 2002). The treatment plan
was individualized for each patient. All patients in the intervention group were provided a pill
sorter, list of correct medications, list of dietary and physical activity recommendations, contact
number available 24 hours per day, and patient education material. Additionally, patients with
limited financial resources were provided, if needed, a scale, a 3-g sodium “meals on wheels”
diet, medications, transportation to the clinic, and a telephone.
Contact with the patient was on a prespecified schedule, and consisted of telephone
follow-up and clinic visits. A telephone nurse coordinator made scheduled follow-up calls to
patients within 72 hours of hospital discharge, then weekly for one month, twice in the second
month, and monthly thereafter, unless a problem occurred that required more frequent contact.
The telephone nurse followed a set script and pursued problems as clinically indicated, but did
not adjust medications over the telephone. Patients had at least monthly clinic visits with a HF
nurse; however, some visits occurred in the home. Patients in the control group were followed as
usual. Data were collected at six months, and patients were followed for an additional three
months. Telephone calls averaged 9.5 per patient, with duration of 16+9 min per call; whereas
clinic visits averaged 8.5 per patient, and the average length of a visit by a HF nurse was 57+21
minutes (Kasper, Gerstenblith, Hefter, et al., 2002). There were 43 HF hospital admissions and 7
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deaths in the intervention group, as compared with 59 HF admissions and 13 deaths in the
control group (p=0.09). Additionally, dietary compliance was described to be good or average in
patients in the intervention group vs the control group, based on a review of dietary history (65
of 94 patients vs 38 of 85 patients, p=0.001). There was no difference, however, in medication
compliance. Moreover, quality of life scores, as assessed by the Minnesota Living with Heart
Failure Questionnaire (Rector & Cohn, 1992), and percentage of patients on target vasodilator
therapy were significantly better in the intervention group. Finally, costs per patient in 1998 US
dollars, were similar in both groups (Kasper, Gerstenblith, Hefter, et al., 2002).
These results may not apply to all patients with HF, because the investigators specifically
targeted patients thought to be at high risk for readmission. It is likely that not all patients require
such an extensive intervention (Kasper, Gerstenblith, Hefter, et al., 2002). Additionally, the
program was multidisciplinary in nature and not designed to analyze the relative contributions of
its various components. Moreover, it is unclear from these data whether telephonic management
alone results in a benefit (Kasper, Gerstenblith, Hefter, et al., 2002). Therefore, further research
is needed to identify which of these components is essential and if a briefer, less intense
intervention will be as effective in a HF patient population.
Although previous studies evaluating the use of multidisciplinary care management have
included telephone follow-up as a component of the intervention (Kasper, Gerstenblith, Hefter,
et al., 2002), with the exception of Jerant et al. (2001), no studies have examined whether
telephonic management alone results in improved outcomes in patients with HF. However, in the
study by Jerant and colleagues (2001), patients also received a home nursing visit shortly after
discharge and a second home nursing visit approximately sixty days later. Therefore, Riegel et
al. (2002) evaluated the effectiveness of a standardized telephonic care-management intervention
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to decrease resource use in patients with chronic heart failure. Three hundred fifty-eight patients
were identified at hospitalization and assigned to receive six months of intervention (n=130) or
usual care (n=228) based on randomization of their physician. Outcome data were collected at
three and six months.
Nurses monitored, educated, and counseled patients by telephone in a standardized
fashion guided by a computer program designed by clinical experts to support national
guidelines for treatment of HF (Konstam, Dracup, Baker, 1994; Packer, Cohn, Abraham, 1999).
The intervention group was telephoned within five days of hospital discharge and thereafter at a
frequency guided by the software and case manager judgment based on patient symptoms,
knowledge, and needs (Riegel, Carlson, Kopp, et al., 2002). During the calls, the nurses educated
patients regarding such topics as medication adherence, diet recommendations, and identification
of worsening signs and symptoms, with the goal of improving intermediary factors that would
influence important outcomes such as hospitalization. Additionally, printed education material
was mailed to patients monthly. Moreover, physicians were sent guidelines for the treatment of
systolic HF with their first notification of patient progress (Konstam, Dracup, Baker, et al.,
1994), and automated progress reports produced by the software on a regular basis (Riegel,
Carlson, Kopp, et al., 2002). Furthermore, physicians were notified of discrepancies between
patients’ reports of medications and treatments vs. actual physician orders. Care for patients in
the usual care group was not standardized and no formal telephonic case management was in
existence. However, these patients presumably received some education regarding HF
management prior to hospital discharge (Riegel, Carlson, Glaser, et al., 2002).
The overall sample was elderly (72+12 years), almost equally divided by sex (51%
female), and functionally compromised (ninety-seven percent were NYHA class III or IV). The
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only significant differences between groups on demographic or clinical descriptors were a higher
use of beta-blockers and a lower incidence of chronic lung disease in the intervention group
(Riegel, Carlson, Kopp, et al., 2002). Patients received an average of seventeen phone calls at
decreasing levels of intensity, length, and frequency over the six month follow-up period
(median, 14 calls; interquartile range, 11-22 calls). The HF hospitalization rate was 45.7% lower
in the intervention group at three months (p= 0.03) and 47.8% lower at six months (p=0.01).
Additionally, heart failure hospital days and multiple readmissions were significantly lower (both
p=0.03) in the intervention group at six months. Furthermore, inpatient heart failure costs were
45.5% lower at six months (p=0.04). A cost savings was realized even after intervention costs
were deducted, and there was no evidence of cost shifting to the outpatient setting. Lastly,
patients in the intervention group reported significantly higher satisfaction with care than those
receiving usual care.
The reduction in hospitalizations, costs, and other resource use achieved using
standardized telephonic case management in the early months after a heart failure admission is
greater than that usually achieved with pharmaceutical therapy and comparable with other
disease management approaches (The Heart Outcomes Prevention Evaluation Study
Investigators, 2000; The Digitalis Investigation Group (1997). The authors (Riegel, Carlson,
Kopp, 2002) suggest that the effectiveness of the approach may be a function of the intensity and
focus of the intervention, standardization, patient characteristics, or an interaction of these
factors. Further study is needed for a clear understanding of specific factors responsible for the
improved outcomes (Riegel, Carlson, Kopp, 2002).
McDonald, et al., (2002) addressed the question of whether multidisciplinary care of HF
can reduce readmissions when optimal medical care is applied in both intervention and control
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groups. Ninety eight patients (mean age, 71+11 years) admitted to the hospital with NYHA
functional class IV HF were assigned to multidisciplinary care (n=51) or routine care (n=47). All
patients received the same components of optimal inpatient medical care of HF, as defined by
specialist-led inpatient care, titration to maximum tolerated dose of ACE inhibitor before
discharge, and attainment of predetermined discharge criteria (symptomatically improved,
weight stable, off all intravenous therapy, and no change in oral regimen for 2 days).
Additionally, those in the multidisciplinary care group received nurse-led education and dietitian
consults on three or more occasions during the index admission, followed by close follow-up for
three months. Telephone follow-up occurred three days after discharge and weekly thereafter
until twelve weeks. Moreover, patients and their next of kin attended the HF clinic at weeks two
and six. Education topics included daily weight monitoring, salt restriction, and disease and
medication understanding. The primary study endpoint was re-hospitalization or death for a HFrelated issue at three months. At three months, four people (7.8%) had events in the
multidisciplinary care group compared with twelve people (25.5%) in the routine care group
(P=0.04). Additionally, readmission for HF was more frequent in the routine care group at
25.5%, compared to 3.9% in the multidisciplinary care group. Furthermore, patients in the
multidisciplinary care group exhibited a greater understanding of HF, medications, and
importance of sodium restriction upon hospital discharge as compared to the routine care group.
The superior knowledge noted at discharge was sustained at 3 months.
These data demonstrate for the first time the intrinsic benefit of multidisciplinary care in
the setting of protocol-driven, optimal medical management of HF (McDonald, Ledwidge,
Cahill, et al., 2002). Moreover, the event rate of 7.8% at three months as the lowest reported rate
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of such a high-risk group, underlines the value of an integrated inpatient and outpatient
multidisciplinary approach to the management of HF.
Both randomized and nonrandomized controlled studies have linked HF case
management to decreased readmissions (Rich, Beckham, Wittenberg, et al., 1995; Fonarow,
Stevenson, Walden, et al., 1997; Stewart et al., 1998), cost savings (West, Miller, Parker, et al.,
1997; Cline, Israelsson, Willenheimer, et al., 1998; Tilney, Whiting, Horrar, et al., 1998), and
improved functional status (Fonarow, Stevenson, Walden, et al., 1997) in mostly homogeneous
settings. Therefore, Laramee et al. (2003) conducted a study to test the effect of hospital-based
nurse case management on ninety-day readmission rate in a heterogeneous population of HF
patients (Laramee, Levinsky, Sargent, et al., 2003).
A total of 287 patients admitted to a five hundred fifty bed academic medical center with
the primary or secondary diagnosis of HF, left ventricular dysfunction of less than forty percent,
or radiologic evidence of pulmonary edema for which they underwent diuresis were randomized
to the intervention (n=141) or usual care (n=146). The intervention consisted of four major
components: early discharge planning, patient and family HF education, twelve weeks of
telephone follow-up, and promotion of optimal HF medications. Patients in the study received
post-discharge care locally from their own cardiologists, internists, or family practitioners. The
dispersed outpatient setting was characterized by considerable variation of follow-up care;
therefore, the objective of the study was to evaluate the effect of hospital-based nurse case
management on readmission rates in a heterogeneous setting (Laramee, Levinsky, Sargent, et al.,
2003).
Patients or family members received telephone calls at one to three days following
hospital discharge, weekly for the first month, and every other week in the second and third
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months. The telephone calls surveyed HF symptoms, medications, self-care activities, adherence
to the treatment plan, and provided opportunity for patients and families to ask questions. Data,
including demographics, NYHA classification, and readmission rates, were collected at
enrollment and twelve weeks. Additionally, adherence to the treatment plan, as measured by selfreport, and patient satisfaction were assessed at four and twelve weeks.
The ninety-day readmission rates were equal for the care-managed and usual care groups,
with both at 37%. Total inpatient and outpatient median costs and readmission median cost were
reduced fourteen percent and twenty-six percent, respectively, for the intervention group.
Patients in the care-managed group were more likely to be taking HF medication at target doses,
but dosages did not increase significantly throughout the twelve weeks. Although both groups
took their medications as prescribed equally well, the rest of the adherence to treatment plan was
significantly better in the care-managed group. Subgroup analysis of patients who lived locally
and saw a cardiologist revealed significantly fewer HF readmissions for the intervention group as
compared to the usual care group, at 2% and 14%, respectively (P=0.03). These results suggest
several limitations to the generalizability of the HF care managed improved outcome link in a
heterogeneous setting. One explanation is that the lack of coordinated system supports and
varied accessibility to care in an extended, non-networked physician setting limits the
effectiveness of the case management (Laramee, Levinsky, Sargent, et al., 2003).
In summary, the randomized trials provide strong support for the observational studies
that multidisciplinary care management programs are efficacious in select patients with HF. Both
randomized and nonrandomized controlled studies have linked HF care management to
decreased readmissions (Rich, Beckham, Wittenberg, et al., 1995; Fonarow, Stevenson, Walden,
et al., 1997; Stewart et al., 1998; Knox & Mischke, 1999; Serxner et al., 1999; Doughty et al.,
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2002; Krumholz et al., 2002; McDonald et al., 2002), cost savings (West, Miller, Parker, et al.,
1997; Cline, Israelsson, Willenheimer, et al., 1998; Tilney, Whiting, Horrar, et al., 1998),
improved functional status (Fonarow, Stevenson, Walden, et al., 1997), quality of life (refs), and
patient satisfaction (refs). Additionally, several studies have shown enhanced patient knowledge,
as well as compliance with medications and diet following a multidisciplinary intervention (refer
to Tables 3-6).
Based on available evidence, significant benefits have consistently been observed
following implementation of multidisciplinary programs for patients with HF (refer to tables 36). However, despite the consistency of these findings, several important limitations must be
recognized and there is considerable opportunity for additional research in this area.
First, most of the studies to date have been conducted as single-center trials at academic
medical centers and in mostly homogeneous settings (refer to tables 1 and 3). Additionally, many
studies recruited hospitalized patients, thus definite conclusions regarding the effect of the
intervention on an outpatient population cannot be drawn. For these reasons, the generalizability
of these findings to routine care of HF patients in the community remains uncertain. Therefore,
there is a need for further studies evaluating HF disease management programs in larger and
more diverse populations and practice settings, particularly the inner city, community hospitals
and physician offices, and rural environments.
Secondly, because of the complexity of the HF syndrome and large number of topics that
are important to discuss, a team approach has proven extremely useful in providing care and
helping patients to understand and retain information about the treatment regimen (Fonarow,
Stevenson, Walden, et al., 1997; Rich, Beckham, Wittenberg, et al., 1995). Indeed, physicians
and a multitude of other clinicians including: advanced practice nurses, home health nurses,
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dietitians, physical therapists, exercise physiologists, pharmacists, other professionals, and
support groups may all play important roles in this process as shown by numerous studies (refer
to Tables 1 and 2). However, many nonacademic centers may lack the necessary personnel to
assemble an effective HF care management team. Additionally, it is unlikely that a single
“cookbook” approach will be effective in a wide range of clinical environments and diverse
patient populations. Therefore, more research should be done to determine the feasibility of
translating disease management teams into clinical practice in various settings. Furthermore, a
variety of HF care management models should be considered, and modified as needed to
accommodate a given clinical environment.
A third limitation relates to the diversity of the components of the care-managed
programs used in clinical trials. Interventions have included simple telephone follow-up, video
monitoring, home visits, clinic visits and preemptive hospitalization. Programs have ranged from
simple telephone follow-up by a nurse coordinator to extensive interventions with multiple
components and comprehensive management teams. The efficacy of each strategy is largely
unknown, and published studies have not been of sufficient size to determine the contribution of
specific components. Additionally, despite the demonstrated benefits of exercise in patients with
heart failure, the value of exercise in the context of a comprehensive heart failure management
program has not been adequately studied.
Another limitation relates to individualization of the treatment plan to fit the needs of
each patient. Table 7 displays the key components of a comprehensive nonpharmacologic heart
failure program as recommended by the AHCPR guideline panel (Konstam, Dracup, Baker, et
al., 1994). Because not all components of the program are appropriate for all patients, treatment
must be individualized and adapted to accommodate the needs and circumstances of each patient.
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Several studies indicate that factors related to patient behavior (such as knowledge of the HF
syndrome, worsening symptoms, and compliance with treatment) account for the large numbers
of hospital admissions (Konstam, Dracup, et al., 1994; Rich, Vinson, et al., 1993; Dracup, Baker,
et al., 1994; Happ, Naylor, et al., 1997; Kasper, Gerstenblith, et al., 2002; Rich, Beckham, et al.,
1995). Other barriers to effective care include the cost of medications and special diets (Kasper,
et al., 2002). Due to the high rate of noncompliance with treatment, future studies should
examine patient knowledge of HF, and interventions based on patient readiness to change (or
adopt) specific lifestyle behaviors.
Lastly, although several studies indicate that factors related to patient behavior account
for the large numbers of hospital admissions (Konstam, Dracup, et al., 1994; Rich, Vinson, et al.,
1993; Dracup, Baker, et al., 1994; Happ, Naylor, et al., 1997; Kasper, Gerstenblith, et al., 2002;
Rich, Beckham, et al., 1995), it has also been suggested that one reason for unsuccessful
treatment may be the patient’s lack of understanding of the treatment plan, owing to the differing
perspectives of the health-care professionals and the patient (Dracup, Baker, Dunbar, et al.,
1994). Moreover, other barriers to effective care include a lack of coordination among various
providers (Kasper, et al., 2002). Therefore, it has been suggested that not only is it necessary to
have a disease specific protocol, but also a structured, integrated approach between the patient
and primary and secondary care (Doughty, Wright, Pearl, et al., 2001).
Furthermore, despite the availability of published HF treatment guidelines, physician
implementation of established guidelines remains suboptimal. Therefore, future studies should
examine the reasons for the lack of guideline implementation and determine ways to promote
greater adherence to established treatment guidelines.
SUMMARY
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Heart failure develops as a response to an insult to the cardiovascular system. This insult
results in a series of cardiac, circulatory, and muscular alterations with short- and long-time
constants. These compensatory adaptations may initially be remarkably effective in normalizing
cardiocirculatory function. Yet, the compensatory changes which are thought to be beneficial at
rest appear to become restrictive during an acute bout of exercise. Furthermore, most
compensatory changes exact a price and eventually give rise to many of the clinical syndrome of
heart failure, including marked exercise intolerance and chronic fatigue.
The management of patients with heart failure is frequently confounded by a host of
medical, behavioral, psychological, social, and economic factors. A considerable amount of the
cost associated with heart failure care is attributable to repeated exacerbations that frequently
require hospitalization. These exacerbations are often secondary to nonadherence to diet,
medication, and activity regimens, inadequate symptom self-assessment and management,
inadequacies in patient and care-giver education, and poor discharge planning and follow-up.
Consequently, the use of a multidisciplinary team approach appears warranted for adequate
management of these patients. In fact, a recent AHA Scientific statement examined the team
management of heart failure patients (Grady, Dracup, et al., 2000) and indicated that components
of successful healthcare delivery models for heart failure include staff skilled in the
understanding of the pathophysiology of heart failure, patient assessment and evaluation of
symptoms, education and counseling (focusing on symptoms and medication compliance),
dietary consultation, and physical activity and exercise recommendations (see Table XII and
XIII).
Multidisciplinary heart failure disease management programs recognize the complexity
of medical, psychosocial, behavioral, and financial issues that are faced by many patients with
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heart failure and their caregivers, and attempt to provide a relatively structured mechanism for
overcoming many of the barriers to effective care. Although the optimal approach to heart failure
disease management remains to be defined and may vary depending on the practice environment
and patient characteristics, it is clear that such programs substantially improve the overall quality
of care for heart failure patients and that they are likely to reduce costs. Although the trials differ
in terms of design, duration, clinical personnel, patient characteristics, settings and outcome
measures, the value of multidisciplinary programs has been consistently shown. Research has
shown consistently that systematic follow-up and early treatment of symptoms can avert
problems before they occur and reduce complications, readmissions, and costs.
Of particular relevance to the management of heart failure is the implementation of an
adequate and tailored physical activity program. Evidence clearly indicates that patients with
stable heart failure should participate in exercise training. The guidelines for and components of
exercise training are similar to other clinical populations. However, the exercise prescription
should be tailored to each patient’s unique demands and goals. As a result of training many of
the peripheral abnormalities improve. These improvements translate to increased exercise
tolerance, reduced activity-related symptoms, and improved quality of life. Finally, exercise
training increases survival time and decreases health care costs in these patients.
Finally, it is clear from the literature that despite the overwhelming evidence of the
efficacy of multidisciplinary programs and the position stand of the American Heart Association,
there continues to be a lack of guideline implementation. Thus future studies need to continue to
develop ways to promote the use of these strategies and to determine ways to enhance greater
adherence in both clinicians and patients to established treatment guidelines.
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